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D. Abstract  
 
Understanding protein interactions with modulators, signalling molecules or inhibitors can 
give information about ligand binding sites, ligand interaction topology and allosteric 
regulation at an atomic level, which is key for the design of novel inhibitors and protein 
molecules. Many techniques in-vitro have been developed and utilised including X-ray 
crystallography, nuclear magnetic resonance (NMR), electron microscopy, mass 
spectrometry etc… Further advances in these biophysical techniques and combining the 
information from the different techniques are still required to provide detailed insights into 
the structure and function of proteins and relate these to the physiological environment.  
Both X-ray crystallography and NMR techniques were explored with a number of previously 
characterised protein models, including Cyclophilin A (CypA) (18 kDa), the catalytic domain 
of Phosphodiesterase B1 from Trypanosoma brucei (TbrPDEB1) (37 kDa) and the catalytic 
domain of Bromodomain 4 BD1 (BRD4-BD1) (15 kDa). The results were mixed for each 
protein system. CypA showed successful NMR spectra but X-ray structures were less 
amenable. TbrPDEB1 was a good crystallographic system, where four novel liganded crystal 
structures were solved, but was deemed unsuitable for NMR studies. BRD4-BD1 was a 







F nuclei.  
Seven novel liganded BRD4-BD1 crystal structures and NMR assignments are presented in 
this thesis. The pair of triple resonance experiments HNCA, HN(CO)CA, HNCACB, 









Cβ nuclei. Major chemical shift differences ranging above 0.3 ppm were observed for 
the residues W81, V87, D88, A89, N93, L94, I146, A150, L158 and K160 with the ligand 
BTB 07004. This chemical shift mapping was in agreement with the binding site in the 
  19 
BRD4-BD1 crystal structures, particularly for the residues W81, V87, L94, Y97, C136, 
Y139, N140 and I146.  
The thesis confirms that combining X-ray crystallography and NMR leads to an advanced 
understanding of ligand interaction sites in proteins. This could be used for generating 
accurate topology maps of ligand-binding sites of any proteins with specific ligands, known 
as the “Group Epitope Mapping” (GEM) in the future and be extended to novel proteins.  
  






1.1     Proteins 
 
Proteins are fundamental molecules in all living cells and play a vital role in all various 
cellular processes [1] – [4]. They are defined as macromolecules due to their large size and 
high complexity [4]. Proteins are essential for developing and maintaining the structure, 
function and regulation of the body’s tissues and organs [1] [2] [4].  
The building blocks of a protein are amino acids [2] – [4]. Proteins are a polypeptide of 
amino acids linked with covalent peptide bonds. The polypeptide sequence can be illustrated 
as the “beads in a string”. The polypeptide chain is formed on the ribosome during translation 
of messenger RNA from a specific gene resulting in protein synthesis in cells. All the amino 
acids consist of an amine group NH2 at one end “amino” and of a carboxylic acid COOH 
group at another end “acid” [1] [3] [4]. The amine group and the carboxyl group are then 
linked together by a peptide bond. In most of the amino acids, both of the amino and carboxyl 
groups are attached to a central carbon atom. In addition, hydrogen atoms and another group 
of atoms (R) that varies with each amino acid type, are attached to the central carbon atom [1] 
[3] [4]. Consequently, the formula for an amino acid is RCH(NH2)COOH; e.g. the simplest 
amino acid found is glycine, which has the following formula of HCH(NH2)COOH [1] [3] 
[4]. 
There are in total 21 different naturally-occurring amino acids, which can be arranged in 
several different ways to deliver different macromolecules, each one assigned with a 
particular function depending on its composition [4]. Each of these amino acids has its own 
and specific properties defined by the side-chain (R), and therefore give its unique 
characteristics in a protein structure. The propensity of the side-chain with polar solvent 
22 
 
(water) determines the classification of the amino acid: hydrophobic/uncharged (low 
propensity with water), polar or hydrophilic/charged (high propensity with water). The      
21 amino acids are: 
- Hydrophilic/charged: lysine (+), arginine (+), aspartic acid (-) and glutamic acid (-) 
- Polar: serine, threonine, asparagine, glutamine, histidine and tyrosine 
- Hydrophobic/uncharged: alanine, valine, leucine, isoleucine, proline, phenylalanine, 
tryptophan, cysteine, selenocysteine and methionine. 
Glycine is an exception, as it does not have a side chain [4]. 
The sequence of amino acids of a polypeptide chain determines the three dimensional 
structure, function and properties of proteins. They are four levels of protein structure: 
primary, secondary, tertiary and quaternary [3] [4].  These four different structural levels 
inter-depend on each other, as together they make several interactions between hundreds to 
thousands of atoms in a highly complex manner [4].  
 
1.1.1 Structure is related to function 
 
Proteins are classified by their wide range of intra- and extracellular functions, e.g. structural 
roles in cytoskeleton, building proteins, catalytic enzymes, homeostasis, transport, storage, 
gene regulation, antibodies in immunity, assembly and hormones [4]. Each protein has a 
specific function in living organisms, such as the well-known, myoglobin, the first protein 
whose structure was revealed by X-ray crystallography [3]. Myoglobin is defined as a 
23 
 
cytoplasmic haemoprotein found in cardiac myocytes and oxidative skeletal muscle fibres, 
and binds O2 using its heme residue (a porphyrin ring:iron ion complex) to provide oxygen to 
the working muscles [5].  
Understanding the three-dimensional structure of proteins is important to deduce the 
associated functions at a molecular level in living cells for applications in protein engineering 
and drug design in pharmaceutical and biotechnological industries [6] [7]. Three-dimensional 
structure of a protein also informs about ligand-binding sites, ligand interactions and 
allosteric regulation [8]. It becomes useful particularly for targeted drug therapy in the design 
of novel inhibitors, but also design of protein molecules [8] (Figure 1.1). With the advent of 
Next Generation Sequencing, which predicts functions of new genes through sequence 
comparison with known protein folds is a key technique in understanding proteomics towards 
rational drug development [9]. Protein structure information can be utilised in the 
development of genomic medicines through the understanding of genetic variations in disease 
characterisation and diagnosis [9] [10].  
 
Figure 1. 1. The structure-function relationship of a protein. Understanding the intimate interaction between 




A large number of changes in a sequence may still lead to the same structure, therefore the 
structure is more conserved than a sequence [4], e.g. the anaerobic enzyme cobaltochelatase 
is involved in the synthesis of water-soluble vitamin B12, whose function was well-known 
even before determination of structure. Cobaltochelatase is an enzyme that catalyses the 
insertion of cobalt into the corin ring of hydrogenobyrinic acid a,c-diamide [4]. 
Cobaltochelatase has a structural similarity with the enzyme ferrochelatase involved in heme 
biosynthesis (Figure 1.2). Although these two enzymes of cobaltochelatase and ferrochelatase 
only have 11 % sequence identity, their functions were discovered using their three-
dimensional structure [4] [11] - [13].  
 
 
Figure 1. 2. The structural similarity between cobaltochelatase and ferrochelatase A) Crystal structure of 
cobaltochelatase (PDB: 1QGO) B) Crystal structure of ferrochelatase (PDB: 2QD4). Although cobaltochelatase 
and ferrochelatase are two different proteins with different functions, and only 11 % sequence similarity, they 
are structurally similar [12] [13].  
 
A                                                                                               
B                                                                                               
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However, a single sequential change in the protein’s ligand binding site can change the ligand 
binding specificity of the protein, altering its associated function and even rendering the 
protein inactive [11].  
Various analytical techniques have been developed to determine the three-dimensional 
structure of a protein, as proteins cannot be visualised by light microscopy [7] [14], such as 
X-ray crystallography, Nuclear Magnetic Resonance (NMR), electron microscopy, mass 
spectrometry and many more evolving techniques [7] [8] [15] – [21].  
 
1.2 Protein binding sites and interactions with ligands 
The function of a protein is fundamentally exerted through the binding of another molecule as 
a trigger. Majority of biological processes are dependent on protein-protein complex or 
protein-ligand complex [22] - [26]. Almost every existing biological reaction derives from a 
protein-ligand interaction, particularly in enzymology [27] [28]. High concentration of 
ligands could bind to multiple receptor pockets, known as allosteric regulation. Examples of 
receptors are enzymes, hormone receptors, cell signalling receptors, neurotransmitter 
receptors [25].  
Proteins interact with other proteins and ligands through a complex array of intermolecular 
interactions (Figure 1.3) [29] [30]. These chemical interactions are controlled by polar 
specific interactions and thermodynamic forces (ionic bonds, hydrogen bonds, van der 
Waals’ Forces and hydrophobic effects) within the binding site [30]. The interactions 
between the protein and the ligand molecule become complex with the flexibility of the 
protein binding sites and the protein structural rearrangements, following the binding of the 
ligand [30].  
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The folding of a protein is driven by reversible chemical processes, defined by an equilibrium 





So K > 1 means predominantly folded and K < 1 means predominantly unfolded. 
At equilibrium and at standard rate, there is a chemical relationship between the equilibrium 
constant and the change in free energy (Gibbs energy): 
G ⦵ = RTlnK 
where R is a constant, T is temperature in Kelvin and Keq is the equilibrium constant [31].  
So G⦵ > 0 means predominantly unfolded and G⦵ < 0 means predominantly folded. 
The change in G
o
 can be subdivided into the enthalpy change (H) and the entropy change 
(S): 
G⦵ = H - TS 
where H is a measure of the heat released or taken up in a chemical reaction, and S is a 










Figure 1. 3. The chemical interactions between a protein and a ligand in a ligand binding pocket             
A) Crystal structure of VHL-HIF-alpha protein (PDB: 4W9H) in complex with the ligand (3JF) with nanomolar 
affinity. Blue-dashed lines represent hydrogen bonds with the structural water (red sphere). VHL-HIF-alpha 
protein is represented as a pale-green surface and residues from VHL-HIF-alpha protein forming the binding site 
as yellow sticks. B) The different 3JF ligand interactions with the protein VHL-HIF-alpha protein, represented 
in WinCoot FLEV. Adapted from: Galdeano C, Gadd MS, Soares P, Scaffidi S, Van Molle I, Birced I, Hewitt S, 
Dias DM, Ciulli A. (2014). Structure-guided design and optimization of small molecules targeting the protein-
protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor 






The function of a protein is dependent on the formation of highly specific binding pockets 
onto which small-molecule ligands would bind with the required affinities tailored to meet 
the needs of cellular biological function [24] [25].  
It is crucial to understand precisely the binding sites within a protein and the interactions 
between receptors and ligands to reveal many biological processes [22] [32] [33], but also to 
apply that knowledge into drug discovery and drug design, particularly on target proteins 
with medical relevance [22] [26] [32] [33]. The prediction of protein binding sites helps with 
the geometry of protein-protein complexes as well as protein-ligand complexes. Examples of 
protein-protein complex are observed in aggregation, dimerisation or oligomerisation, 
causative of disease states such as Alzheimer’s, Parkinson’s and prions disease [22] [25]. 
Examples of protein-ligand complex are observed in membrane-bound G-protein coupled 
receptors, which are activated in response to a ligand, leading onto various downstream 
signal transduction pathways [23].  
 
1.3 Protein and Ligand Binding Affinity Studies 
 
The binding of ligands to proteins is studied using KD, the dissociation constant of the 
reversible binding process. KD informs about the concentration of ligand required to activate 
the receptor, yielding a biological response or desensitisation of the receptor [23] [27].  
Understanding KD is key for the knowledge of ligand-protein binding affinity, as it informs 
about the potency and efficacy of the ligand. KD provides crucial mechanistic insights into 
signalling pathways [23]. KD of protein-ligand interactions are usually found in the  
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nano-molar (nM) range, representing a strong binding. KD can also range in much weaker 
(milli-molar mM or micro-molar µM) or stronger (pico-molar pM) affinities. For instance, 
catecholamine epinephrine binds to beta-adrenergic receptors at low affinity (2 µM), whereas 
biotin binds to avidin at a very exceptionally high affinity of 1 femto-molar (fM). 1 fM of 
biotin is enough to activate avidin, therefore a very potent ligand [23] [27].  
The interacting forces are interpreted from equilibrium binding kinetic measurements. KD is 
calculated from a mathematical equation with molecular models, based on the stoichiometry 
of the binding equilibrium [23] [27]. This provides a quantification of chemical interactions 
between the ligand and the protein receptor. The quantification from the KD values 
determines the strength of interactions of protein-ligand as thermodynamic measure. 
However, the calculations become difficult to manipulate as the protein’s size and complexity 
increase [23] [27].  
 
1.3.1 Techniques used for determining binding affinities 
 
 Many biophysical techniques are used to determine the molecular interactions controlling 
biological processes, either high-throughput or low-throughput screening techniques. These 
could be used for rationally controlling the protein function by altering the interactions of the 
protein complex [23] [27].  
Enzyme-Linked Immunosorbent Assays (ELISA) and Surface Plasmon Resonance (SPR) are 
the most common techniques used for getting KD values. These techniques are based on 
immobilising either the protein receptor or the ligand of the complex, and detecting binding 
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by a specific signal upon addition of the other partner of the complex, e.g. colorimetric 
change for ELISA and resonance change in SPR [23].  
Radiometric ligand binding assay requires a radioactive isotope labelled ligand. It can 
identify the KD of a ligand to a receptor directly on living cells and/or tissues, by detecting 
the radioactivity of the ligand in relation to its concentration [23].  
Isothermal Titration Calorimetry (ITC) is used to investigate the thermodynamics of protein-
ligand interactions. ITC involves the detection of ligand binding to its receptor through heat 
change [23].  
Fluorescence Correlation Spectroscopy (FCS) monitors the size-dependent diffusion times in 
solution. Recently, FCS was used in cell membrane complexes. A similar technique to FCS is 
micro-scale thermophoresis carried out in-vitro in solution [23].  
NMR titration experiments monitor the chemical shift changes caused by gradual addition of 
ligands while maintaining the protein concentration constant. The chemical shift changes are 
plotted against the varying concentration of ligand and KD is determined from the plot [34].  
 
1.3.2 The use of protein binding sites into drug design 
 
Understanding ligand interaction sites is crucial for structural-based drug design, utilising the 
three-dimensional atomic structure of protein-ligand complexes by X-ray diffraction, cryo 
electron microscopy and NMR [35] - [37]. The design of new lead small-molecule 
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compounds for targeted disease states has also become within the last 20 – 30 years with the 
study of protein-ligand complexed structures at the atomic scale [24] [38].  
Since the localisation of functional sites on proteins has become an important area of interest, 
several computational methods have been developed to identify protein-protein interactions 
or protein-ligand interactions with low molecular weight drug-like compounds [22] [33] [37] 
[39]. The prediction of ligand binding-sites identifies large pockets involved in the binding of 
ligands [37]. The developed methods are based on sequence conservation, geometric and 
physico-chemical surface properties. The existing web-accessible methods for determining 
protein and ligand binding sites have been optimised with proteins with and without the 
presence of ligands [22]. Recent studies use phylogenetic analyses to identify key areas in the 
protein with a potential for high binding affinity by comparing with other proteins of known 
function with structural similarity [37].  
The recent advances in structure-based drug design and improved knowledge about the 
energetics and dynamics of protein binding interactions have led to the implementation of 
protein-protein or protein-ligand interaction modulators [33]. These include:  
i) Development of computational techniques to identify “hot spot” single residues 
energetically contributing for protein/ligand binding.  
ii) Hypothesizing possible binding sites from non-ligand bound structures.  
iii) Identification of allosteric binding sites as alternative sites to main binding 
pockets.  
iv) Docking studies focusing on protein flexibility and external solvent effects on the 
electrostatic binding interactions.  
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v) Development of small fragment library to screen for modulators interfering with 
protein-protein interactions [33].  
 
1.4 The determination of protein structure using X-ray 
crystallography 
 
One of the main reasons for the success in computational structure guided drug design is the 
well-established methodology of protein X-ray crystallography. X-ray crystal structure 
informs about the key residues in ligand binding sites and the solvent interactions of proteins 
with ligands at atomic resolution. X-ray crystallography has helped in the synthesis and 
design of new biomolecules, e.g. Protein engineering of subtilisins to improve stability in 
detergent [40], and ligands through structure-based design. Historically, the first crystal 
protein structure was solved after 22 years in 1957. To date, the Protein Data Bank (PDB) 
consists of more than 90,000 entries, with 90% of structures solved by X-ray crystallography 
[11] [15] - [17] [20] [39] [41] [42].  
1.4.1 The process of protein X-ray crystallography 
 
X-ray crystallography is critically built on the principles of physical chemistry and 
thermodynamics. The formation of crystal nuclei and the growth of protein crystal are 
illustrated in Figure 1.4 [7]. The concentration space is divided into the undersaturated and 
supersaturated zones by the solubility curve. Protein will not crystallise in the undersaturated 
zone. The supersaturation zone is sub-divided into three zones based on the level of 
supersaturation: precipitation zone, nucleation zone and metastable zone. The precipitation 
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zone is the area where amorphous aggregates appear due to too many nuclei forming rapidly. 
The nucleation zone is the area where crystallisation occurs with the formation of few nuclei. 
The metastable zone is the region where crystallisation is induced with mechanical shock or 
seed crystal, as the protein solution has not entered the nucleation zone for a long time [7] 
[43].   
 
Figure 1. 4. Two-dimensional crystallisation phase diagram. The diagram shows the variation of protein 
concentration against precipitating agent concentration. The supersaturation of a protein solution results in 
crystallisation. Crystallisation can occur in two different zones: nucleation zone or metastable zone. (I) 
Crystallisation and/or (II) Precipitation (white arrows) decrease the protein concentration in the supersaturated 
state [7] [43]. Adapted from: Beat Blattmann and Patrick Sticher (2009) Growing crystals from protein. Science 




Supersaturation is achieved by gradual decrease in protein solubility with precipitates, such 
as salts, organic solvents, polyethylene glycol (PEG) or ammonium sulfate. Precipitates 
compete with protein for hydration, resulting in an increased protein concentration due to low 
water availability to the protein [7] [43]. As the concentration of precipitant slowly increases, 
the amount of water solvent available for the protein ultimately decreases, resulting in protein 
precipitation and protein crystallisation if the conditions are optimal [4] [7] [43]. The most 
common method to grow protein crystals is vapour-diffusion through hanging-drop or sitting-
drop (Figure 1.5), although other methods such as dialysis exist [7] [14]. The solubility of the 
protein is dependent on many factors, including temperature, concentration of precipitant, 
concentration of protein, pH of the buffer, additives (effectors, ligands, coenzyme substrates, 
inhibitors), ionic strength, organism source of protein, reducing/oxidising environment, metal 
ions, rate of equilibration and so on [4] [7] [14] [43].  
The initial protein concentration within the drop is dependent on the protein solubility, i.e.: 
the higher the protein solubility, the higher the required protein concentration. Crystallisation 







                                           
Figure 1.5. The vapour-diffusion method. The concentration of the precipitant in the reservoir solution is 
initially higher than in the protein drop. As the concentration of precipitant increases in the drop, the water 
solvent will evaporate towards the reservoir, increasing the protein concentration and reducing the volume of the 
drop. During the gradual increase of protein concentration, the protein will attain supersaturation and crystallise, 
if all the other factors (pH etc.) are optimal [44]. Adapted from: 
www.bio.davidson.edu/molecular/MolStudents/spring2003/Kogoy/protein.html 
 
The crystallisation screens are a number of pre-made solutions with different precipitants, 
buffers, salt concentrations, which identify the “hit” condition producing crystals using the 
hanging-drop method in a 24-well crystallisation plate. The “hit” condition is optimised to 
obtain large single well-ordered crystals for X-ray diffraction experiments. Crystals are 
grown in a timescale ranging from hours to weeks (Figure 1.6) [4] [7] [14] [43] [44]. 
Common commercial screens used are Hampton Research, Molecular Dimensions or Qiagen. 
In cases of extensive screening, 96-well plates also exist, using 15 μL of protein sample for 
96 different crystallisation conditions screening [4] [7] [14] [43] [44]. Special robotics 
connected to computers is nowadays available in industries to rapidly perform the screening 
experiments, requiring only a couple of minutes for the whole process to complete [4] [7] 




Figure 1. 6. Example of lysozyme protein crystals in a hanging-drop experiment [45]. From: 
www.proteinstructures.com/Experimental/Experimental/crystallization-tools.html 
 
The protein is recombinantly expressed and purified in relatively large quantities 
(approximately 10 mg/mL) in high purity and homogeneity [7]. The sample quality is 
assessed by Dynamic Light Scattering (DLS) or Small-Angle X-ray Scattering (SAXS) 
experiments to identify poly-dispersity from oligomerisation or aggregation in the protein 
solution, which can prohibit crystallisation [4]. The protein stability in different buffers, 
different ligands or additives can be determined by Differential Scanning Fluorometry (DSF) 
[4], which uses conventional real-time Polymerase Chain Reaction (PCR) instrument to 
identify low-molecular weight ligands that stabilise proteins [46]. Circular Dichroism (CD) 
Spectroscopy and analytical ultracentrifugation are other types of biophysical characterisation 
experiments used with X-ray crystallography for further protein structural characterisation. 
These techniques determine the correct folding and activity of the protein. CD is a common 
spectroscopic technique that measures the CD of proteins over a range of wavelengths. It is 
used to study the chirality of biological molecules. It also determines the different factors, 
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such as temperature or pH that can affect the formation of secondary structure with or 
without ligand molecules [47] [48]. Analytical ultracentrifugation is used for quantitatively 
analysing protein molecules in solution. It combines three optical systems, such as 
absorbance, interference and fluorescence, which determine precise sedimentation in real-
time [49].  
 
1.4.2 Crystal Definitions 
 
A protein crystal consists of a regular packing model, known as the lattice model, where all 
the lattice points are in the same environment [50]. A crystallographic unit cell is formed by 
the joining of all lattice points with the highest symmetry, and a protein crystal is formed by 
the association of adjoining three-dimensional unit cells. The parameters of unit cells are 
defined by three vectors (a, b, c) and angles (α, β, γ). The space group of a crystal is the set of 
symmetrical elements of molecules arranged in a unit cell [50] [51]. Different space groups 
or crystal systems from the crystal lattice symmetry exist: triclinic, monoclinic, 
orthorhombic, tetragonal, trigonal, hexagonal and cubic. Several types of lattice centring are 
formed with the translational symmetry in three dimensions [50] [51]. These seven space 
groups and lattice centring lead to fourteen types of lattices: “Bravais lattices” (Figure 1.7). 
Thirty-two point groups symmetry operations used on a protein molecule include rotation 
axes, inversion axes and mirror planes, which are dependent to the external symmetry of a 
crystal. In addition, translation components result in screw axes and glide planes, totalling 
230 possible space groups in a crystal from a Bravais lattice [52]. Protein chirality reduces 
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the number of possible space groups to sixty-five, as it does not permit mirror planes, glide 
planes or inversions [50] – [53]. 
 
 
Figure 1.7. Bravais Lattices in three dimensions. Seven space groups from the crystal lattice symmetry lead 









1.4.3 X-ray diffraction of protein crystal 
 
The crystals are cryocooled by plunging in liquid nitrogen to protect the crystals from 
radiation damage by the emission of very high intensity X-ray waves at the synchrotron.     
X-ray crystallographic data is collected at 100 degrees Kelvin [4] [7] [14]. Alternatively, in-
situ crystallisation can be performed by placing the crystal plates directly into a lower 
intensity of X-ray beam. Prior to cryo-cooling, the crystals are briefly treated with a        
cryo-protectant solution, preventing crystalline ice formation in the drop around the crystal. 
Commonly used cryo-protectant solutions are ethylene glycol or glycerol [4] [7] [14] [43] 
[44].  
In the beam, the crystal is exposed to monochromatic X-ray for a short period of time ranging 
from seconds to minutes depending on the intensity of the X-ray source beam-line, while the 
crystal is being rotated, changing its orientation and diffraction images collected typically 
from 0.1 to 1 degree a time, to collect a complete data set [4] [15] [41]. While most of the    
X-rays pass through the crystal, some X-rays interact with the electrons of the atoms. The 
electrons of the protein crystal’s atoms diffract the X-ray beam into a pattern of scattered 
spots, known as the protein diffraction pattern recorded by the X-ray detector (Figure 1.8) [4] 
[15] [41]. The higher the numbers of electrons present in the atom, the greater the scattering 
power.   
Regular arrangement of atoms in a protein crystal results in a constructive interference of the 
scattered X-ray waves and therefore an accurate diffraction pattern is formed [15] [41]. At 
least one thousand diffraction spots are needed for solving a protein structure from a well-




Figure 1. 8. Example of X-ray diffraction pattern. Cyclophilin A protein has a space group P 32 2 1. X-ray 
diffraction occurs as a result of X-ray wave hitting electrons of atoms within the crystal. The collision causes the 
wave to split and produce a scatter of waves by the electrons. Thus each atom contributes to each reflection 
through the electrons, hence each reflection informs about the atomic arrangements of the protein [4] [15] [41]. 
Data generated from own experiments.  
 
In 1913, Sir William Bragg first investigated single crystal diffraction using monochromatic 
radiation in contrast to von Laue’s earlier work on copper sulphate crystals where the X-ray 
radiation was polychromatic. Sir William Bragg described scattering as reflections from 
crystal “planes” (Figure 1.9) [15]. According to the Bragg’s law, diffraction maxima are only 
observed when the path difference between the planes of the scattered waves is equal to the 




𝒏𝝀 = 𝟐𝒅𝒔𝒊𝒏𝜽 
where  is the radiation wavelength, d is the distance between the two waves,  is the angle 
of reflections and n is an integer.  
 
              
Figure 1.9. Schematic diagram of Bragg’s diffraction equation. Reflected X-rays will be in the same phase 
as the incident X-rays if the path difference between them is equal to an integer (n) of the X-ray wavelength. 
Therefore X-rays will interfere constructively with the electrons from different atoms in the protein crystal [54]. 
Adapted from: http://www.academia.edu/16183346/MLE2101_Lab_Report 
 
1.4.4 X-ray data acquisition and processing 
 
The X-ray data is processed to obtain a reflection file (mtz) using processing softwares such 
as CCP4 package, XDS, Xia2, fast_dp and HKL-200, which extract the relative intensities of 
the diffracted X-ray beam [4].  
Xia2 automatically reduces the macromolecular crystallography (MX) diffraction data and 
determines the success of the diffraction dataset. It processes a complete MX dataset, 
containing multiple sequences of images at one or several wavelengths from images to 
structure with the help of the CCP4 Suite Package [54].  
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These steps are difficult to process during X-ray data collection with the increase in 
throughput of MX beamlines. Therefore, XDS (an independent software written by Wolgang 
Kabsch in Heidelberg), Scala and other tools from the CCP4 Suite Package (Mosflm) process 
the data automatically, while the user collects X-ray data. Synchrotron sources have started to 
have their own MX auto-solving and data processing softwares, e.g. fast_dp at Diamond 
Light Source [4]. “Conventional user interface” can also be implemented to manually input 
further information using natural language. Xia2 process complex sweeps of data (a single 
sequence of images), in comparison to single sweeps of data processed by XDSME, fast_dp 
and RADP, which are scripts to automate the usage of XDS in a beamline [4]. Most of the 
MX datasets are formed of more than one wavelength, consisting of more than one sweep. 
Therefore, all of the data must be scaled and merged together in the same intensities [4]. 
XDS and Scala are series of scripts that can be run on any data processing servers, and they 
convert the diffraction images to mtz reflection files. The mtz files are used for the 
refinement of structure solution in the later stages [4]. The diffraction images are processed in 
the following way:  
i) Indexing the diffraction pattern: positions of the observed reflection spots are 
analysed and the unit-cell vectors are determined. This is where the space group is 
identified [4]. 
ii) Integration of the data: the unit cell model is refined and the experimental 
geometry is integrated using profile-fitting methods. This step measures the 
intensities of all the reflections in the dataset [4].  
iii) Scaling: all the raw integrated intensity data are not always on the same scale and 
are all placed on a common measurement to correct the systematic experimental 
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effects. Softwares such as aimless and scala aim to eliminate the systematic 
differences from the intensities by modelling the experiment. The scaling needs 
the dataset to have the right symmetry assigned and consistent definitions of the a, 
b and c unit cell vectors. In some instances, the shape of the protein could be 
misleading, and therefore could be a higher symmetry than the crystal symmetry 
itself. In these cases, it would be worth repeating the indexing and integration 
steps with the appropriate symmetry again. Unfortunately, the space group can 
only be confirmed and validated once the final structure is fully refined, which is 
quite inconvenient, as it required in the early stages of refinement. Scaling is 
dependent on replication of measurements based on crystal symmetry. So before 
scaling it is recommended to identify the point-group symmetry of the diffraction 
pattern, which can be determined using the Pointless software [4].  
iv) Merging: all the scaled symmetry-related observations data are then averaged in 
each wavelength [4].  
The resolution of the X-ray data is important in the processing of X-ray crystallographic data. 
Resolution in the context of X-ray crystallography can be defined as the total number of 
unique diffraction intensities collected for the given crystal lattice dimensions. High quality 
crystals diffract better, giving a better resolution. The quality of the electron density maps 





1.4.5 Molecular Replacement and Refinement 
 
Protein solution and solving is known as refinement, and is achieved with CCP4 package and 
WinCoot for the molecular graphics (Figure 1.10). The software compare experimental data 
with an existing model of the target protein structure through a process called molecular 
replacement to solve the phase problem [4]. The comparison is useful when solving flexible 
regions in the protein or missing atoms, resulting in negative/poor electron density map [4].  
The model protein is first rotated and translated into the same position as the experimental 
target protein. A Fourier transformation of the model is used to calculate the structure. The 
comparison between the calculated structure or experimental data (Fcalc) and the model 
protein structure or existing data (Fobs) is measured by the refinement (R-factor), 
determining how closely the calculated data matches the observed data. R-factor indicates 
how well the refinement is incorporated within the protein structure [4].  
𝑹𝒄𝒓𝒚𝒔𝒕 =
𝜮𝒉𝒌𝒍 ||𝑭𝒐𝒃𝒔|  − 𝒌 | 𝑭𝒄𝒂𝒍𝒄|| 𝐱 𝟏𝟎𝟎%
𝜮  |𝑭𝒐𝒃𝒔 |
 
The refinement factor is described in percentage (%). The temperature factor (B-factor) 
measures the ordering of protein structure. The lower the temperature factor the higher the 
quality of the protein structure and well-ordered packing [4]. Other factors include the 
Ramachandran plot, bond distances and bond angles, which are monitored throughout the 
refinement process to ensure that the model geometry is in the expected range [4]. 
Isomorphous replacement and multiple wavelength anomalous dispersion are also used to 
determine phases and assign each reflection for a given phase in a diffraction experiment, 





Figure 1. 10. Positive and negative electron density of X-ray crystallography maps of TbrPDEB1 on 
WinCoot.  
A) Green positive densities, corresponding to water molecules, ligands (BTB 01148) or buffer molecules  B) X-
ray crystallographic data shows red negative densities, where atoms are missing or not geometrically correct. 
[4]. Data generated from own experiments.  
The process of protein crystallisation, data acquisition, data refinement and processing are 







Figure 1. 11. The workflow summary for protein structure determination using X-ray crystallography 
[7]. Adapted from: Beat Blattmann and Patrick Sticher (2009) Growing crystals from protein. Science in School 
Spring 11: 30-36  
 
1.4.6 The limitations of X-ray crystallography 
 
X-ray crystallography is dependent on the formation of good quality crystals: only well-
ordered crystals have the potential to diffract to high resolution and produce a clear atomic 
pattern [41]. Technically, X-ray crystallography has been considered as a slow and difficult 
technique because of the task of growing high-quality crystals and optimisation of conditions 
[7]. Crystals are also at high risk of radiation damage, requiring the need for a cryoprotectant 
solution [41] [42]. Crystallisation artefacts could also pose a problem in X-ray 
crystallography. In this case, an artefact is defined as a different protein found in the crystal 
structure, other than the one expected. There are four reasons why artefacts could occur: (i) 
the wrong protein is expressed and purified (or co-purified) instead of the anticipated protein 
of interest. Generally, host proteins from E. coli could be purified during the process of 
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recombinant expression. (ii) the protein of interest is contaminated with an exogenous 
protein, such as DNAse during cell lysis or proteases/thrombin during his-tag cleavage. (iii) 
fusion protein is used to express a target protein, and only the fusion protein is purified and 
crystallised. (iv) human error leading to production of the wrong protein (mislabelling) [42]. 
 
1.5 Nuclear Magnetic Resonance 
 
1.5.1 Principle  
 
NMR Spectroscopy is used to determine the structure of biological proteins [8] [16] [19] - 
[21] [41]. In contrast to X-ray cystallography, NMR proteins are analysed in solution under 
physiological conditions [8] [41]. The protein solution is placed in a strong magnetic field 
and bombarded with radio waves. NMR resonances can be measured and they have a certain 
ppm value relative to a standard. The resonances can be defined as the energy of absorption 
and the intensity of the signal, which is proportional to the strength of the magnetic field. The 
NMR active nuclei absorb electromagnetic radiation at a frequency characteristic of the 
isotope. NMR produces complete spectra of signals, including set of distances between 
atomic nuclei [15] [21] [41], used to determine the model of the protein. Short inter-proton 
distances and torsion angles can also be measured [8]. Therefore, NMR can present various 





NMR also provides structural information of flexible regions and inherently flexible proteins 
[41]. Although it is a relatively rapid technique [19], it cannot provide structural details of 
large proteins (> 60 kDa), due to the presence of overlapping peaks in the spectra and signal 
broadening due to slower tumbling rates [41], and therefore it is only applicable to small to 
medium proteins for complete structural assignment. 
 
1.5.2 Saturation-Transfer Difference NMR  
 
NMR can determine structure and ligand-binding interactions between protein and ligands at 
an atomic level through Saturation-Transfer Difference (STD) NMR. This proton-based 
technique is often utilised as a screening tool to identify compounds that bind to a target 
protein. These “NMR hits” are then usually characterised by X-ray crystallography to give a 
complete picture of the ligand protein interactions at an atomic level. The closer the ligand is 
to the receptor, the stronger the STD signal will be; and therefore that will help to pinpoint 
the responsible areas in the receptor for binding through the Nuclear Overhauser Effect 
(NOE) transfer [55] [56]. The NOE is the process through which the polarisation of a nuclear 
spin is transferred from one nuclear spin population to another magnetic nucleus close in 
space through cross-relaxation using decoupling process or by a selective 180-degree pulse. It 
is commonly used to find out intra- and inter-molecular distances between a protein receptor 
and a ligand molecule [55] [56]. It causes the change in intensity of one nuclear resonance 
when the transitions of another nuclear resonance are affected by irradiation. Decoupling is 
the process by which an irradiation of a signal at a particular resonance frequency can affect 
the coupling of a nucleus to any others within the protein molecule [55] [56]. This effect can 
be accomplished within a timeframe of milliseconds, when the coupling will be all 
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deactivated. Saturation can be defined as the induction of the transitions between the α and β 
states of a proton being equilibrated following its irradiation (Figure 1.12). NOE can be 
quantitatively summarised by the following equation, determining the NOE signal at a given 
nucleus i when nucleus S is saturated [55] [56], 
ηi(S) = (I - I0) / I0 
where I0 corresponds to the normal intensity of a resonance; I corresponds to the intensity 
observed (i) as a result of irradiating another resonance (S) within the same protein molecule 
[57].  
 
Figure 1. 12. The Nuclear Overhauser Effect. An irradiation will cause the spin population of a nucleus X to 
be altered and will be transferred to the magnetic nucleus A. Therefore, X will cause T1 relaxation of A by the 
interaction of their respective magnetic poles, known as dipole-dipole interaction. Dipole interaction is different 
to J coupling interaction, the latter being the polarised interaction between the bonding electrons of a molecule, 
and not through space-effect polarisation. T1 relaxation time can also be referred to spin-lattice relaxation time 
[55]. It measures the time at which the net magnetisation vector reaches its ground level of low energy state [55] 
[56]. When nuclei drop energy levels from high energy to low energy, it is often referred as the loss of energy to 
the surrounding nuclei. The term “spin-lattice” originates from the analyses of solids using NMR in the form of 
lattices [57] [58]. From: http://www.usp.br/massa/2014/qfl2144/pdf/22_Maio_2014.pdf [58]  
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STD-NMR is solely based on the signals of the ligand using small quantities of unlabelled 
proteins, and critically does not require any NMR information about the receptor [59]. This 
technique is used in ligand binding interactions occurring with a membrane-bound receptor, 
as membrane receptors can lose their structures and functionality when removed from their 
lipid environment [56]. This method can also be applied to protein-ligand and protein-peptide 
interactions [60], and can quickly produce data of even complex ligands and complex 
proteins with numerous post-translational modifications [61]. This method is popular in 
pharmaceutical industries, where thousands of compounds and fragments can be screened.  
STD-NMR is the selective irradiation and saturation of the protein by intra-molecular spin-
diffusion, achieved by a 1-Dimensional (1D) NMR experiment for 1-2 seconds, which details 
about the total number of ligand-binding sites in the protein [55] [56] [62]. Then, the ligand is 
added to the protein and the saturation will naturally spread onto the ligand by intermolecular 
saturation transfer. Based on the intensity of the signal in the STD-NMR spectrum of the 
individual protons between the ligand and the protein, the proximity of the ligand’s protons to 
macromolecule’s surface can be deduced according to the NOE [56]. All the non-specific 
binding of the ligand to the protein receptor will be determined. Finally, by subtracting the 
non-specific binding spectrum from the total binding spectrum, the difference spectrum will 
result, which is interpreted as the specific binding of the ligand to the macromolecule [55] 







Figure 1. 13. The concept of Saturation-Transfer Difference. The red coloured sphere represents the area 
responsible for binding, as it is in close contact with the receptor and the signal stays strong. The clear sphere 
represents the area that is not involved in the binding process, and therefore its signal decreases as no STD 
signal takes place.  The green coloured sphere represents no binding; as there is no STD signal occurring. 
However, tight binding can also show no signal [63]. From: Hiraishi N, Tochio N, Kigawa T, Otsuki M, Tagami 
J (2013) Monomer-Collagen interactions studied by Saturation Transfer Difference NMR. Journal of Dental 
Research 92(3):284-8 
 
The techniques are dependent on the ligand’s binding affinity range, which is related to the 
ligand-protein dissociation constant rates (KD and/or IC50). Only ligands with low binding 
affinities (micro-molar µM range) to intermediate binding affinities can be detected using 
these NMR screening methods [63] [64] [65].  
More involved NMR experiment helps one to understand the intimate interaction between 
small molecule ligands and proteins’ receptors, and plot a map called “Group-Epitope 
Mapping” (GEM) [55] [56] [59] [61] [62]. This map would indicate the exact regions in a 
receptor responsible for binding to a particular type of ligands. 
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1.5.3 Advanced NMR Screening Methods 
 
“Structure-Activity-Relationship” (SAR) by NMR technique is characterised as the best 
technique to be employed for proteins smaller than 30 kDa, because it provides detailed 




H TROSY-based screening techniques can be used for larger protein targets; however, 
they require spectral assignment and are highly complex due to the spectral overlap [65] [66].  




N HSQC screening data, the 
conformation of the bound ligand using the NOE transfer through STD-NMR experiments, 
but also the accurate binding docking of the ligand to the protein’s binding site using isotope-
labelled NOESY experiments [65] [66]. NMR can yield even more detailed structural 
information when combined with other computational methods such as 3D database 
searching, virtual screening and structure-based ligand design [65] [66]. 
1.5.4 The development of fragment libraries 
 
NMR is particularly popular technique in the field of fragment screening using ligand-
observed NMR methods, identifying highly selective fragments, especially in cases of 
designing compounds targeting narrow binding pockets [64] [65]. Based on the identity of the 
selected compounds, novel scaffolds are developed in the practice of drug design and 
development [64] [65].  
Introduction of cryo-cooled NMR probes have improved the screening of ligands to a 
particular protein target with increased sensitivity and reduced experiment times. This 
technology enables to screen more than 50 compounds for a same protein target at a time and 
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rapidly identifies positive binding ligands and negative non-binding ligands. Similarly to 
other NMR screening methods, this ligand-based NMR technology requires ligands with low 
to medium affinities [66] [67]. With the advancement of the technology, only small 
concentrations of protein and ligands are needed for a high quality data with increased 
resonance sensitivity, in comparison to the usual high concentrations around 10 mg/mL [66] 
[67]. However, mixtures containing up to 100 compounds for screening can lead to spectral 
overlap. In these cases, the data has to be separately de-convoluted using sophisticated 
software to yield the individual spectra of multiple bound ligands [66] [67].  
The NMR screening technique remains an attractive high-throughput technique for its 
simplicity and its use in wide range of applications, such as protein-protein interactions, 
protein-ligand interactions, and as well as protein-nucleic acid interactions [64] [55]. This 
development is key in recognising a large number of low to medium binding affinity ligands 
to a target protein, assisting in the building of a pharmacore model of the protein’s active site 
[65] [55] [66] - [69].  
 
1.6 Other biophysical techniques in protein structure 
determination 
 
There are several other techniques that can be used for the purpose of mapping protein 
structures and ligand-binding sites but they are much less information rich and provide only 
low resolution data. These include molecular electron microscopy, cryo-electron microscopy, 




1.6.1 Biological Electron Microscopy  
 
It is used for the structural and chemical analysis of large proteins that are sometimes difficult 
to solve by X-ray crystallography or NMR [69] [70]. Electrons are used to visualise the shape 
of individual protein or biological protein complexes in a three-dimensional format [69] [70]. 
Electron diffraction can also be combined to electron microscopy for proteins embedded in 
membranes to obtain a high-resolution three-dimensional data and has the advantage of 
reducing beam damage to the specimen [41] [69]. Electron tomography obtains several views 
of different parts of a protein, which are then assembled to provide an overall three-
dimensional shape [41]. Low resolution electron microscopy envelopes can be combined with 
X-ray crystallography or NMR to obtain more precise structural information about the protein 
and can help validating the findings by complementary approach [41] [69] - [71].  
It is difficult to preserve the biological specimens, due to their aqueous and light elements 
composition, making the diffraction and visualisation very poor [71] [72]. The visualisation 
can slightly be improved with the negative stain technique, which is used to heighten the 
contrast in a sample. However, it still can cause modifications in the protein [71] [72].  
Therefore, electron cryo-microscopy is used instead, where cryoprotectants are used to 
preserve the specimens, such as liquid-nitrogen [70]. Nevertheless, the samples must also be 
kept at low temperatures during the visualisation process on the electron microscopy and the 
beam of electrons must be reduced as much as possible in order to avoid structural damage to 




1.6.2 Mass Spectrometry and Protein Mass Mapping  
 
Mass spectrometry and tandem mass spectrometry are tools used to characterise the structure 
of proteins, and provide information about the elemental composition of protein complexes 
[73] - [77]. Proteins can either be observed directly or in the presence of sequence-specific 
proteolytic enzymes that would chemically modify and segment the protein into fragments. 
The resulting peptides are then analysed with mass spectrometry connected to a computing 
software, where the charged peptides are arranged according their mass [73] [75] [77]. 
Interestingly, protein mass mapping can also be used to determine the quaternary structures 
of proteins complexes, by highlighting the intra-protein structures [73] [76] [77]. Moreover, 
like the other techniques mentioned, it can provide information about protein-protein 
interactions and protein-ligand interactions, elucidating the individual residues and amino 
acids responsible for binding [73] [76] [77]. Electrospray ionisation [73] - [75] [77] and 
affinity chromatography can also be combined with mass spectrometry to monitor protein 
folding [73]. Ionisation has contributed a lot to the improvement of mass spectrometry, as it 
permits one to ionise peptides and small proteins directly, and informs about the molecular 
weight of proteins [74] [75].  
 
1.6.3 Small Angle X-ray Scattering (SAXS)  
 
The main problem of X-ray crystallography is the low like-hood of flexible proteins to form 
crystals. This can be overcome by SAXS, which is a technique used to characterise structures 
in the nanometer range. It is generally applied to the study of membrane proteins and is less 
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time-consuming than other structure-determining techniques. Low resolution techniques can 
be combined with higher resolution techniques to interpret the results [78] [79].  
 
1.7 Aims and Hypotheses 
Although many techniques have been developed and optimised over the past years, as 
described above, further research is still taking place to achieve better biophysical techniques 
[77]. Most structural details of proteins have been so far determined by single methods, 
although combined refinements have also been done in the past [80]. Thus, we also aim to 
combine both X-ray crystallography and NMR to understand about the general structure and 
ligand-binding sites. Our hypothesis is that better structural details and ligand-binding 
interaction topology will be obtained by combining both methods.  
In order to test this methodology, a number of “model” proteins used were Cyclophilin A 
(CypA) (18 kDa), the catalytic domain of Phosphodiesterase B1 expressed from 
Trypanosome brucei (TBrPDEB1) (37 kDa) and the catalytic domain of human 
Bromodomain-4 BD1 (BRD4-BD1) (15 kDa), which are well characterised protein systems 
by X-ray crystallography. These proteins will be the starting proteins of the thesis.  
This combined technique could serve as a tool for protein structure determination and 
ultimately drug discovery, as accurate information about the ligand- binding sites would be 
attained very precisely and quickly, even when the crystal structure is not available. 









2.1  Materials 
 
2.1.1  Chemicals 
 
Most of the chemicals and antibiotics used in this study were purchased from Sigma-Aldrich 
Ltd. Other materials were obtained from different other suppliers as follows: Agar, Agarose 
and IPTG from Melford Laboratories Ltd, NaCl, tris-HCl, 100% (v/v) glycerol and EDTA 
from Fisher Scientific Ltd, 0.2 μM Minisart single use syringe filters from Sartorial Epsom 
Ltd, Genejet Mini-Prep Kit, Genejet Gel Extraction Kit, NuPage SDS-PAGE gels, One Shot 
TOP10 chemically competent cells and SyBr Safe Stain from Life Technologies, T7 express 
competent cells from New England Biolabs, Precision Plus Protein
TM
 Prestained Marker and 
Coomassie Brilliant Blue R 250  from Bio-Rad, PCR Reagents (Q5 Reaction Buffer, dNTP 
mix, 100 bp DNA ladder and dye) from Promega, EDTA-protease free tablets from Roche, 
thrombin and TEV from Abcam, Hampton 24-well plates, micro-bridges, Polyethylene 
Glycol 3350 for X-ray crystallography from Hampton Research, X-ray crystallography 
coverslips from Molecular Dimensions, concentrators from Corning Ltd, NAP columns and 





N ammonium sulfate, D2O and D6-DMSO from Goss Scientific, 







2.1.2  Bacterial Plasmids 
 
Table 2. 1. Bacterial Plasmids 
 
Plasmids were provided by Charles River Early Discovery Laboratory, Ingram Building, 
Giles Lane, Canterbury, Kent, CT2 7NZ; and Ke’s Lab, Huanchen Wang, The University of 
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2.1.3  Media and solutions for bacterial work 
 
Luria-Bertani (LB) broth: - Tryptone                       10 g  
                                          - Yeast extract                   5 g  
                                          - NaCl                                5g  
 
Made up to 1 L with dH2O and autoclaved.  
 
Luria-Bertani (LB) agar: - Tryptone                         10 g  
                                         - Yeast extract                    5 g  
                                         - NaCl                                5 g  
                                         - Bacterial Agar               16 g  
 
Made up to 1 L with dH2O and autoclaved. Antibiotics were added at a concentration of     
100 μg/mL per plate.  
 
2 xYT broth: - Tryptone                       16 g  
                      - Yeast extract                 10 g  
                      - NaCl                               5 g  
                      - Glucose                         0.4 %  
 




2 xYT agar:   - Tryptone                       16 g  
                      - Yeast extract                 10 g  
                      - NaCl                               5 g  
                      - Glucose                         0.4 %  
                      - Bacterial Agar               16 g  
Made up to 1 L with dH2O and autoclaved. Antibiotics were added at a concentration of    
100 μg/mL per plate. 
Minimal Media broth: 
Component (stock 
concentration) 
     Stock concentration Working concentration Sterilisation method 
(
15
NH4)2SO4  (x 50) 30 g/L 0.6 g/L Filter 
 
PO4 / NaCl  (x 10) 
68 g/L Na2HPO4 
30 g/L KH2PO4 
5 g/L   NaCl 
6.8 g/L Na2HPO4 
3.0 g/L KH2PO4 
0.5 g/L   NaCl 
 
Autoclave 




EDTA Trace   
(x 100) 
10 g/L EDTA 
3.2 g/L MnCl2 
1 g/L FeCl3 
0.1 g/L ZnCl2 
20 mg/L CuCl2 
20 mg/L CoCl2 
20 mg/L H3BO3 
0.1 g/L EDTA 
32 mg/L MnCl2 
10 mg/L FeCl3 
1 mg/L ZnCl2 
0.2 mg/L CuCl2 
0.2 mg/L CoCl2 





MgSO4  (x 1000) 246 g/L 0.246 g/L Filter 
Cacl2  (x 1000) 44.1 g/L 44.1 mg/L Filter 
Biotin (x 1000) 1 g/L 1 mg/L Filter 





150 g/L 3 g/L Filter 
MilliQ H2O - - Autoclave 
Antibiotic As required As required Filter 
 
Table 2. 2. Minimal Media Components 
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Super Optimal Broth (SOB):  - Tryptone                       10 g  
                                                - Yeast extract                   5 g  
                                                - NaCl                           0.25g  
                                                - 250 mM KCl                5 mL  
 
Made up to 500 mL with dH2O and autoclaved.  
Before using the SOB, 5 mL of 2 M sterile MgCl2 were added. SOB was usually stored 
without the addition of MgCl2.  
 
Super Optimal Medium (SOC): - Tryptone                       20 g  
                                                   - Yeast extract                   5 g  
                                                   - NaCl                             0.5g  
                                                   - 250 mM KCl           0.186 g  
 
Made up to 1 L with dH2O and autoclaved.  
Just before using the SOC, 10 mL of 1 M sterile MgCl2 and 20 mL of 1 M filter-sterilised 











Antibiotic Stock concentration Working concentration 
Ampicillin 100 mg/mL 150 μg/mL 
Carbenicillin 100 mg/L 150 μg/mL 
Kanamycin 30 mg/mL 30 μg/mL 
 




Additive Stock concentration Working concentration 
Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) 
1 M 1 mM 
MgCl2 2 M 20 mM 
Glucose 1 M 20 mM 
 
Table 2. 4. List of additives  
2.1.4  Media and solutions for DNA work 
1 x TBE Buffer: - tris Base                          10.8 g  
                           - Boric Acid                         5.5 g  
                           - 0.5 M EDTA  pH 8.0         4 mL  
 
Made up to 1 L with dH2O.  
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 1 % (w/v) Agarose: - Agarose                          1 g  
 
Made up to 100 mL with 1 x TBE buffer, and dissolved by heating in the microwave. 
 








Figure 2. 1. 10 μL Hyperladder separated on a 1 % (w/v) agarose gel  
 
6 x DNA Loading Buffer: - Sucrose                             4 g  
                                          - Bromophenol Blue       25 mg  
                           





2.1.5  Solutions for protein work 
 
2.1.5.1  Solutions for Nickel Affinity Chromatography 
 
His Charge Buffer: -  0.1 M NiSO4                          0.15 g 
Made up to 10 mL with dH2O.  
 
Nickel Strip Buffer: - 20 mM NaH2PO4  pH 7.4  
                                                 - 0.5 M NaCl 
                                 - 50 mM EDTA 
 
Nickel Chromatography Buffer A (CypA): - 50 mM tris  pH 7.8  
                                                                                                       - 300 mM NaCl 
                                                                     - 30 mM imidazole 
                                                                     - 1 mM beta-mercaptoethanol 
 
Nickel Chromatography Elution Buffer B (CypA): - 50 mM tris  pH 7.8  
                                                                                                                    - 300 mM NaCl 
                                                                                  - 530 mM imidazole 




Nickel Chromatography Buffer A (tbrPDEB1): - 20 mM tris  pH 8.0  
                                                                                                              - 300 mM NaCl 
                                                                            - 10 mM imidazole 
                                                                            - 10 % (v/v) glycerol 
                                                                            - 1 mM beta-mercaptoethanol 
 
Nickel Chromatography Elution Buffer B (tbrPDEB1): - 20 mM tris  pH 8.0  
                                                                                                                           - 300 mM NaCl 
                                                                                          - 260 mM imidazole                                                                                        
                                                                                         - 10 % (v/v) glycerol 
                                                                                         - 1 mM beta-mercaptoethanol 
 
Nickel Chromatography Buffer A (BRD4): - 50 mM Hepes  pH 7.5  
                                                                                                       - 500 mM NaCl 
                                                                     - 10 mM imidazole 
                                                                     - 5 % (v/v) glycerol 
 
Nickel Chromatography Elution Buffer B (BRD4): - 50 mM Hepes  pH 7.5  
                                                                                                                    - 500 mM NaCl 
                                                                                  - 250 mM imidazole 
                                                                                  - 5 % (v/v) glycerol 
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2.1.5.2  Solutions for Desalting 
 
Desalt Buffer (CypA): - 25 mM NaH2PO4  pH 6.5  
                                                       - 0.5 mM DTT 
                                                                                  
Desalt Buffer (tbrPDEB1): - 20 mM tris  pH 7.5  
                                                                  - 100 mM NaCl 
                                            - 5 % (v/v) glycerol 
                                            - 1 mM beta-mercaptoethanol 
 
2.1.5.3  Solutions for ion-exchange chromatography 
 
IEX Buffer A (CypA): - 50 mM Hepes  pH 6.8  
                                                       - 1 mM DTT 
                                     - 2.5 mM EDTA 
                                     - 100 μM phenylmethanesulfonyl fluoride 
IEX Elution Buffer B (CypA): - 50 mM Hepes  pH 6.8  
                                                                          - 1 mM DTT 
                                                 - 2.5 mM EDTA 
                                                 - 400 mM NaCl 
                                                 - 100 μM phenylmethanesulfonyl fluoride 
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IEX Buffer A (tbrPDEB1): - 20 mM tris  pH 7.5  
                                                                  - 100 mM NaCl 
                                            - 5 % (v/v) glycerol 
                                            - 1 mM beta-mercaptoethanol 
                                          
IEX Elution Buffer B (tbrPDEB1): - 20 mM tris  pH 7.5  
                                                                                     - 1 M NaCl 
                                                         - 5 % (v/v) glycerol 
                                                         - 1 mM beta-mercaptoethanol 
 
2.1.5.4  Solutions for gel filtration chromatography 
 
GF Buffer (CypA): - 25 mM tris  pH 7.5  
                                                - 100 mM NaCl 
                                - 0.5 mM DTT 
                                - 0.5 mM EDTA 
 
GF Buffer (TbrPDEB1): - 20 mM tris  pH 7.5  
                                                           - 50 mM NaCl 
                                        - 5 % (v/v) glycerol 
                                        - 1 mM beta-mercaptoethanol 
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GF Buffer (BRD4): - 10 mM Hepes  pH 7.5  
                                                 - 50 mM NaCl 
                                 - 5 % (v/v) glycerol 
 
For NMR experiments, the protein was always eluted in the following buffer: 
 
GF Buffer: - 25 mM NaH2PO4  pH 6.5  
                            - 100 mM NaCl 
                   - 1 mM DTT 
 
2.1.5.5  Solutions for SDS gels 
 
Coomassie Stain: - Coomassie Brilliant Blue R250            1 g  
                             - Methanol                                             50 % (v/v) 
                             - Glacial Acetic Acid                             10 %  
 
Made up to 1 L with dH2O. The solution was stirred for 3-4 hours and then filter through 
Watman filter paper.  
 
Destain Buffer:    - Methanol                                             50 % (v/v) 
                             - Glacial Acetic Acid                             40 %  
 
Made up to 1 L with dH2O. 
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Figure 2. 2. 10 μL Precision Plus Protein All Blue Stain applied to SDS-Page 
4-12% Bis-tris gel from Promega  
 
                                            
2.1.6  Media and solutions for X-ray crystallography work 
 
All solutions, if not purchased, were filtered through a 0.2 μM filter unit prior to use. 
















35% - 41% Ammonium 
Sulfate (stock of 66%), 
0.1 M Tris-HCl pH 7.2 - 
8.5 (stock of 1 M).  
14% - 24% PEG 3350 
(stock of 50%), 0.4 M 
Sodium Formate (stock 
of 5 M), 0.3 M Guanidine 
Chloride (stock of 5 M), 
0.1 M MES pH 6.5 (stock 
of 1 M).  
 
3.5 M - 5 M Sodium 
Formate (stock of 5 M). 
Reservoir Volume 500 μL 1,000 μL 500 μL 
Drop Volume 2 μL 2 μL 2 μL 
Protein Concentration 16 mg/mL 10 mg/mL 10 mg/mL 
Incubation 
Temperature 




40 % Ammonium 
Sulfate, 0.1 M tris-HCl 
pH 7.2 - 8.5, 15 % 
glycerol 
16 % PEG 3350, 0.4 M 
Sodium Formate, 0.3 M 
Guanidine Chloride, 0.1 
M MES pH 6.5, 20% 
Ethylene Glycol 
4 M Sodium Formate, 
20% Ethylene Glycol 
 
 
Table 2. 5. The crystallisation conditions for each protein  
 
Cyclophilin A: Necessary information for determining the protein concentration using 
nanodrop: Extinction coefficient (ε) is 8,610 M-1cm-1 ; MW=18,000 Da ;                                 
A = ε x concentration x path length 
Phosphodiesterase B1: Necessary information for determining the protein concentration using 
nanodrop: Extinction coefficient (ε) is 14,150 M-1cm-1 ; MW=37,000 Da 
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Bromodomain 4:  Necessary information for determining the protein concentration using 
nanodrop: Extinction coefficient (ε) is 26,270 M-1cm-1; MW=15,000 Da 
 
2.1.7  Ligands  
 
All the ligands used in this study have been provided by different suppliers, which are 
summarised in the following sub-sections. 
 
2.1.7.1  Ligands for Cyclophilin A 
 
Ligands for Cyclophilin have been originally obtained from Sigma-Aldrich Ltd, but have 
been kindly provided by Dr Michelle Rowe. All the compounds were prepared at a stock 
concentration of 30 mM and stored at room temperature. All ligands were dissolved and 












































                                                                                                                                                              
Table 2. 6. List of CypA ligands 
 
2.1.7.2  Ligands for Phosphodiesterase B1 
 
Ligands for TbrPDEB1 have been provided by VU Free University of Amsterdam as part of 
their collaboration. Stocks have been prepared at variable concentrations. All ligands were 






Table 2. 7. List of TbrPDEB1 ligands 
 
2.1.7.3  Ligands for Bromodomain 4 
 
Ligands for Bromodomain 4 have been provided by Maybridge Ltd (Cambridge) as part of 
their collaboration. All the ligands have been prepared at a stock concentration of 100 mM 
























































































































2.2  Microbiological Methodology 
 
2.2.1  Sterilisation Methods 
 
Unless stated otherwise, all the media and buffers used for microbiological purposes were 
sterilised by autoclaving at 121 °C, 1 bar pressure for 15 minutes. Substances that were 
sensitive to high temperatures were sterilised using 0.2 μM Minisart single use syringe filters.  
 
2.2.2  Preparation of E. coli Competent Cells 
 
A sterile loop was used to scrape off a portion from a commercial aliquot of T7 express 
competent cells and were streaked onto an LB agar plate without any antibiotic resistance, 
and incubated at 37 °C overnight. The next day, a 50 mL SOB media starter culture was 
inoculated from a single colony without antibiotic. The culture was incubated at 37 °C with   
~ 200 rpm shaking until an OD600 of 0.5. The cells were harvested at 3,000 rpm (The 
Beckman SX4750A Centrifuge with an Allegra X-15R rotor) for 15 minutes at 4 °C, and the 
pellet was resuspended in 25 mL of ice-cold 50mM CaCl2. The cells were left on ice for       
30 minutes and centrifuged again at 3,000 rpm (The Beckman SX4750A Centrifuge with an 
Allegra X-15R rotor) for 15 minutes at 4 °C. The pellet was resuspended in 2mL of ice-cold 
50 mM CaCl2 containing 15% (v/v) sterile glycerol. The cells were rapidly aliquoted into     
50 μL samples and stored at -80 °C.  
77 
 
2.2.3  Transformation of E. coli Competent Cells  
 
One aliquot of competent cells was defrosted on ice for 10 minutes and 1 μL of plasmid DNA 
was added, and the cells were incubated on ice for a further 30 minutes, heat-shock was 
performed in the water-bath at 42 °C for 1 minute. The cells mixture was then kept on ice 
again for 2 minutes before the addition of 300 μL of SOC media. Incubation at 37 °C in a 
dry-block for 60 minutes was done and the cells were then plated on LB-agar containing the 
appropriate antibiotics and incubated at 37 °C overnight. 
 
2.2.4  Preparation of glycerol stocks 
 
For the purpose of long-term storage of bacterial cells, glycerol stocks were prepared. Just 
before the induction step in the protein production bacterial expression protocol (c.f.: 2.3.1),  
1 mL culture sample was collected. The 1mL pre-induction culture volume was transferred 
into 100 μL aliquots in cryotubes. Ice-cold sterile glycerol was added to the aliquots to a final 
concentration of 10% (v/v). The aliquots were stored in ice for 30 minutes and frozen at         
-80 °C. 
2.2.5  Inoculation of LB starter cultures from glycerol stocks 
 
100 μL of fully thawed glycerol stock was added to an LB medium containing the 
appropriate antibiotic. The culture was incubated overnight at 37 °C shaking at ~ 200 rpm.  
78 
 
2.2.6  Isolation of plasmid DNA 
 
Plasmids were isolated from 1-5mL overnight E.coli culture in LB medium using a GeneJet 
Spin Mini-Prep Kit. The DNA plasmid was isolated following the manufacturer’s 
instructions. The concentration of the nucleic acid was measured on the nano-drop (BioDrop 
Ltd) using the elution buffer as the nano drop blank solution. Plasmids were stored at -20 °C.  
 
2.3  Recombinant Protein Overproduction 
 
2.3.1  Production of recombinant protein of a pET in T7 express competent cells 
in enriched culture medium  
 
A starter culture was prepared by inoculating 25 mL LB medium supplemented with 
appropriate antibiotics with a single colony. The starter culture was incubated at 37°C 
shaking at 200 rpm for 2-3 hours and used to inoculate the main cultures of 1 L LB medium 
supplemented with appropriate antibiotics. The main culture was incubated at 37 °C shaking 
at 200 rpm until an OD600 of ~ 0.6 was reached. The culture was moved at 20 °C with 
shaking at 200 rpm until OD600 of 0.85 was reached. 500 μL of culture pre-induction sample 
was taken and stored at -20 °C until use. 1 mM of IPTG was added to induce recombinant 
protein overproduction at 20 °C at 160 rpm overnight.  
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On Day 2, another 500 μL of culture post-induction sample was taken and was stored at         
-20 °C until use. The main culture was harvested by centrifugation at 6,500 rpm (Beckman 
JLA-16.250) for 20 minutes. The supernatant was discarded; pellet was weighed and frozen 
at -80 °C until needed. 
 
2.3.2  Production of recombinant protein of a pET in T7 express competent cells 
in minimal medium for the purpose of isotopic labelling 
 






C), recombinant fusion protein, the 
minimal medium recipe described in table 2.1 was used. Phosphate, Na2SO4 and EDTA trace 
elements were all added in an Erlenmeyer flask that was five times the culture volume 
required and sterilised by autoclaving. All other components were prepared separately as 
stock solutions and sterilised using 0.2 μM Minisart single use syringe filters and added 
aseptically to the flask prior to inoculation.  
A single colony was picked from a fresh LB plate and used to inoculate 2 x 50 mL minimal 
medium starter cultures supplemented with the appropriate antibiotic. 
The starter cultures were grown overnight at 37 °C shaking at 200 rpm overnight until OD600 
reached 0.6 - 1.0. The cells were sedimented in a benchtop-centrifuge at 3,500 rpm (The 
Beckman SX4750A Centrifuge with an Allegra X-15R rotor) for 15 mins and the cells pellet 
was resuspended in 4 mL of minimal medium without antibiotic. The 4 mL were used to 
inoculate 3 x 400 mL main cultures supplemented with the appropriate antibiotic. The 
cultures were grown at 37 °C shaking at 200 rpm until OD600 of 0.6 was reached. From this 
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stage onwards, protein production in minimal medium was carried out the same as described 
for protein production in enriched medium (c.f.: 2.3.1).  
 
2.4  Molecular Biology Methodology 
 
2.4.1  Design of primers 
 
A list of all primers designed for amplification purposes in this study can be found in Table 













TTGTCCACAGTCAGCAATGGTGAT 3′  
XhoI 
 
Table 2. 9. List of primers. The restriction sites are underlined in each of the sequences. The segment of the 







2.4.2  Polymerase-Chain Reaction (PCR) 
 
All PCR reactions were carried out in a Techne 3Prime Thermal Cycler using the Q5 High-
Fidelity DNA Polymerase in sterile Eppendorf tubes.  
The standard PCR reactions performed are described in Table 2.10. The reactions were set up 
on ice.  
 μL  
10 x Q5 Reaction Buffer 5 
dsDNA template (clone) 0.2 
oligonucleotide primer concentration, forward 1 
oligonucleotide primer concentration, reverse 1 
dNTP mix (10 mM) 1 
nuclease-free water 41 
 
Table 2. 10. Standard PCR reaction 
Total reaction 
volume was 50 
μL.Step 
Temperature (°C) Duration (minutes) Number of cycles Function 
1 95 1 30 Denaturation 
2 55 1 30 Annealing 
3 72 1 30 Elongation  
4 4 HOLD HOLD HOLD 
 
Table 2. 11. Standard temperature protocol of PCR reaction 
The final PCR product was analysed by agarose gel electrophoresis (c.f.: 2.4.3). 
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2.4.3  DNA Gel Electrophoresis 
 
2.4.3.1  DNA Agarose Gel 
 
The size of DNA fragments to be separated determines the percentage of agarose gel to be 
used [160]. In this study, 1% (w/v) agarose gel were used. An agarose gel was prepared in     
1 x TBE buffer with the addition of SyBr Safe (10 μL). DNA loading dye buffer: sample was 
prepared on the basis of 1:10 ratio. A maximum of  20 μL sample was loaded in each well of 
the agarose gel, and the gel was run at 80 volts for ~ 1 hour.  
 
2.4.3.2  Visualisation of DNA 
 
DNA was stained with the SyBr Safe dye. It intercalates between the base pairs of DNA. 
SyBr Safe works by absorbing the UV blue light at 509 nm and emitting green light at       
524 nm [161]. The DNA was observed after placing the stained DNA gel onto a 
transilluminator and photographed through a red filter.  
 
2.4.4  Extraction and purification of DNA fragments from agarose gels 
 
Once the DNA band at the desired size was identified, the DNA fragment was excised using 
a clean scalpel razor blade. The DNA was then extracted and purified from the excised gel 
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slice using the GeneJet Gel Extraction Kit according to the manufacturer’s instructions. The 
concentration of DNA was assessed using nano drop measurements using the elution buffer 
as the nano drop blank solution.  
 
2.4.5  Preparation of restriction digests 
 
All reactions were carried out in sterile Eppendorf tubes and performed as outlined in Table 
2.12. The corresponding buffers for the enzymes were used as directed by New England 
BioLabs information. The digested reactions were gently mixed by pipetting and centrifuged 
for 1 minute at low speed. The reactions were incubated at 37 °C for 2 hours.  
 
 
Table 2. 12. Standard Insert/Vector Digestion Protocol.  (Total reaction volume was 50 μL). 
 
2.4.6  DNA Ligation 
 
All DNA ligation reactions were carried out in sterile Eppendorf tubes following the standard 
ligation protocol as described in Table 2.13. The ligation reaction was gently mixed by 
pipetting and centrifuged for 1 minute at low speed. The reaction was incubated at 20 °C 
 Insert Preparation (μL) Vector Preparation (μL)  
Mini-prepped DNA plasmid 20 5 
10 x Buffer 5 3 
N-terminal restriction enzyme 2 1 
C-terminal restriction enzyme 2 1 
nuclease-free water 21 20 
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overnight. The ligation mix was then incubated on the following day at 4 °C for three nights, 
instead of 3 hours (this was determined after several rounds of optimisation experiments). For 
the purpose of cloning the digested DNA insert into the vector, the ligation reaction was 
transformed by chemically competent cells One-Shot TOP10. 5 μL of ligation mix was added 






Table 2. 13. Standard Ligation Protocol. Total reaction volume was 10 μL.  
 
2.4.7  Mini Prep 
 
Few colonies deriving from the transformation using chemically competent cells were 
randomLy picked. It was crucial to carefully select colonies that were not close to each other 
on the LB plate. The selected colonies were individually streaked on four different LB agar 
plate with the same antibiotic resistance from which they were picked up in order to have 
replicates of the selected colonies as back-up, and immediately inoculated into 3 mL of LB 
medium with antibiotic. The four replica LB plates were incubated at 37°C overnight. The 
LB cultures were incubated at 37 °C with shaking at ~ 200 rpm overnight.  
 μL  
Insert DNA Digest 6 
Vector DNA Digest 2 
10 x T4 DNA Ligase Buffer 1 
DNA Ligase 1 
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LB cultures were grown overnight and a mini-prep was performed to isolate the plasmids. 
The plasmids were generated using the exact same protocol as highlighted in section 2.2.7. 
The concentrations of the purified DNA plasmids were assessed by nano drop measurements 
using the elution buffer as the nano drop blank solution.   
 
2.4.8  Identification of the colony containing both vector and insert DNA 
 
2.4.8.1  Digestion by Insert 
Each individual mini prepped plasmid was digested again with restriction enzymes. All the 







Table 2. 14. Standard Digestion by Insert Protocol.  Total reaction volume was 50 μL 
 
Each of the reactions were gently mixed by pipetting and centrifuged for 1 minute at low 
speed. The reactions were incubated at 37 °C for 2 hours. 
 μL  
Mini-prepped DNA plasmid 20 
10 x Buffer 5 
N-terminal restriction enzyme 2.5 
C-terminal restriction enzyme 2.5 




2.4.8.2  Sequencing  
 
DNA sequences were verified by sequencing carried out by Beckman Coulter Genomics 
(Hope End, Takeley, Essex CM22 6TA) [151] with plasmids at a concentration of 100 ng/μL.  
 
2.5  Biochemical Methodology 
 
2.5.1  Protein Purification Methods 
 
All the purifications were generally performed at 4 °C, but certain purification preparations 
were also done at room temperature at 20 °C. The purifications were undertaken on the Äkta 
protein purification system.  
Pellets were defrosted and resuspended in the appropriate 10 x the weight of the wet-cell 
pellet binding buffer containing EDTA-free protease tablets. The cells were disrupted at      
25 kpsi 4°C using the Constant Cell Disruption System. The lysate was centrifuged at    
18,000 rpm (The Centrifuge Beckman with JA-25.50 rotor) at 4 °C for 30 minutes. The 
resulting pellets were discarded and the supernatant containing the protein. Buffers used 




2.5.1.1  Immobilised Nickel Affinity Chromatography (IMAC) 
 
IMAC is a form of affinity chromatography based on the interaction between divalent metal 










) and specific polyhistidine 
amino acid chains fused to the recombinant protein. This strong interaction is achieved by the 
donor groups on the histidine imidazole ring bonding with the immobilised metal matrix [81].  
IMAC was either performed on an Äkta system using 5 mL HiTrap Chelating Columns (GE 
Healthcare) or by gravity flow chromatography with NiNTA matrix for very small volume 
preparations.  
The column was equilibrated with 5-10 column volumes (CV) (Nickel Chromatography 
Buffer A) at 2 mL/min flow-rate and the supernatant resulting from section 2.5.1 was loaded 
onto the 5 mL HisTrap Chelating Column at 1 mL/min. After removal of non-specifically 
binding proteins with washes of 5 CV Buffer A at 2 mL/min, the recombinant protein of 
interest was eluted using a buffer containing of a high concentration of imidazole (Nickel 
Chromatography Buffer B) at 5 mL/min. The elution was monitored at A280 nm.  
 
2.5.1.2  Buffer-Exchange columns 
 
The presence of high concentrations of imidazole or salt can destabilise the protein [82]. 
Therefore, proteins eluted from IMAC were desalted by buffer exchange through a          
26/10 HiPrep Desalting Column into desalt buffers [82]. The column was equilibrated with   
5 CV of mobile phase buffer at 5 mL/min flow-rate. 
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2.5.1.3  Ion-Exchange Chromatography (IEC) 
 
Another common method used for purifying protein molecules is IEC, which purifies protein 
molecules on the basis of their ionic charge [83]. There are two different types of ion-
exchange chromatography: cation-exchange chromatography consisting of a negatively-
charged matrix and attracting positively charged molecules; anion-exchange chromatography 
containing a positively charged matrix and attracting negatively charged molecules [83]. The 
number and position of the ionic groups on the sample molecule and on the functional ionic 
group on the matrix determines the strength of the ionic interaction [83].  
IEX was either performed on an Äkta system using 5 mL HiTrap Chelating Columns or 
gravity flow chromatography using DEAE Sepharose matrix for very small volumes 
preparations. The buffers used vary according to the protein’s pI or the protein’s acid 
dissociation constant (pKa). The pH of the mobile phase buffer should be between the pI or 
pKa of the charged molecule and the pKa of the charged group on the column matrix, and it 
generally must be with low salt concentrations, as salt has ionic strength. In this study, most 
of the ion-exchange chromatography was undertaken using weak anion-exchanger.  
The column was equilibrated with 5-10 CV of IEX Buffer A at 2 mL/min. The protein 
sample was then loaded onto the column at 1 mL/min. After loading, the column was washed 
with 5-10 CV of IEX Buffer A until baseline stable at 2 mL/min flow-rate. The protein was 
eluted by increasing the salt concentration in the IEX Buffer B using a linear gradient at        
5 mL/min. Molecules with weakest ionic interaction start to elute first, and the stronger 




2.5.1.4  Heparin Chromatography 
 
Heparins are known as linear polysaccharides that are negatively charged. They bind to a 
variety of biomolecules such as enzymes, serine protease inhibitors, growth factors, 
extracellular matrix proteins, DNA binding proteins and hormone receptors. Heparins are 
commonly used in chromatography as an ion-exchanger with high charge density [84]. For 
the purpose of heparin chromatography, 1 mL HiTrap Heparin Column was used. Heparin 
columns act the same way as cation exchanger and were used exactly in the same way, as 
described in section 2.5.1.3. 
 
2.5.1.5  Gel Filtration Chromatography 
 
Gel Filtration, also known as size-exclusion chromatography, is a type of chromatography 
separating proteins, peptides and oligonucleotides on the basis of size. The gel filtration 
column is made up of a bed of porous beads, through which the molecules pass at different 
speeds [85] [86]. Smaller molecules would diffuse into the pores of the beads, and would get 
retarded, whereas larger molecules enter less or completely avoid the beads and get eluted 
first. Gel filtration is usually the last step of any purification process, as it also serves as a 
method of buffer exchange [85] [86].                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
Gel filtration chromatography was undertaken using Superdex S75 16/60 and HiPrep 
Sephacryl S300 26/60 columns. The efficiency of the columns was determined by the 
calibration of the columns using Gel Filtration Markers Kit for Protein Molecular Weights 
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29,000 - 700,000 Da. The kit consists of Carbonic Anhydrase (29 kDa), Albumin (66 kDa), 
Alcohol Dehydrogenase (150 kDa), beta-amylase (200 kDa), Apoferritin (443 kDa), 
Thyroglobulin (669 kDa) and Blue Dextran (2,000 kDa). The calibration of the column was 
undertaken following the instructions on the kit’s manual.  
Columns were equilibrated with 1-2 CV of mobile phase buffer (Buffer A) at 2 mL/min. The 
protein sample was concentrated using 10 K MW cut-off Centricon to 2 mL and loaded onto 
the column. The elution was collected in 4 mL fractions at 1 mL/min. 
 
2.5.1.6  Affinity tag removal 
 
For X-ray crystallography purposes, the polyhistidine tag was removed by incubating the 
eluted protein with thrombin or TEV (stock 2 units/μL) on the basis of 5 units/mL and 2 
units/mL respectively at 4°C overnight. For NMR purposes, the tag was usually not cleaved.  
 
2.5.2  Purity of protein samples 
 
Purity was assessed by SDS PAGE gel. SDS-PAGE is a powerful technique that separates 
proteins on the basis of their size by electrophoresis by using a discontinuous polyacrylamide 
gel and sodium dodecyl sulfate (SDS) as a denaturation method for the proteins [87] [88].  
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4 x loading dye sample (LDS) was added to the protein sample. The samples were boiled at      
95 °C for 15 minutes and 10 μL of the sample were loaded onto the NuPage SDS gel, along 
with a protein marker with defined molecular weights. The gel was run at 200 volts,           
120 amps for 30 minutes. The SDS-PAGE gel was stained on Coomassie Blue for 1 hour and 
30 minutes, and destained using destain buffer and distilled water until the bands were 
visible.  
Figure 2. 3. Chart of Bradford Assay 
 
Bradford Assay was performed to determine the presence of proteins eluting from gravity-















Protein Concentration (mg/mL) 
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nano-drop measurement. Dilution series were prepared with a standard of different 
concentrations of bovine serum albumin (BSA) and Bradford reagent, from which protein 
concentration of samples were determined.  
 
2.5.3  Crystallisation 
 
Crystallisation experiments were performed using the hanging drop or sitting drop vapour 
diffusion methods [144]. They were usually incubated at a constant temperature of either       
4 °C or 20 °C in a crystal growth incubator (Molecular Dimensions) for a day or until growth 
of crystal was observed. Initial conditions were screened against additive screens Hampton 
Research I (HR2-138) and II (HR2-428) on the automated Mosquito system TTP LabTech.  
Crystallisation conditions are listed in Table 2.5.  
 
2.5.3.1  Hanging Drop Crystallisation 
 
Hanging Drop experiments were carried out in 24 well Hampton plates. Each experiment 
involved siliconizing a cover slip and pipetting onto it a 2 μL drop consisting of an equal 
mixture of protein solution and reservoir precipitant solution. For optimisation purposes, 
different drop sizes, as well as protein to reservoir ratios were varied. Hanging drops were 





2.5.3.2  Sitting Drop Crystallisation 
 
Sitting Drop experiments were carried out in 96 well Greiner plates.  In each well of the 
plate, 2 μL drop consisting of an equal mixture of protein solution and reservoir precipitant 
solution were tried. For optimisation purposes, different drop size with different proportions 
were tried. Sitting drops were equilibrated against 320 μL of reservoir solution. The plate was 
sealed with plastic film (Hampton Research) [144].  
 
2.5.3.3  Soaking of protein crystals with ligands 
 
A common method of preparing a protein-ligand complex is to soak a protein crystal in 
reservoir solution containing an excess of ligand. Generally a ratio of 1:1 protein:ligand is 
initiated depending on the binding efficiency and affinity of the ligand. The ligand 
concentration should ideally be 10-1000 x the dissociation constant (KD) of the ligand [162].  
A separate crystallisation plate was prepared by adding micro-bridges to the wells that 
contained 1 mL of the reservoir solution. 20 μL were added to the micro-bridge and crystals 
were quickly transferred into the drop using loops. Ligand was then added to the micro-
bridge drop, and then sealed with a coverslip. The drop was regularly checked to see if the 
ligand was well dissolved and the crystals were still in intact condition. Soaks were incubated 




2.5.3.4  Co-crystallisation of protein with ligands 
 
In cases where protein-ligand complexes could not be obtained through soaking experiments, 
co-crystallisation experiments were set up. Here the protein is incubated with ligand before 
crystallisation [162] [163].  
For co-crystallisation experiments, a ratio of 1:2 protein:ligand ratio was adopted. The protein 
sample was initially centrifuged at low speed for 5 minutes at 4 °C to remove any 
precipitants. Ligand was added to the protein and the mixture was incubated on ice for          
30 minutes. The mixture was spun again briefly at low speed on the microfuge at 4 °C, and 
the crystallisation tray was prepared as described in section 2.5.3.1.  
 
2.5.3.5  Crystal Archiving  
 
For data collection purposes, the crystals were cryo-cooled in liquid nitrogen. The crystals 
were carefully picked up using loops, and placed on the cryoprotectant solution. The 
cryoprotectant solution prevents against cracking of the crystal due to the freezing conditions. 
The crystals were then picked up and inserted into the crystallography pucks, which were 





2.5.3.6  Data Collection and Processing 
 
All X-ray crystallography data was collected at Diamond Synchrotron Oxfordshire and 
processed through Xia2 software. The data were refined using Refmac5 which is part of the 
CCP4 package. The structures were visualised and corrected using WinCoot. The further 
refinement were performed with Buster program run on a Linux system [45] [138] [139]. 
 
2.5.4  Nuclear Magnetic Resonance (NMR) 
 
All the NMR experiments were undertaken at the Protein NMR facility based at the 
University of Kent on a Bruker Avance III 600 MHz NMR spectrometer with a 4-channel 
and 5-amplifier configuration. The experiments were performed, processed and analysed by 
Dr Mark Howard, Dr Michelle Rowe and Dr Gary Thompson.  
Protein samples were required at a concentration of 10 mg/mL concentration in deuterated 
GF Phosphate Buffer. The sample is deuterated with 5-10 % (v/v) D2O (Goss Scientific). 
Three different types of tubes were used: 3 mm tubes taking 200 μL sample, 5 mm Shigemi 
tube taking 300 μL sample, and 6 mm tube taking 600 μL sample [89]. The tubes were 
cleaned with distilled water and dried with compressed air after usage. The NMR data was 
processed and analysed using TopSpin and Kaleidograph softwares. The assignments were 




2.5.5  Mass Spectrometry (MS)  
 
MS is an analytical chemistry tool used to measure the molecular mass of a protein sample. It 
measures the amount and type of chemicals present in a sample [90] [91]. CD is a common 
spectroscopic technique that measures the chirality of proteins over a range of wavelengths 
[92] [93]. All the MS and CD experiments were undertaken at the Bimolecular Science 
Facility at the University of Kent. MS were performed using Electrospray Mass Spectrometer 
Bruker micrOTOF-Q and CD using Circular Dichroism Spectropolarimeter JASCO J-715. 
All the experiments were performed, processed and analysed by Mr Kevin Howland. 
For MS experiments, protein samples with a concentration of 100 μg/mL were prepared in a 
volume of 100 μL.  
 Chapter 3  
 
 
The Determination of the Structure 
of CypA and Ligand Binding Sites 




This chapter’s main emphasis is to understand the interactions of CypA with the ligands 
3’aminoaetophenone, 4′ sulfamoylbenzoic Acid and 6′ aminoindazole using X-ray 
crystallography and various NMR methodologies, and to characterise the protein residues 
involved in ligand binding. The different NMR experiments are ligand-observed 
1
H STD,         
1
H WaterLOGSY and 
1





N HSQC.  
 
3.1 Introduction about Cyclophilin A (CypA) 
 
CypA is an 18 kDa archetypal protein that derives from the cyclophilin or immunophilin 
families, and is encoded by the gene Peptide Prolyl Isomerase A (PPIA) [94] [95]. It is 
ubiquitously distributed, structurally well-conserved in evolution [95], and present in both 
eukaryotes and prokaryotes, including plants, insects, fungi and bacteria [96] – [101]. The human 
cyclophilin family consists of 16 different cyclophilin proteins that are distinct from each other 
in terms of structural architecture.  CypA is known as the most abundant family member within 
the cyclophilins, as it accounts to nearly 0.1 - 0.6 % of the total number of cytosolic proteins, and 
is the first identified member in mammals among the family. Unlike other cyclophilin members, 





3.1.1 Functional Studies of CypA 
The protein’s predominant function is involved in protein folding and trafficking through the 
activity of its peptide prolyl cis-trans isomerase (PPIase) [95]. PPIase enzymes catalyse the 
isomerisation of peptide bonds from trans-form to cis-form in proline residues, which contributes 
to the fidelity of folded proteins in the cell [103] - [105].  
CypA was hypothesised to be an intracellular protein, but recent studies showed that 
inflammatory stimuli, such as hypoxia, infection, and oxidative stress, can also lead to the 
secretion of CypA. The secreted form of CypA can then act as an autocrine or paracrine factor 
that is able to mediate intercellular communication [106]. The growth of mouse embryonic stem 
cells is indeed mediated by the autocrine factor stimulation of the extracellular CypA on 
endothelial cells and vascular smooth muscle cells (VSMC) using pro-inflammatory signals [95] 
[106] [107]. Both the intracellular and extracellular forms of CypA can be involved in 
pathogenicity. Lower doses of extracellular CypA promote cell migration and proliferation, 
whereas higher doses lead to cytotoxicity, highlighting the biphasic effect of the protein [95] 
[108] [109].  
CypA is also able to attract leukocytes, monocytes and lymphocytes using its potent chemotactic 
signals [95]. Apart from its protein folding and trafficking functions, CypA is also involved in 
many biological roles and is often defined as a protein with multi-functional properties, such as 
T-cell activation, T-cell assembly, immune-modulation, chaperoning and cell signalling. Helekar 
et al. confirmed that CypA is involved in the maturation of homo-oligomeric receptors by either 
acting directly or indirectly as a prolyl isomerase or as a molecular chaperone [95] [110] [111]. 
The protein is therefore involved in several pathological conditions, mostly inflammatory 
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disorders [95]. Examples include the role of CypA in the pathogenesis of abdominal aortic 
aneurysm, atherosclerosis and other cardiac diseases [95] [112]. CypA has been shown to be also 
involved in the pathogenesis of diabetes [113], virology [95] [114] – [116], cancer [117] – [120], 
neurodegenerative disorders (Alzheimer’s Disease) [121], rheumatoid arthritis [122] – [125], 
sepsis [126], asthma [127], periodontitis [128] and ageing [129] [130].  
 
3.1.2 Structure of CypA 
Human CypA consists of two α-helices that surround an eight-stranded anti-parallel β-barrel 
structure, which itself encloses a hydrophobic core made up of seven aromatic rings and 
hydrophobic residues (18 kDa). This hydrophobic core region is considered as the active site of 
the protein, and is where most inhibitors bind (Figure 3.1) [95] [131] [132].  
 
Figure 3.1. CypA crystal structure (PDB: 3K0O) Ribbon representation of CypA crystal structure (PDB: 3K0O) 
showing two α-helices surrounded by eight-stranded anti-parallel β-barrel structure. 
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3.1.3 CypA as drug target 
 
The immunosuppressive drug Cyclosporine A (CsA) binds to CypA in a ternary complex with 
calcineurin to exert its inhibitory effects, and is the most well characterised and tightest binding 
inhibitor of CypA identified so far. CsA is able to inhibit both the cytosolic and secreted form of 
CypA, and exerts its effects by blocking the activity of the PPIase [133] [134]. CsA binds to the 
hydrophobic core region ranging from His 114 to Lys 121, and four β-strands ranging from      
β3-β6. The CsA-CypA complex then binds to the interface between the catalytic and regulatory 
subunits of calcineurin. A crystal structure of the CypA-CsA complex has been successfully 





Figure 3.2. Crystal structure of CypA complexed with Cyclosporine (CsA) (PDB: 1CWA) CypA is shown as 
green ribbon and CsA as red sticks.  
CsA inhibits the calcium-calmodulin activated serine/threonine-specific protein phosphatase 
calcineurin, preventing the biological function of calcineurin and the translocation of nuclear 
factors in activated T-cells (NF-AT) from the cytosol to the nucleus (Figure 3.3). This 
collectively results in the prevention of the transcription of genes responsible for encoding pro-
inflammatory cytokines [133] [134]. The binding of the CypA-CsA complex to calcineurin has 
been shown to stabilise the complex itself, and the proteins in the complex show increased 
resistance to damage by proteolysis. When CsA binds to CypA, the charges and hydrophobicity 
of the complex become conjoined with the binding site of calcineurin [133] [134].  
A number of inhibitors of CypA are known of which NIM811 & MM218 are the most important. 
NIM811 is a derivative of CsA and is known to act as an anti-inflammatory inhibitor of CypA. It 






Figure 3.3. Chemical structure of Cyclosporine (CsA) and its derivative NIM811. Adapted from: Ma, S., 
Boerner, J. E., TiongYip, C., Weidmann, B., Ryder, N. S., Cooreman, M. P., & Lin, K. (2006). NIM811, a 
cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha 
interferon. Antimicrobial agents and chemotherapy, 50(9), 2976-82. 
MM218 is another potent anti-inflammatory inhibitor of CypA, which selectively inhibits the 
extracellular fraction of CypA. In comparison to CsA, it has a better mode of action and anti-
inflammatory effectivity in animal models with acute lung diseases and myocardial repercussion 
injuries [134].  
Due to its involvement in many cellular processes, CypA displays an important target in drug 
discovery. It is a particular challenge to discover specific therapeutic agents to inhibit particular 
functions without affecting others and causing cross-reactivity with other cyclophilin isoforms 
[97] [133] [134].  
Apart from drug discovery itself, it is crucial to identify other mechanisms by which CypA 
achieves its role in inflammatory diseases. It is currently known that CD147 plays a key role 
with CypA to lead to a number of inflammatory-related pathways. However, it is unlikely that it 
is the sole receptor to unequivocally mediate all the cellular responses associated with CypA. 
Therefore, determining other receptors for CypA is essential to understand the CypA pathway 
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better, and to optimally design therapeutic drugs that prevent the binding of CypA to those 
receptor targets in the treatment of inflammatory diseases [95] [133] [134]. Further structural 
characterisation by X-ray crystallography would serve to improve the current understanding of 
the mechanisms underlying specific interactions of cyclophilins with different targets.  
 
3.2  Recombinant expression and purification of CypA from E.coli 
and crystallisation 
 
3.2.1 Recombinant expression and purification 
 
Recombinant human CypA (165 residues) was expressed and purified to homogeneity. CypA 
was expressed from a pET21a ampicillin resistant plasmid using E.coli T7 express cells grown in 
2 x YT media. A bacterial pellet of 8 g was obtained from 1 L culture. The cells were lysed by 
sonication. The first step of purification involved ion-exchange chromatography using a 5 mL   
Q SP Hi-Trap column [83]. The column was equilibrated with buffer A (50 mM HEPES pH 6.8, 
1 mM DTT, 2.5 mM EDTA and 100 μM phenylmethanesulfonyl fluoride) and the lysate applied. 
Protein was eluted using buffer B (50 mM HEPES pH 6.8, 1 mM DTT, 2.5 mM EDTA, 400 mM 




Figure 3. 4. Purification of CypA by ion-exchange chromatography Fractions from the ion exchange column 
applied to a  4-12 % (w/v) Bis-tris SDS-PAGE. The gel shows ~ 70 % purity of CypA at the expected molecular 
weight of 18 kDa after ion-exchange chromatography. FT: flow-through, MP: marker protein, A7-A12: fractions 
from ion-exchange of CypA protein. 
CypA – 18 kDa 
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The pooled fractions were then concentrated down to 2.5 mL. The final step of the purification of 
CypA was gel filtration chromatography using GF Buffer on a Superdex S-75 Column using 
25mM tris-HCl (pH 7.5), 100mM NaCl, 0.5 mM DTT and 0.5mM EDTA for both equilibration 
and elution [85], as described in 2.5.1.5 (Figure 3.5). The protein was well expressed and the 
final purified yield was 25 mg per litre. 
 
Figure 3. 5. Elution Profile of CypA using a Superdex S-75 Column Gel Filtration Chromatography The blue 
trace shows absorption at 280nm in mAU. The peak at fractions B3 - C2 (blue rectangle) is from the elution of 





3.2.2 Protein Crystallisation 
 
The crystallisation of CypA was performed using crystallisation conditions described by Pflugl 
G. et al. (1993) [135]. CypA was concentrated to 16 mg/mL, equivalent to ~ 0.9 mM for 
crystallisation (2.5.3.1). The best crystals for diffraction were obtained from conditions with    
35% - 44% ammonium sulfate at pH 8.5 after 24 hours at 20 °C (Figure 3.6). The CypA crystals 
have the morphology of thin needles. The crystals diffracted to 2.5 Å on beamline I04 at a 
wavelength of 0.97949 Å, and a temperature of 100 Kelvin with a 100 % exposure for              
0.1 seconds / 0.1º oscillation.  
 
 
Figure 3. 6. CypA crystals were grown under conditions of 40 to 41 % ammonium sulphate A) 40 % and        





3.3  Crystallographic Solutions of CypA 
 
3.3.1 Addition of Ligands 
Compounds for soaking were identified by Dr Samantha Lodge (NMR Facility, The University 
of Kent) from a range of compounds known to bind to the mitochondrial form of CypA (CypD). 
The three best hits were selected for crystallographic studies and had KDs within the 
concentrations range of micro-molar to nano-molar (Table 3.1). Previous unpublished work has 
proven that 4′ sulfamoylbenzoic Acid is able to bind to CypA (Dr Samantha Lodge). 
 
Table 3. 1. Summary of the soak and co-crystallisation experiments with CypA  Data obtained,  No data 
obtained  
 
The three compounds were dissolved to give 30 mM stocks in DMSO and crystal soaks were 
prepared at a ratio of 3 : 1 ligand to protein excess (0.9 mM) for each of the compounds. Crystals 
were soaked for 2 days at 20 °C before cryo-cooling in liquid nitrogen with 40 % ammonium 
Ligand SPR (KD) Types of 
crystallisation 
Soak Co-Crystal 
3′ aminoacetophenone 0.06 mM Soak / Co-Crystal   
4′ sulfamoylbenzoic 
Acid 
> 1 mM Soak    
6′ aminoindazole > 1 mM Soak / Co-Crystal   
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sulfate cryosolvent prior to data collection. Immediate archiving of the                                  
CypA-4′ sulfamoylbenzoic acid soak was necessary to prevent the crystals from dissolution. This 
could be due to the compound binding to the protein, and causing conformational changes 
leading to alterations in the crystal morphology. The co-crystals were prepared at a ratio of 2 : 1 
ligand to protein excess under the same conditions as the apo crystal crystallisation conditions.  
The crystals soaked with 3′aminoacetophenone did not diffract, possibly due to DMSO 
intolerance. No data could be collected for 4′ sulfamoylbenzoic Acid due to bad crystal quality 
from the soaks and no crystals were grown from co-crystallisation. 
 
3.3.2 Data collection and processing 
All data was collected at DIAMOND on the IO4.1 beamline at a wavelength of 0.97949 Å, at a 
temperature of 100 Kelvin with a 100 % exposure for 0.1 seconds / 0.1º oscillation. The space 
group was orthorhombic P31 2 1 (Figure 3.7).  
Data was auto-processed through Xia2. A simple molecular replacement with Phaser into P31 2 1 
was performed using the apo structure of CypA as a search model. Ten rounds of structural 
refinement using Refmac5 [136] were performed and the difference density maps were examined 
for presence of the ligand. Once the presence of the ligand was identified, the structure was 
finalised with Buster [137] [138]. The crystallographic data is summarised in Table 3.2 and 3.3. 
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Figure 3. 7. X-ray diffraction pattern of CypA. Data reduction software including xia2 and fast_dp were used to 
detect the space group as P 31 2 1 [138] [139]. The diffraction intensities observed result from diffraction of the X-
ray beam passing through the crystal which is a repeating array of CypA proteins. 
 
3.3.3 Crystallographic Data, Refinement and Ramachandran Plot Statistics with 
ligands 
Tables 3.2 and 3.3 outline a summary of the crystallisation data collection and structural 
refinement details of CypA. The data was solved and refined through Phaser-Molecular 
Replacement, Refmac5 and Wincoot.  
Compound APO 
Space Group P 31 2 1 
Presence of Ligand No 
Unit cell dimensions (Å) (a,b,c) 59.98, 59.98, 94.18 















Table 3. 2. Summary of the X-ray crystallography data collection of CypA.  
Number of observed  
reflections 
13,948 
Number of unique reflections 9,758 
Oscillation range per frame (°) 0.1 
Overall rotation (°) 180 
Resolution Range (Å) 47.09 – 2.25 
Multiplicity 7.2 (6.3) 
Completeness (overall) (%) 99.4 
Mean I/sigma (I) (overall and last shell) 14.9 (2.4) 
Rmerge (%) (overall and last shell) 16.93 
Compound APO 
Maximum Resolution ( Å) 2.5 
R-factor (%) (last shell) 17.65 
R-free (%) 23.07 
RMSD Bond Lengths (Å) 0.0154 
RMSD Bond Angles (°) 1.6791 
Average B-factor Protein (Å
2
) 38.04 













Figure 3. 8. Overlay of CypA refined coordinates crystal structure as deposited 3K0O. The crystal structure of 
CypA consists of two α-helices surrounded by eight-stranded anti-parallel β-barrel structure, as expected (Figure 
3.1). The overlay of the ribbon crystal structure of CypA refined coordinates (green) with published crystal structure 
of ribbon CypA 3K0O (magenta) shows a near perfect match. (all heavy atom RMSD = 0.421) [140] [141].  





 (number of atoms) 1 
Ramachandran Plot preferred (%) 96.30 
Ramachandran allowed (%) 3.70 




Figure 3.8 confirms that the crystal structure of CypA matches with the published crystal 
structure of CypA (3K0O), with the presence of two α-helices surrounded by an eight-stranded 
anti-parallel β-barrel structure [140].  
Neither of the ligands 3′ aminoacetophenone or 6′ aminoindazole bind to CypA. The results 
suggest that the soak concentration was not high enough for the binding to take place. A closer 
look into the active site was undertaken to investigate the difference between the ligand binding 
sites of CypA and CypD (Figures 3.9). 
 
Figure 3. 9. Comparison of CypA refined coordinates crystal structure with CypD complexed with the ligands        
A) Overlay of CypA refined coordinates (green) with ribbon CypD (blue) complexed with deposited 
3′ aminoacetophenone (red stick ligand) (PDB Code: 3R59). B) Overlay of the refined coordinates for CypA (green) 
and CypD (blue) complexed with deposited 6′ aminoindazole (3R56). The overlays show the absence of 















Figure 3. 10. Comparison of the active site of CypA with CypD complexed with ligands A) Overlay of CypA 
(yellow) with CypD complexed with 3′ aminoacetophenone (3R59) (cyan). B) Overlay of CypA (yellow) with CypD 
complexed with 6′ aminoindazole (3R56) (green).  
 
The overlays displayed in Figure 3.10 show the position of the ligands within active site of 
CypD. However, the same ligands did not bind to CypA. When comparing CypA to CypD, it is 
observed that glutamic acid 165 (E165) at the C-terminus of CypA, occludes the active site. The 
crystal packing of CypA causes E165 to obscure the active site of the protein and prevents the 
binding of any ligands by blocking the binding site. As a result, an alternative crystal form, such 
as small block crystals, was sought, which could also be suitable for in-situ crystallisation at 








CypA    VNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMC  62 
         NP V+ D+  +G+PLGRV  EL AD VPKTAENFRAL TGEKGFGYKGS FHR+IP FMC 
CypD    GNPLVYLDVDANGKPLGRVVLELKADVVPKTAENFRALCTGEKGFGYKGSTFHRVIPSFMC  62 
 
CypA    QGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWL  122 
        Q GDFT HNGTGGKSIYG +F DENF LKH GPG+LSMANAGPNTNGSQFFICT KT+WL 
CypD    QAGDFTNHNGTGGKSIYGSRFPDENFTLKHVGPGVLSMANAGPNTNGSQFFICTIKTDWL  122 
 
CypA    DGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE  165 
        DGKHVVFG V EGM++V+ +E FGS++G+TSKKI I DCGQL 
CypD    DGKHVVFGHVIEGMDVVKKIESFGSKSGRTSKKIVITDCGQLS  165 
 
Figure 3. 11. Comparison of CypA and CypD protein sequences. The protein sequence of the CypA sample used 
in the experiments was compared with CypD (Uniprot ID: P30405). The differences between the two sequences are 
highlighted in green. The most interesting change is shown in red, where E165 is substituted to S165 in CypD, 
which may explain why the ligands do not bind to CypA.  
 
The protein sequences of CypA and CypD were compared (Figure 3.11) and it was clear that the 
E165 does not exist in CypD, and therefore it may suggest that this prevents the binding of the 






3.4 Protein Crystallisation Optimisation 
 
3.4.1 Crystallisation Conditions 
 
Several different conditions under which CypA crystallises have been published. Screening trials 
were set up around these conditions to improve crystals quality. The different conditions 
attempted were as follows: 
- 10 – 41 % ammonium sulfate Conditions, pH 8.5 [137], [CypA] = 16 mg/mL, at 20 °C [142].  
- 14 – 24 % polyethylene glycol (PEG) 8000, pH 7.2 – 8.2 [138], [CypA] = 10 mg/mL and 
16mg/mL, at 20 °C [143].    
- 1.2 M – 2.2 M malic Acid, pH 7.2 – 8.2 [79], [CypA] = 10 mg/mL at 20 °C                       
(PDB Code: 3K0O) [80]. 
 
Unfortunately, the changes in the conditions did not improve the morphology of the CypA 
crystals.  
Sitting-drop experiments were set up with conditions, as described in 3.2.2 and 3.2.3 (2.5.4.2), 
using 320 μL of reservoir solution [144]. However, CypA crystals grown from sitting-drop 
experiments did not improve in quality.  
 
117 
3.4.2 Micro-seeding experiments 
 
Micro-seeding is an experiment to improve crystal quality. Small splinters of the original crystal 
are used to introduce a nucleation point. For this purpose, CypA needle crystals were harvested 
and re-suspended in mother reservoir solution. Seeds can be introduced in two different ways; 
either by a process called streak micro-seeding or dilution micro-seeding. In the streak micro-
seeding method, seeding is achieved by picking a small proportion of the reservoir solution, and 
touching it to the smashed crystals before returning to the reservoir which is then sealed. Dilution 
micro-seeding involves the creation of a dilution series from the initial mother liquor containing 
the micro-seeds [145]. The number of dilutions in the series can be varied. Unfortunately, both of 
these techniques did not result in an improvement of crystal morphology or quality.  
 
3.4.3 Additive Screen Experiments 
 
The Hampton Research I (HR2-138) and II (HR2-428) additive screens were used on an 
automated Mosquito system TTP LabTech, with 96 different conditions, designed to stabilise the 
protein and improving the solubility of the sample resulting in an improved crystal packing. The 
additive screens consisted of 1 mL of 96 different additives, containing multivalent cations, salts, 
amino acids, dissociating agent linkers, polyamines, chaotropes, co-factors, reducing agents, 
polymers, chelating agents, carbohydrates, polyols, detergents, non-detergents, amphiphiles, 
osmolytes, organics (non-volatile) and organics (volatile) [146]. These agents did not help in the 
improvement of CypA crystal quality. 
118 
3.4.4  Concentration of the protein sample 
 
In an attempt to improve crystal quality, a series of crystallisation were performed with CypA 
concentrations [147] ranging from 5 mg/mL (0.3 mM) to 25 mg/mL (1.4 mM) (Figure 3.12). 
Drops from 5 mg/mL to 8 mg/mL CypA concentration were clear and did not show any evidence 
of crystallisation. Similarly drops from 18 mg/mL to 25 mg/mL CypA concentration had only 








Figure 3. 12. Variation of the concentration of CypA. A) 16 mg/mL (1 mM) CypA at 43% ammonium sulfate pH 
7.2 20 °C. B) 12 mg/mL (0.7 mM) CypA at 40% ammonium sulfate pH 7.2 20 °C. C) 8 mg/mL (0.5 mM) CypA at 
40% ammonium sulfate pH 7.2 20 °C 
Although block-like CypA crystals could not be obtained using this approach, sharper and 
medium-quality crystals were possible with a CypA concentration of 8 mg/mL. However, the 
crystal packing problem was still not resolved with the new crystal form (3.12C). It was 
therefore decided to perform in-situ mutagenesis experiments to remove C-terminal E165 residue 
of the CypA sequence.  
A B C 
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3.5  Mutagenesis of Cyclophilin A 
 
3.5.1 Sequence of wild-type CypA 
The uniprot data of wild-type (identifier: P62937-1) did not show any evidence of post-
translational modifications occurring at the residue of C-terminal E165 (Figure 3.13). E165 does 
not contribute to the formation of any secondary structural motifs. Therefore, truncation of E165 
is not expected to affect the structure of the protein [148]. 
 
Figure 3. 13. Protein sequence of wild-type CypA. The protein consists of 165 residues, and has a mass of 18,012 
Daltons. This sequence belongs to the isoform 1 (identifier: P62937-1) [148].  
 
Interestingly, a number of mutagenesis experiments have already been performed on CypA 
before. The experiments are all substitution experiments, at positions 89, 106 and 165 [149] – 
[150]. The residue E165 had been substituted previously for D165. The previous substitution 
performed at E165 is enough evidence to suggest that the residue can be subjected to directed 
mutagenesis without causing effects to the function of the protein [150].  
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3.5.2 Directed mutagenesis of wild-type CypA 
 
The CypA gene was subjected to in-situ mutagenesis to remove the C-terminal residue E165. 
Successful mutagenesis was verified by an analysis carried out by Beckman Coulter Genomics 
[151]. The gene sequence was translated into a protein sequence and aligned with the wild-type 
CypA protein sequence in order to identify the differences using the vector NTI software tool 
(Figure 3.14) [152]. 
Wild-type CypA (1) MVNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKG (50) 
Mutant CypA    (1) MVNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKG (50) 
 
Wild-type CypA (51) SCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSM (100) 
Mutant CypA    (51) SCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSM (100) 
 
Wild-type CypA (101) ANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNG (150) 
Mutant CypA    (101) ANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNG (150) 
 
Wild-type CypA (151) KTSKKITIADCGQLE----- (170) 
Mutant CypA    (151) KTSKKITIADCGQLHHHHHH (170) 
 
Figure 3. 14. Comparison of Wild-type CypA and Mutant CypA protein sequences 
 
3.5.3 Recombinant Expression and Purification of the mutant CypA 
Recombinant human mutant CypA (170 residues) was expressed and purified to homogeneity. 
CypA was expressed from a pET21a ampicillin resistant plasmid using E.coli T7 express cells 
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grown in 2 xYT media. A bacterial pellet of 11 g was obtained from 1 L culture. The cells were 
lysed by sonication. The first step of purification involved nickel-affinity chromatography using 
a 5 mL His-Trap HP column [81]. The column was equilibrated with Buffer A (50 mM tris-HCl 
pH 7.8, 300 mM NaCl, 30 mM imidazole and 1 mM 2-beta mercaptoethanol) and the lysate 
applied. Protein was eluted using Buffer B (50 mM tris-HCl pH 7.8, 300 mM NaCl,                  
30 mM imidazole, 500 mM imidazole and 1 mM 2-beta mercaptoethanol) and straight through a 
26/10 HiPrep Desalting Column using Buffer C (25 mM NaH2PO4, 0.5 mM DTT pH 6.5), as 
described in 2.5.1.2 (Figure 3.15 and Figure 3.16). 
 
Figure 3. 15. Elution Profile of mutant CypA on His-Trap 5 mL Immobilised Nickel Affinity 




Figure 3. 16. Purification of mutant His-CypA using Nickel-Affinity Chromatography. The 4-12 % (w/v) Bis-
tris gel shows ~ 70 % purity of CypA at the expected molecular weight of 18 kDa after immobilised nickel affinity 
chromatography. MP: marker protein, LYS: Lysate, Ni: Nickel Elution, FT: Flow-through. 
 
CypA – 18 kDa 
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The final step of the purification of CypA was gel filtration chromatography [85] using GF 
Buffer (25 mM tris-HCl (pH 7.5), 100 mM NaCl, 0.5 mM DTT and 0.5 mM EDTA) on a 
Superdex S-75 Column for both equilibration and elution, as described in 2.5.1.5 (Figure 3.17 
and Figure 3.18). The protein was well expressed and the final purified yield was 50 mg per litre.  
Figure 3. 17. Elution Profile of mutant CypA on Superdex S-75 Column Gel Filtration Chromatography. 
Fractions A10 - B9 (blue rectangle) show the elution of aggregated protein, and fractions B6 - B2 (red rectangle) 





Figure 3. 18. Purification of mutant His-CypA by Gel Filtration Chromatography. The purified fractions on the 
4-12 % Bis-tris gel shows ~ 90 % purity of protein at the expected molecular weight of 18 kDa after gel filtration 
chromatography. MP: marker protein. Fractions A10-B6 represent aggregates and fractions B5-B3 represent the 
mutant protein. 
 
3.5.4 Mass spectrometry of mutant CypA 
 
Electrospray mass spectrometry (MS) was performed to measure the molecular mass of the 














Figure 3. 19. Mass spectrometry spectrum plot of mutant CypA. The results show the presence of two 
observable peaks. The base peak, which is the most intense ion, is Mr = 18,706.0 Da, the second peak has a 
molecular mass of Mr = 18,574.8 Da.  
 
Two peaks were observed at 18,706.0 Da and 18,574.8 Da. The major peak corresponds to the 
mutant CypA (18,706.23 Da). The minor peak at 18.5 Da has a difference of 131.2 from the 
major peak. The relative ratio mass corresponds to the loss of methionine, which has a molecular 
weight of 131.19 Da. Loss of methionine from the N-terminal due to methionine amino-
peptidase is a common post-translational modification in E.coli [153].  
 
3.5.5 Crystallisation of the mutant CypA 
 
After verification of purity and the exact mass of mutant CypA, the protein was used for 
crystallisation trials using the same conditions as for the wild-type CypA. Since the residue E165 
was removed, a change in crystal packing can be expected. The protein was therefore subjected 
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to further optimisation, including trials of previously used conditions, protein concentration 
variation and additive screens. None of these techniques led to crystal formation. It appears that 
the single amino acid truncation resulted in a complete change in the crystallisation pattern of the 
protein. Alternatively, the presence of the his-tag could have also prevented the crystallisation of 
the protein, as the protein sequence is modified. Therefore, although site-directed mutagenesis 
was successful, the binding of the CypD ligands into the mutant CypA could not be validated 
using X-ray crystallography.  
This result shows the utility of NMR, which does not rely on the additional step of protein 
crystallisation, and could give an answer of binding modes while the protein is in solution. The 
lack of a crystal structure should not always be a barrier for understanding the structure of a 
protein-ligand complex and the interactions of residues with ligands, which in this case could not 
be achieved using X-ray crystallography with CypA.  
 
3.6 NMR screening methods on protein-ligand binding with CypA 
 





H WaterLOGSY and 
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3.6.1 NMR Sample Preparation of CypA/3′aminoacetophenone and CypA/            
4′ sulfamoylbenzoic Acid complexes 
 
The binding of 3′aminoacetophenone and 4′sulfamoylbenzoic Acid with CypA was evaluated 
using STD [56] [59], WaterLOGSY [154] and CPMG experiments [155] from a sample 
expressed in E.coli T7 express cells grown in rich LB media and purified into GF Buffer          
(25 mM tris-HCl (pH 7.5), 100 mM NaCl, 0.5 mM DTT and 0.5 mM EDTA) as described in 
Chapter 2.5.1.5. Binding experiments were carried out with 0.2 mM CypA with the addition of 
either 8 mM 3′aminoacetophenone and 4′ sulfamoylbenzoic Acid. 
 
3.6.2 NMR Sample STD Data Acquisition 
 
1
H STD experiments [56] [59] were acquired on a Bruker Avance III 600 Hz spectrometer at 
25°C, with 16,384 points (spectral width 9615 Hz) in the direct F1 dimension (
1
H), with a total 
number of 256 scans were acquired with an acquisition time of 0.85 seconds. Saturation was 
achieved using EBURP2 pulses of length 20 ms or 50 ms for 3′aminoacetophenone and 
4′sulfamoylbenzoic acid, respectively. The type of water suppression used was excitation 
sculpting and the spectra were referenced against water. Saturation was applied at -0.7 / -30 ppm 
for the on and off resonance experiments respectively. The relaxation delay time (D1) in the 
experiments was 2.5 seconds. Data were zero filled and Fourier transformed using TopSpin 3.2 






Figure 3. 20. 
1
H STD experiments performed at 25 °C on 0.2 mM CypA protein complexed with 8 mM           
3’ aminoacetophenone. Blue spectrum off-resonance spectrum; Red spectrum final difference STD spectrum. STD 
spectrum of 3′aminoacetophenone binding to CypA. The blue asterisk (*) represents the 3′aminoacetophenone 
peaks.  
 
The principle of STD-NMR is based on saturation transfer from the protein to a bound ligand. 
Transfer of saturation is achieved by selectively saturating the protein resonances through a soft 
pulse. Through spin diffusion (which is efficient for large molecules), the saturation is then 
spread throughout the entire protein molecule. When a ligand binds to the protein, the saturation 




H cross-relaxation [56] [59]. As a result, 
protons from the ligand that are closer to the protein receptor surface receive more saturation 




H     (ppm) 
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receive any saturation at all via this route. Typically, two experiments are carried out, where in 
one the protein is saturated (on resonance) and in the second the saturation pulses are placed a 
long way off resonance typically -30 ppm (off resonance). The off-resonance spectrum should 
show the ligand alone and the on-resonance should show the ligand signals with reduced 
intensities depending on how much saturation is transferred. Thus, the difference between on- 
and off-resonance gives the STD difference spectrum, revealing signals from ligand protons, 
which have bound to the saturated protein receptor [56] – [59].  
The 3′ aminoacetophenone peaks (highlighted with *) show binding at 2.5 ppm and no binding at 
7.5 ppm (Figure 3.20), where the signals are completely attenuated in the STD difference 
spectrum. This suggests that 3′ aminoacetophenone is a weak binder to CypA. 
 
 
Figure 3. 21. 
1
H STD experiments performed at 25 °C on 0.2 mM CypA protein complexed with 8 mM           
4′ sulfamoylbenzoic Acid. Blue spectrum off-resonance spectrum; Red spectrum STD difference spectrum, the blue 
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The 4′ sulfamoylbenzoic acid peak at 8 ppm shows binding (*, Figure 3.21), this data agrees with 
the hypothesis that the negative crystallographic result with CypA could be due to damage to the 
crystals during the binding of the ligand (c.f: 3.3.1). 
 
3.6.3 An Introduction to WaterLOGSY 
 
WaterLOGSY is a complementary to STD and is based on the transfer of saturation from bound 
water molecules instead of the protein. The resonance of the water molecules is selectively 
excited, and the magnetisation is transferred to protons using the NOE mechanism. The 
resonance of the water molecules is excited and transferred by one of three mechanisms: 1) 
direct transfer from water to ligand in protein-bound waters. 2) indirect transfer between bound 
waters to the protein by exchange followed by spin diffusion and transfer to ligand. 3) direct 
exchange of protons in the binding site followed by transfer. The signals for unbound and bound 
ligands are opposite (Figure 3.22 A). This method is useful in understanding protein ligand 
interactions with ligands at micro-molar affinities in structure-based drug discovery [154] [156].  
 
3.6.3.1 NMR Sample WaterLOGSY Data Acquisition 
 
1
H WaterLOGSY experiments were acquired on a Bruker Avance III 600 Hz spectrometer at 
25°C, with 32,768 points (spectral width 9615 Hz) in the direct F1 dimension (
1
H) with a total 
number of 256 scans measured within an acquisition time of 1.70 seconds. Water inversion was 
achieved using a 6.4 ms eSNOB inversion pulse, the nOe mixing period was 1.2 seconds, during 
which a low power of 10G/cm Z gradient pulse was applied. Further suppression of the protein 
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signals was achieved using 20 cycles of CPMG with an inter-pulse delay of 1 millisecond. The 
relaxation delay time (D1) in the experiments was 2.0 seconds. Data was processed using 
TopSpin 3.2 and line broadening of 1.0 Hz was applied (Figures 3.22B and 3.23). Excitation 













Figure 3. 22. 
1
H WaterLOGSY experiments performed at 25 °C on 0.2 mM CypA protein complexed with       
8 mM 3′ aminoacetophenone. (A) Typical spectrum of protein-ligand binding observed by WaterLOGSY. Binding 
A                                                                                               
- CYPA 
+ CYPA B                                                                                               
1
H     (ppm) 
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is characterised by inversion of peaks in the WaterLOGSY spectrum (B) Blue spectrum 3′ aminoacetophenone only; 
Red spectrum 3′ aminoacetophenone complexed with CypA. All the 1H signal ligand peaks (*) in the red spectrum 
(+ CypA) are in the same direction as the blue spectrum (- CypA). Adapted from (A): http://fragmentech.univ-
lyon1.fr/waterlogsy-experiment/ [154] 
 
Figure 3. 23. 
1
H WaterLOGSY experiments performed at 25 °C on 0.2 mM CypA protein complexed with        
8 mM 4′ sulfamoylbenzoic Acid. Blue spectrum 4′ sulfamoylbenzoic Acid only; Red spectrum 4′ sulfamoylbenzoic 
Acid complexed with CypA. All the 
1
H signal ligand peaks (*) in the red spectrum (+ CypA) are inverted in the 




H peaks shows weak binding of the ligand to the protein in WaterLOGSY 
experiments [156]. Therefore, Figure 3.22 B) indicates no binding of 3′ aminoacetophenone to 
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Figure 3.23 shows the inversion of peaks (+ CypA), indicating binding of 4′ sulfamoylbenzoic 
Acid to CypA (both at 2.5 ppm and 8 ppm), validating the STD results.  
3.6.4 An Introduction to Carr-Purcell- Meiboom Gill (CPMG) 
 
CPMG is another experiment commonly used as a screening tool to identify compounds that 
bind to a protein. It is based on the measurement of transverse or spin-spin T2 relaxation of any 
nucleus. Positive binding results in the attenuation of the signal, whereas non-binding does not 
change the spectrum. Effectively, signals have a higher rate of T2 when bound to a slow tumbling 
protein [155].  
 
3.6.4.1 NMR Sample Carr-Purcell- Meiboom Gill (CPMG) Data Acquisition 
 
1
H CPMG experiments [155] were acquired on a Bruker Avance III 600 Hz spectrometer, with 
16,384 points (spectral width 9615 Hz) in the direct F1 dimension (
1
H), with a total number of 
128 scans. The CPMG element of the sequence used a total of 600 cycles of refocusing period of 
1 millisecond. The relaxation delay time (D1) in the experiments was 0.001 seconds. Data was 
acquired over an acquisition time of 0.85 seconds. Data was processed in Topspin 3.2 using a 








Figure 3. 24. 
1
H CPMG experiments performed at 25 °C on 0.2 mM CypA protein complexed with 8 mM 
3′ aminoacetophenone. (A) Typical spectrum of protein-ligand binding observed by CPMG. Binding is 
characterised by attenuation of peaks in the CPMG spectrum (B) Blue spectrum 3′ aminoacetophenone only; Red 
spectrum 3′ aminoacetophenone complexed with CypA. The ligand 1H signal peaks (*) in the red spectrum (+ 
CypA) are attenuated in comparison to the blue spectrum (- CypA). 
A                                                                                               
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Figure 3. 25. 
1
H CPMG experiments performed at 25 °C on 0.2 mM CypA protein complexed with 8 mM       
4′ sulfamoylbenzoic Acid. Blue spectrum 4′ sulfamoylbenzoic Acid only; Red spectrum 4′ sulfamoylbenzoic Acid 
complexed with CypA. The ligand 
1
H signal peaks (*) in the red spectrum (+ CypA) are attenuated in comparison to 




H peaks shows binding of the ligand to the protein in CPMG experiments [155]. 
Therefore, Figure 3.24 B) indicates binding of 3′ aminoacetophenone to CypA through the 
attenuation at 7 ppm and Figure 3.25 indicates binding of 4′ sulfamoylbenzoic Acid of CypA at 
7.5 ppm.  
These NMR screening methodologies are good tools to identify ligands/fragments that bind to 
the protein in comparison to X-ray crystallography. However, none of these ligand-based 
techniques are able to inform us about the key residues in the protein binding site, and therefore 
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observed methods for the prediction of protein ligand interactions in the application in structural-
based drug discovery [155].  
 
3.7 Characterisation of CypA by NMR Spectroscopy 
 
Analysis of the protein-ligand interactions in NMR is usually undertaken with the full 
assignment of 
15
N isotopically labelled protein, for which the protein needs to be folded and 
stable at 25 °C [157] – [159].  
 









N HSQC is a heteronuclear experiment performed on proteins, which provides a chemical 
shift ‘fingerprint’  which is often used  to determine the stability of the protein for further 
experiments. The sharpness and dispersion of the peaks over the available spectral range 
correlate with the folding of a protein [157] – [159].  
This experiment identifies all the hydrogen-nitrogen correlations. It is based on the transfer of 
magnetisation from hydrogen to an attached 
15
N nuclei through a large 1 bond J-HN-coupling. A 
chemical shift is measured from the nitrogen and the magnetisation is then transferred back to 





N HSQC originate mostly from backbone amide groups, but tryptophan side-chain Nɛ - 
Hɛ groups and asparagine/glutamine side chains Nδ - Hδ2/Nɛ - Hɛ2 groups can also be 
identified. Other visible groups in such a spectrum can be Arginine Nɛ - Hɛ peaks, but the Nɛ are 
usually outside the excited region [157] – [159].  
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The stability of CypA was investigated by proton-based experiments at 25°C using a 
15
N 
isotopically enriched sample expressed in E.coli T7 express cells grown in minimal media and 
purified in GF Buffer (25 mM NaH2PO4, 100 mM NaCl and 1 mM DTT pH 6.5) as described in 












H Heteronuclear Single Quantum Correlation (HSQC) experiment was acquired on a 
Bruker Avance III spectrometer at 600 MHz (F2) and 60 MHz (F1) at 25°C, with 1024 points 
(9000 Hz) in the direct F2 dimension (
1
H) and 256 points (2100 Hz) in F1 (
15
N) indirect 
dimensions. There was a total number of 8 scans per increment each with an acquisition time of 
0.11 seconds in F2 dimension. Watergate was the water suppression technique. The relaxation 
delay time (D1) in the experiments was 1.2 seconds. The size of the real spectrum was 4096 in 
the F2 dimension and 512 in the F1 dimension (Figure 3.26). 
15N Chemical Shift (ppm) 
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The samples were in 90% H2O and 10% D2O. 
 




N HSQC Spectrum of CypA at 25 °C. The peaks are all sharp and clear, which suggest that the 





N HSQC experiments confirm that the protein is folded and informs the presence of certain 
types of amino acid groups. However, the spectrum needs to be assigned using through-bond 
triple resonance experiments to be able to match each peak with a specific amino acid from the 
CypA protein sequence [157] – [159].  
15N  chemical shift  (ppm) 
              1H (ppm)                                
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The assignment was not attempted, as the findings could not be compared with a valid X-ray 
structure, as part of this combined method approach study, because no ligand binding occurred in 
the crystal structure.  
 
3.8 Summary and Discussion 
 
Chapter 3 has attempted to characterise the structure of CypA using X-ray crystallography and 
both ligand and protein-observed NMR methods. CypA was studied in complex with the ligands 
3′ aminoacetophenone, 4′ sulfamoylenzoic acid and 6′ aminoindazole. Previous STD 
experiments show that the ligands that bind to CypD also bind to CypA. This chapter extends 
over the NMR characterisation of CypD ligands in CypA. 
X-ray crystallography studies revealed that the crystal packing of CypA did not allow the 
binding of the ligands to CypA. This appears to be due to C-terminal residue E165, obstructing 
the ligand binding site of CypA. In an attempt to overcome the packing effect hindering the 
binding site and create a new crystal form, in-situ mutagenesis was performed to remove C-
terminal E165, but the crystallisation of mutant CypA did not yield suitable crystal samples of 
3′ aminoacetophenone, 4′ sulfamoylbenzoic Acid and 6′ aminoindazole complexed with CypA; 
this might be explained by the presence of the His-tag, which was not removed due to absence of 
a thrombin cleavage site.  




H WaterLOGSY and 
1
H CPMG were 
performed to show that 3′ aminoacetophenone and 4′sulfamoybenzoic acid bind to CypA. 
However, none of these ligand-based techniques are able to inform about the key residues in the 
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protein binding site, and therefore are limited to simply identifying ligand “hits”. CypA was then 




N experiments.  
CypA was an intended as an example to illustrate the need for an advanced NMR method to 
determine ligand binding sites. This study highlighted the requirement for full protein 
assignment [159] and how NMR interaction of 
1
H ligand-based observations can be used in the 
absence of an X-ray structure. As the protein- and ligand-observed NMR studies could not be 
compared with X-ray structure for validation purposes, this target protein was abandoned. 
 
 Chapter 4  
 
 
The Determination of the Structure 
of TbrPDEB1 and Ligand Binding 




This chapter’s main emphasis is to understand the interactions of TbrPDEB1 with the ligands 
VUF 14234, PPS 59083, VUF 14450 and PPS 60036 using X-ray crystallography and 
various NMR methodologies, and to characterise the protein residues involved in ligand 
binding.  
 
4.1 Introduction about Phosphodiesterase B1 in Trypanosoma 
brucei (TbrPDEB1) 
 
TbrPDEB1 is a cyclic nucleotide phosphodiesterase expressed in Trypanosoma brucei, and 
along with TbrPDEB2, it has been genetically and pharmacologically characterised as an 
important virulence factor and therapeutic target for the neglected disease, human African 
Trypanosomiasis (HAT) or African Sleeping Sickness [164] – [166]. The demands for the 
development of new drugs for this target are increasing, and the current treatment options 
available lead to serious and even sometimes lethal side effects [166] [167]. Trypanosoma is 
a type of protozoa unicellular parasite that belongs to the order of kinetoplastida, due to the 
presence of a kinetoplast. A kinetoplast is an organelle containing DNA in the mitochondria 
of the organism. The Trypanosoma parasite is unique by the presence of a single flagellum, 
which is critical for motility, cell division, morphogenesis, attachment to host and vector 
cells, immune evasion, and the viability and pathogenicity of the parasite [164] – [169].  
 
4.1.1 Functional Studies of TbrPDEB1 
Both TbrPDEB1 and TbrPDEB2 are catalytic enzymes, selectively mediating hydrolysis of 
the ubiquitous secondary messenger cyclic adenosine mono-phosphate (cAMP) to AMP. 
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CO2-regulated adenylate cyclases, embedded in membranes or in the cytoplasm of eukaryotic 
cells, convert adenosine tri-phosphate (ATP) to cAMP. cAMP signal activates the regulatory 
subunit of protein kinase A (pkA), cAMP-gated ion channels, or the guanidine-nucleotide 
exchange proteins EPAC1 and EPAC2 (Figure 4.1). The cAMP signal is usually terminated 







Figure 4.1. PDEs regulate the hydrolysis of cAMP. Adenylate cyclase is responsible for the conversion of 
ATP to cyclic AMP.  Cyclic AMP then activates protein kinase enzymes which results in phosphorylation of 
proteins responsible for gene activation. Phosphodiesterases mediate the hydrolysis of cAMP and can terminate 
the cAMP signal. Adapted from: Janicak PG et al: Principles and Practice of Psychopharmacotherapy, 2nd 
Edition, Lippincott, Williams & Wilkins, 1997 [170]  
 
Seebeck’s group showed that RNA interference (RNAi) against either of TbrPDEB1 or 
TbrPDEB2 revealed an observable phenotype in the development of the parasite. However, 
simultaneous RNAi against both of the enzymes resulted in complete cell lysis within 48 hour 
of RNAi induction. The simultaneous RNAi of both enzymes caused a 1000-fold increase in 
cAMP concentration within few hours, which was not observed in RNAi of individual 
cAMP ion channels 




TbrPDEs. Impaired division of trypanosomes and cell lysis occur following the accumulation 
of intracellular cAMP. Both of the enzymes can functionally complement each other, 
highlighting the importance of both enzymes in-vitro and in-vivo [165]. Therefore, drug 
discovery and treatment should be strongly targeted at both enzymes at the same time to 
significantly alter cAMP levels and cause the parasitic death [164] – [169].  
 
Figure 4.2. The construct of PDEB1-Tbr in pET28a was provided by the Free University of Amsterdam 
(VU). TbrPDEB1 and TbrPDEB2 reveal very close sequence identity. The TbrPDEB1 enzyme consists of two 
ubiquitous N-terminal GAF domains, where cAMP binds (D234 - E554) and a catalytic domain (V586 - R908), 
causing the hydrolysis of cAMP into AMP.  
 
Although TbrPDEB1 and TbrPDEB2 reveal very close sequence identity, they are both 
located at distinct sub-cellular localisation. TbrPDEB1 is located in the flagellum within the 
flagellar skeleton, and most of TbrPDEB2 is found throughout the cell body distributed 
between the flagellum and cytoplasm. A small portion of TbrPDEB2 is also found in the 
flagellum. cAMP signaling occurs in the flagellum in Tbr. Luginbuehl’s transfection of pro-
cyclic trypanosomes with green-fluorescent protein (GFP) reporters studies show that the    
N-termini of both enzymes are essential for determining their corresponding sub-cellular 
localisations. Mutation of residues in the N-terminal regions of those enzymes showed that 
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single amino acid substitutions can re-locate the enzymes from cell body to flagellar skeleton 
[168] [169].  
 
4.1.2 Structure of TbrPDEB1 
 
The TbrPDEB1 enzyme consists of two ubiquitous N-terminal GAF domains, where cAMP 
binds (D234 - E554) and a catalytic domain (V586 - R908), causing the hydrolysis of cAMP 
into AMP (Figure 4.2). Inhibition of the catalytic domain of TbrPDEB1 and inhibition of the 
full-length occur at the same inhibitor concentrations, indicating that the catalytic domain is 
the driver of the enzyme activity. The catalytic domain (37 kDa) consists of sixteen α- helices 
and no β- strands (Figure 4.3). The active site of the protein consists of two divalent metal 
atoms, zinc and magnesium, each forming an octahedral geometry. TbrPDEB1 has also a 
parasite-specific P-pocket directly adjacent to the active site and consists of the invariant 
Q874 on helix H15 and residues from the M-loop and helix H14 on the opposing sides. The 
parasite-specific P-pocket is also found in Leishmania major PDEB1 (Lmj) and 




Figure 4.3. TbrPDEB1 crystal structure (PDB: 4I15) The catalytic domain (37 kDa) consists of sixteen α- 
helices and no β- strands (Figure 4.3). The active site of the protein consists two divalent metal atoms, zinc and 
magnesium, each forming an octahedral geometry. TbrPDEB1 also shows the presence of a parasite-specific P 
pocket, which is found to be directly adjacent to the active site. Metal ions are shown in blue (magnesium) and 
red (zinc).  The H-loop and M-loop form the P-pocket (pink). The structure is shown as two molecules in the 







4.2  Recombinant expression and purification of TbrPDEB1 from 
E.coli and crystallisation 
 
4.2.1 Recombinant expression and purification 
The first step of purification involved nickel-affinity chromatography using Buffer A on 5 
mL His-Trap Column (20 mM tris-HCl pH 8, 300 mM NaCl, 10 % (v/v) glycerol,                1 
mM 2-beta mercaptoethanol, 10 mM imidazole) for equilibration, and Buffer B                (20 
mM tris-HCl pH 8, 300 mM NaCl, 10 % (v/v) glycerol, 1 mM 2-beta mercaptoethanol, 10 













 Figure 4.4. Elution Profile of mutant TbrPDEB1 on His-Trap 5 mL Immobilised Nickel Affinity 
Chromatography and 26/10 HiPrep Desalting Column The peak of elution (red rectangle) represent the His-
tagged TbrPDEB1 protein. The protein was immediately desalted through 26/10 HiPrep Desalting Column to 
remove high concentrations of imidazole. 
  
Figure 4.5. Purification of TbrPDEB1 by Nickel-Affinity Chromatography. The purification fractions on 
the 4-12 % (w/v) Bis-tris gel show ~ 70 % purity of TbrPDEB1 at the expected molecular weight of 37 kDa 
after nickel affinity chromatography (Ni). Lys: lysate, FT: flow-through, Ni: Nickel elution of TbrPDEB1.  
TbrPDEB1 – 37 kDa 
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The first eluted fraction was subjected to thrombin cleavage (stock: 2 units/μL) cleavage and 
was added on the basis of 5 units/mL, and the fraction was stored at 4 °C overnight. The next 
step of purification was ion-exchange chromatography using Buffer A on 5 mL Hi-Trap 
Column (20 mM tris-HCl pH 7.5, 100 mM NaCl, 5 % (v/v) glycerol, 1 mM 2-beta 
mercaptoethanol) for equilibration, and Buffer B (20 mM tris-HCl pH 7.5, 1 M NaCl,            
5 % (v/v) glycerol, 1 mM 2-beta mercaptoethanol) for elution (Figure 4.6).  
 
Figure 4.6. Elution Profile of TbrPDEB1 on Hi-Trap 5 mL Ion Exchange Chromatography 
 
The final step of the purification of TbrPDEB1 was gel filtration chromatography using GF 
Buffer on Superdex S-75 Column (20 mM tris-HCl pH 7.5, 50 mM NaCl, 5 % (v/v) glycerol, 
1 mM 2-beta mercaptoethanol) for both equilibration and elution, as described in 2.5.1.5 




Figure 4.7. Elution Profile of TbrPDEB1 on Superdex S-75 Column Gel Filtration Chromatography.  
Fractions A12 - B2 (red rectangle) show the elution of the pure protein TbrPDEB1.  
 
As the gel filtration chromatography trace appears to elute three different species, fractions 
A12-B11, B10-B5 and B4-B2 were run separately on an SDS-PAGE Coomassie gel. All the 
fractions confirmed to the presence of pure TbrPDEB1 protein and did not show any 
heterogeneity in the protein sample. Unfortunately, the SDS-PAGE gel was photographed 
during the time of the experiment. The gel was considered good enough to test the purity of 
the protein, and therefore mass spectrometry was not performed. In the event that the protein 
would not crystallise, mass spectrometry would have been done to clarify the level of purity.   
 
4.2.2 Protein Crystallisation 
 
The crystallisation of TbrPDEB1 was performed following the crystallisation conditions 
described by Huanchen Wang et al. (2010). CypA was concentrated at 10 mg/mL, equivalent 
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to ~ 0.3 mM for crystallisation (2.5.3.1). The best crystals for diffraction were obtained from    
14% - 24% PEG3350 pH 6.5 conditions after 24 hours at 20 °C (Figure 4.8). 
 
 
Figure 4.8. TbrPDEB1 Crystals in 20 % PEG 3350 pH 6.5 Conditions The TbrPDEB1 crystals always tend 
to grow as diamonds and can grow up to a diameter of 5 microns. There are micro-crystals at the edge of the 
drop. The crystals diffracted to 2.0 Ǻ on IO4.1 beamline at a wavelength of 0.97949 Å, temperature of 100 
Kelvin with a 100 % exposure for 0.1 seconds / 0.1º oscillation.  
 
Crystals diffracted to 2.0 Ǻ resolution and their space group was C 21. Huanchen Wang 








4.3  Crystallographic Solutions of TbrPDEB1 
 
4.3.1 Addition of Ligands 
 
Compounds for soaking were identified and Surface Plasmon Resonance (SPR) was 
undertaken by VU Free University (Amsterdam) to detect molecular interactions of ligands 
with TbrPDEB1, and determine the corresponding binding affinities (IC50) using DMSO 
stock compounds. Thirteen hits were selected for crystallographic studies within the micro-
molar to nano-molar ranges.  Only four ligands were successfully solved in complex with 
TbrPDEB1.  
 
Table 4. 1. Summary of the soak and co-crystallisation experiments with TbrPDEB1  Data obtained,  
No data could be obtained due to DMSO intolerance in soaks or no crystals were grown in co-crystallisation. 
 
Ligand SPR ( IC50) Types of 
crystallisation 
Soak Co-Crystal 
PPS 59083 100 nM Soak / Co-Crystal   
PPS 60036 0.44 μM Soak / Co-Crystal   
VUF 14450 6.2 μM Soak / Co-Crystal   
VUF 14234 5.6 μM Soak / Co-Crystal   
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Compound solids were dissolved to 50 mM stock in DMSO. Compounds were used in 
equimolar ratio with protein concentration (0.9 mM). Crystals were soaked for 2 days at 4 °C 
before cryo-cooling in liquid nitrogen with 20 % Ethylene Glycol for data collection.  
The co-crystals were performed at a ratio of 2 : 1 ligand to protein excess under the same 
conditions as apo crystal crystallisation conditions.  
 
4.3.2 Data collection and processing 
 
All data was collected at DIAMOND on IO4.1 beamline at a wavelength of 0.97949 Å, at a 
temperature of 100 Kelvin with a 100 % exposure for 0.1 seconds / 0.1º oscillation. The space 
group was orthorhombic C 21 (Figure 4.9).  
Data was auto-processed through Xia2 [138]. A simple molecular replacement with Phaser 
into C 21 was performed using the apo structure of TbrPDEB1 as search model. Ten rounds of 
structural refinement using Refmac5 [136] were performed and the difference density maps 
were examined for presence of the ligand. Once satisfied with the presence of the ligand, the 





Figure 4.9. X-ray diffraction pattern of TbrPDEB1 Auto-solving softwares such as xia2 and fast_dp were 
used to detect the space group of C 21. The diffraction intensities in the diffraction image of TbrPDEB1 
represent a reflection of each atom in the TbrPDEB1 protein, generated from the X-ray beam passing through 
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180 180 180 180 
Resolution 
Range (Å) 
64.565 – 2.582 79.42 – 2.00 57.65 – 2.24 57.97 – 2.14 



























































Table 4. 3. Summary of the X-ray crystallography structure refinement and Ramachandran Plot statistics 
of TbrPDEB1 with ligand structures. 
Compound VUF14234 PPS 59083 VUF 14450 PPS 60036 
Maximum 
Resolution (Å) 

































































































































Figure 4.10. Overlay of TbrPDEB1 refined coordinates crystal structure with deposited PDB: 4I15 The 
crystal structure of TbrPDEB1 consists of sixteen α-helices and no β-sheets structure, as expected (Figure 4.3). 
The overlay of the ribbon crystal structure of TbrPDEB1 (green) with ribbon crystal structure of TbrPDEB1 
(PDB: 4I15) (cyan) shows a near perfect match [164].  
 
Figure 4.10 confirms that the crystal structure of TbrPDEB1 matches with the published 
crystal structure of TbrPDEB1 (PDB: 4I15), with the presence of sixteen α-helices and no    
β-sheets. TbrPDEB1 is formed of two molecules, chain A and chain B, forming a dimer in 
the crystallographic asymmetric unit in the crystal lattice [164]. Chain A’s active site is partly 
protected from solvent because it is more engaged with the crystal lattice contacts. Since the 
formation of this dimer is not related to the biological function of the protein, the 
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dimerisation is considered as a crystallographic artefact. This has not any significant impact 
on the overall conformation of the protein since both molecules A and B are identical [164].  
 
4.3.4 TbrPDEB1 with ligands structures 
 
 
Figure 4.11. Crystal structure of TbrPDEB1 refined coordinates co-crystallised with the ligand VUF 
14234 The ligand VUF 14234 binds to Chain B of TbrPDEB1. A detailed view reveals that VUF 14234 is 




. VUF 14234 is directed 




Figure 4.12. Overlay of crystal structures of TbrPDEB1 in complex with the ligands PPS 60036 (blue), 
PPS 59083 (red) and VUF 14450 (orange) The ligands have bound to TbrPDEB1 in the same site but with 
different binding modes. The ligand PPS 59083 binds to both molecules A and B of TbrPDEB1 but in the same 
active site. A detailed view into the binding site reveals that ligand binding in the P-pocket of TbrPDEB1 is 
conserved [164]. 
 
All the solved crystal structures of TbrPDEB1 complexed with different ligands either by co-
crystallisation or soaking show a common binding site with different modes of binding due to 
chemotype groups as observed in the known P-pocket binding site with Piclamilast [171]. As 




Binding site analysis was required in all complexes to identify key residues and interactions, 
as well as unique features. Ligplot studies [172] were undertaken to investigate the residues 
responsible for ligand binding, which would help in the design of potential drugs for the 
treatment of HAT by inhibiting the activity of TbrPDEB1.  
 
4.3.5 Analysis of the TbrPDEB1 active site 
                                                                                     
Figure 4.13. Ligplot representation of the binding site of TbrPDEB1 with VUF 14234 (A) |2Fo-Fc|αc 
electron density map of ligand VUF 14234 complexed with TbrPDEB1 contoured at 0.67 σ. (B) Ligplot 
representation of the interactions of VUF 14234 with key residues in TbrPDEB1 (dashed red semi-spheres lines 
represent hydrophobic interactions and green dashed lines representing hydrogen bonding) 
 
 






Figure 4.14. Ligplot representations of the binding site of TbrPDEB1 with different ligands (A) PPS 59083 
in Chain A of TbrPDEB1 (B) PPS 59083 in Chain B of TbrPDEB1 (C) PPS 60036 (D) VUF 14450 Dashed red 
semi-spheres represent hydrophobic interactions; green interactions represent hydrogen interactions.  
All these ligands are binding to TbrPDEB1. Their interactions with the key residues in TbrPDEB1 are being 





responsible for binding are common in the ligand binding site of TbrPDEB1. All the ligands commonly interact 
with the residue Q874 from the P-pocket.  
 
Figures 4.13B and 4.14 show that the ligands are predominantly stabilised by hydrophobic 
interactions. There is also the presence of the conserved hydrophobic interaction between the 
carbon atoms of the ligands and the residue Q874 from the helix H15 of the P-pocket, as seen 
in previous studies [164] – [169]. These ligands are good scaffolds for the design of Tbr 
inhibitors due to their specificity for the P-pocket [173]. Figure 4.13A shows the Wincoot 
representation of the VUF 14234 ligand bound to the TbrPDEB1, where the incorporation of 
the ligand is well established. Figures 4.13B and 4.14 confirm that the key residues involved 
in binding in TbrPDEB1 are M785, D822, I823, N825, A837, V840, T841, L859, M861, 
F862, G873, F877 and Q874.  
Apart from the conserved residues in the ligand binding site of TbrPDEB1, the ligand PPS 
59083 also makes hydrogen interactions with the residues Y845, M868 and E869. The ligand 
PPS 60036 makes hydrogen interactions with the residues L870 and N867. The ligand VUF 
14450 makes hydrogen interactions with the residues W836, A837 and Y668.  
All these Ligplot interactions have characterised the ligand binding site of TbrPDEB1, which 
are highly conserved throughout all the studied structures. The residue Q874 plays a major 
role by forming hydrophobic interaction with each of the ligands studied.  
Normal fragment-based approaches for drug screening require high concentration bio-assay 
or biophysical screening by SPR, NMR, ITC or Thermal Shift Assay to identify bindings 
followed by X-ray crystallography to determine three-dimensional positions for optimal 
chemistry follow-up.  X-ray fragment screening alone does not provide binding affinities but 
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instead can be used as primary screen method. NMR can be used to infer binding affinity 
information through STD-NMR and titration experiments. NMR can only be used as a three-
dimensional technique if the isotopically labelled protein is fully assigned, but the assignment 
can help in understanding protein-ligand interactions therefore obviating the need for X-ray 
crystallography.  
 
4.4 Characterisation of TbrPDEB1 by NMR Spectroscopy 
 
Analysis of the protein-ligand interactions in NMR is usually undertaken with the full 
assignment of 
15
N isotopically labelled protein, for which the protein needs to be folded and 
stable at 25 °C.  




H TbrPDEB1  
 
The stability of TbrPDEB1 was investigated by proton-based experiments at 25 °C from a 
15
N isotopically enriched sample expressed in E.coli T7 express cells grown in minimal 
media and purified in GF Buffer (25 mM NaH2PO4, 100 mM NaCl and 1 mM DTT pH 6.5) 





Figure 4.15. Spectrum of 
1
H TbrPDEB1 at 25 °C: proton experiment with water suppression Spectrum 
between 6 and 10 ppm represent the amide/aromatic region and side chain NH2; spectrum between 0 and 6 ppm 
represent the alpha region, water suppression and side chains CH, CH2 and CH3; spectrum between 0 and -2 
ppm represent the methyl/aliphatic region. The peaks are broad and not dispersed, revealing that the protein is 




H TbrPDEB1 experiment (Figure 4.15) shows that the protein peaks are broad and not 
dispersed, indicating that the protein is unfolded and the GF buffer conditions are not suitable 
for the protein to remain stable. The broad peaks arise from the overlapping of the residual 
peaks due to dimerisation of the protein.  
The 
1
H TbrPDEB1 spectra however contains very sharp and intense resonances that are not 
protein in nature. These could be derived from non-deuterated DTT present in the final gel 
filtration buffer. They could also be from glycerol, which was present in Nickel Affinity 
buffers, desalting buffer and ion-exchange buffers, and not completely filtered out during the 
final buffer exchange in the gel filtration chromatography. This could also arise from residual 















H Heteronuclear Single Quantum Correlation (HSQC) experiment was acquired on the 
spectrometer Avance III 600 MHz (F2) and 60 MHz (F1) at 25°C, with 1024 points         
(9000 Hz) in the direct F2 dimension (
1
H) and 256 points (2100 Hz) in F1 (
15
N) indirect 
dimensions using 50 ms EBurp Pulse 2. There were a total number of scans of 8 within an 
acquisition time of 0.11 seconds in F2 dimension and 0.07 seconds in the F1 dimension. The 
relaxation delay time (D1) in the experiment was 1.5 seconds. Watergate was the water 
suppression used with pulsecal. The size of the real spectrum was 4096 in the F2 dimension 







N HSQC Spectrum of TbrPDEB1 at 25 °C None of the TbrPDEB1 protein peaks in the 
spectrum can be identified. The peaks are all broad and unclear, suggesting that the protein is unfolded and 
cannot be assigned with further triple resonance through-bond experiments. 
                            1H      chemical shift                            (ppm) 






N HSQC experiments (Figure 4.16) confirm that TbrPDEB1 is unfolded and does not 
inform about any of amino acid groups. The spectrum cannot be assigned through-bond triple 
resonance experiments, as none of peaks can be matched with a specific amino acid from the 
TbrPDEB1 protein sequence. A perfect spectrum would not be expected for this sample, as it 
is a 37kDa alpha helical protein and this is not a TROSY spectrum. It could be a result of 
aggregation and there could be some internal dynamics (a dimer in solution).  
 
4.4.3 NMR experiments with temperature variation 
 
The stability of TbrPDEB1 was investigated by proton-based experiments at a temperature 
range from 25 °C to 50 °C from a 
15
N isotopically enriched sample expressed in E.coli T7 
express cells grown in minimal media and purified in GF Buffer (25 mM NaH2PO4, 100 mM 
NaCl and 1 mM DTT pH 6.5) as described in Chapter 2.5. The final concentration of the 
protein was 0.3 mM.  
 
Increasing the temperature at which the spectrum of an NMR sample is measured at is a good 
technique to improve the resolution and decrease the broadness of overlapping NMR peaks 
by decreasing the rotational correlation time of the protein. However, improvements in the 
spectrum’s quality  due to a decrease in the rotational correlation time have to be balanced 
against a reduction in the stability of the proteins fold as it approaches its thermal unfolding 
limit leading to aggregation or exchange with unfolded or partially folded species. (Figure 






Figure 4.17. Spectrum of 
1
H TbrPDEB1 at 25 °C to 50 °C A) The red spectrum represents the data at 25 °C 
and the blue spectrum at 35 °C. B) Yellow 25 °C, purple 35 °C, green 40 °C, red 45 °C and blue 50 °C. The 


















Increasing the temperature did not improve the resolution or the resonance of the 
1
H 
TbrPDEB1 spectrum. The broadness and low-dispersion of the lines were still observed at all 
temperatures, indicating that TbrPDEB1 was not suitable for NMR characterisation studies. 
Again non-protein peaks are present in the spectra, which could be explained by DTT, 
glycerol and/or residual water. 
 
4.5 Summary and Discussion 
 
Chapter 4 has attempted to characterise the structure of TbrPDEB1 using X-ray 
crystallography and NMR methods. TbrPDEB1 was studied in complex with the ligands 
VUF 14234, PPS 59083, PPS 60036 and VUF 14450. X-ray crystallography studies revealed 
a conserved binding mode, where the active site consisted of magnesium and zinc ions. The 
residue Gln874 was conserved in all the crystal structures, which is the main residue from the 
parasite-specific P-pocket. In fact, all the ligands investigated in this study were directing 
themselves towards the P-pocket residue, which suggested that this P-pocket can be used as 
an important target in the design of therapeutic drugs for the treatment of HAT.  
 




H experiments resulted in broad and 
poorly dispersed peaks. Optimisation by increasing temperatures from 25 °C to 50 °C did not 
improve the spectra of TbrPDEB1. Therefore, the NMR screening methods could not be 




H experiments with a ligand 




TbrPDEB1 was a good crystal example, as the interactions of the ligand with the protein 
could be characterised with the four different ligands studied. The protein’s size, stability in 
NMR buffer and NMR tumbling rate were considered as limiting factors for such NMR 
studies. Therefore, this study highlighted that not all proteins can be suitable for the purpose 
of drug design using the NMR technique. However, this work is part of a publication in press 
with Nature Chemical Biology for its contribution in the treatment of HAT.  




Crystal Structures of BRD4-BD1 in 






BRD4 (PDB code: 3MUK) (EC 3.1.1.31) is a nuclear protein belonging to the bromodomain 
and extra-terminal domain (BET) family, and is the most characterised protein within the 
BET family, which also consists of BRD2, BRD3 and BRDT (Figure 5.1). The BET 
bromodomain family members’ main role is to recognise and selectively bind to discrete 
patterns of acetylated protein residues. Acetylation of histones is an important post-
translational modification, affecting lysine residues in all histones and regulating DNA 
transcription, replication, repair and recombination [176] - [180]. Among those different post-
translational modifications that exist in histones, including methylation, phosphorylation, 
ubiquitination and sumoylation, acetylation remains the most abundant histone modifications 
in humans, generally associated with active genes and ruling gene expression [180]. Histones 
are commonly acetylated by histone acetyltransferases, and deacetylated by histone 
deacetylases [179]. Histone and non-histone protein acetylations mediate their functions by 
recruiting bromodomains on acetylated lysine and specifically interacting with them, which 




Figure 5. 1.Phylogenetic tree of the human bromodomain family and substrate recognition of 
bromodomains. (A) A total number of 61 bromodomains have been identified in 46 different proteins in the 
human proteome, which are actively involved in a wide range of cellular functions [176] - [181]. The 
phylogenetic tree is based on sequence alignments of predicted BRDs. Some BRDs recognise several targets, for 
which the domains are mentioned in brackets. BRD4 protein is the best characterised within the BET family. (B) 
Overlay of mouse BRD4 (orange cartoon model) with mouse BRDT (green cartoon model) with mono-
acetylated Lys14 in histone H3 (orange sticks) and a di-acetylated H4 peptide mono-acetylated on both Lys5 
and Lys8 (green sticks). (C) Surface representation in similar orientation [176] – [181].  
Adapted from: Susanne Muller, Panagis Filippakopoulos and Stefan Knapp (2011) Bromodomains as 
therapeutic targets. Expert Reviews in Molecular Medicine. 13(29) [183]  
 
 
All BET bromodomain family members possess two related and tandem bromodomains, 
BRD4-BD1 and BRD4-BD2 in their N-terminal domain and extra-terminal domain, each 
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recognising and binding to acetylated lysine residues on histone and non-histone proteins. 
Unlike the other BET family members, BRD4 contains a unique extended C-terminal 
domain. The bromodomain proteins are highly conserved and they both contain similar 
hydrophobic binding pockets (Figure 5.2). [176] – [181].  
 
Figure 5. 2. Domain organisation of the bromodomain BRD4 and extra-terminal domain (BET). The 
evolutionarily conserved domains found in BRD4 are bromodomain 1 (BD1), bromodomain 2 (BD2), extra-
terminal (ET), motif B and SEED (Ser/Glu/Asp-rich region – not shown in the diagram). Motif A and the 
carboxyl-terminal motif (CTM) are present only in some family members. Numbers indicate the amino acid 
limits of the human protein [176] – [181]. Adapted from: Chiang CM (2009) Brd4 engagement from chromatin 
targeting to transcriptional revolution: selective contact with acetylated histone H3 and H4. F1000 Biol. RFep. 
1(98). [184]  
 
Bromodomains are formed of approximately 110 residues that are arranged into a package of 
four α-helices, which are known as αZ, αA, αB and αC. The four helices are interconnected 
through loops, which are named ZA and BC loop regions, and the loops form a deep 
hydrophobic pocket, which is responsible for binding to acetylated lysine residues (Figure 





Figure 5. 3. Comparison of (a) BRD4 crystal structure (PDB: 3MUK) with (b) experimental BRD4 crystal 
structure and the protein sequence of BRD4. (A) Crystal structure of BRD4-BD1 (3MUK). The protein 
surface is shown in gray. The purple ribbons represent the αZ, αA, αB and αC helices, which are interconnected 
by ZA and BC loops. The loops form the hydrophobic acetyl-lysine binding pocket. (B) Apo crystal structure of 
BRD4-BD1 is compared with 3MUK, and it is clear that both the structures are similar. Adapted from: Silviya 
D. Furdas, Luca Carlino, Wolfgang Sippl and Manfred Jung (2012) Inhibition of bromodomain-mediated 
protein-protein interactions as a novel therapeutic strategy. Med. Chem. Commun. (3) 123-134 [185]  
 
5.1.1 Functional Studies of BET BRD4 
 
BRD4 binds many partners, including acetylated histone 3 (H3) and histone 4 (H4) tails as 
part of the maintenance of the architecture of chromatin, and acetylated v-rel avian 
reticuloendotheliosis viral oncogene homolog A (RelA) by binding to acetylated lysine 310 
and thereof stabilising nuclear NF-κB in the control of DNA transcription.  The unique extra 
terminal domain of BRD4 can also interact with many chromatin modifiers, such as histone 
methyltransferase NSD3 [176] – [181] [183]. BD1 and BD2 bind to the acetylated histone 




positive transcription elongation factor b. As the transcription elongation factor B is 
responsible for the phosphorylation of RNA Polymerase II by CDK9, bromodomain binding 
promotes the transcription elongation (Figure 5.4) [176] – [181] [183] [184].  
Figure 5. 4. Mechanism of transcriptional regulation by BRD4 [150] Bromodomains are transcriptional co-
activators. BRD4-BD1 and BD2 bind to acetylated histone tails (H3/H4), and form complex with the acetylated 
cyclin T1 subunit of the transcription elongation factor B (PTEFB; the complex formed by cyclin-dependent 
kinase 9 (CDK9) and its activator cyclin T), leading to phosphorylation of the carboxy-terminal heptat repeat 
region of RNA polymerase II (RNA Pol II). Adapted from: Panagis Filippakopoulos and Stefan Knapp (2014) 
Targeting bromodomains: epigenetic readers of lysine acetylation. Nature Reviews Drug Discovery. 13, 337–
356 [186].  
 
Jung et al. studies proved that the strongest interactions of BRD4 BD1 and BD2 are with di- 
and tetra- acetylated peptides derived from the histone 4 N-terminal tail. They have also 
demonstrated that the neighbouring residues around the acetylated lysine significantly 
influence the binding mode of the bromodomains. Bromodomain binding is highly selective, 
as they specifically bind to designated patterns of acetylation with appropriate neighbouring 
amino acids. Moreover, not only promoter regions are recognised by bromodomains, but also 
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inter- and intra-genic regions. In fact, the BRD4 ET domain also binds to chromatin 
modifiers, such as the histone methyltransferase NSD3 [181].  
 
5.1.2 BET BRD4 as drug target 
 
Discovery of BRD4 inhibitors, such as JQ1 and I-BET151 have helped to have better insights 
in the understanding of the function of BRD4 (Figure 5.5). It has shown that BRD4 binds to 
target genes that are part of the cell cycle control and tumour diseases, such as c-Myc, c-Fos 
and cyclin D1. As such, BRD4 is an attractive target in certain tumours and cellular 
proliferative disorders Shi et al. have shown that a rare cancer NUT midline carcinoma 
(NMC) is believed to be caused by the genotype of a fusion between BRD4 (or BRD3) and 
the nuclear protein (NUT) initiated by a mutation of chromosomal translocation. Clinical 
trials using xenograft models have demonstrated in “in-vivo” that addition of the BET 





Figure 5. 5. Interactions of BRD4-BD1 with JQ1 (A) Overlay of the mouse BRD4–H3K14ac peptide 
complex28 (brown cartoon protein model with green stick peptide model) with the human BRD4-JQ1 (purple 
cartoon protein model with yellow stick ligand model) complex structure. The hydrogen bond formed to the 
conserved asparagine (N140) in the peptide complex is shown as yellow dashed lines.  (B) |2Fo-Fc|αc electron 
density map of inhibitor JQ1 extracted from the BRD4-BD1/JQ1 complex contoured at 2 σ. Adapted from: 
Panagis Filippakopoulos et al. (2010) Selective inhibition of BET bromodomains. Nature 468: 1067-1073 [186].  
 
Similarly, several other clinical studies with BRD4 and JQ1 have started in the treatment of 
haematological malignancies, such as acute myeloid lymphoma, acute lymphoblastic 
leukaemia, lymphoma, paediatric B precursor acute lymphoblastic leukaemia and multiple 
myeloma. Additionally, BET inhibitors have played inhibitory roles in solid tumours, 
including glioblastoma, neuroblastoma, lung cancer and melanoma, confirming that BET 
inhibitors have anti-proliferative effects [176] – [180].  
The other common BET inhibitor, I-BET762, has been shown to protect again endotoxic 
shock and sepsis, therefore BRD4 may also be implicated in inflammation and inflammatory 
disorders.  Other studies show that herpes and papilloma viruses use BRD4 in the host biotic 
chromosomes for their propagation during cell division. These multiple examples highlight 
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that the binding of BET bromodomains to acetylated lysines is a key determinant for the 
activation of many downstream cellular targets [176] – [180].  
 
5.1.3 Structural studies highlighting key residues and interactions in BET BRD4 
protein 
Structural studies of BET bromodomains co-crystallised with histone-derived peptides 
demonstrated that there is a conserved asparagine residue in the BC loop of BRD4-BD1 
making a hydrogen bond contact with the substrate acetyl-lysine side chain (Figure 5.6). This 
conserved residue and bonding is also observed in other bromodomains. Similarly, NMR 
studies of the complex BRD4-BD2 with NF-κB-K310 also revealed important interactions, 
such as Asn433 from the protein forming a direct hydrogen bonding with the acetylated 
lysine. Moreover, several other residues from the ZA loop, as well as the αB and αC regions, 
are also involved in the interactions with acetylated lysine. These “apo” structures were 
compared with crystal structures complexed with BET inhibitors, including JQ1 or                
I-BET762, and the comparison highlighted that the inhibitors bind to the loop regions in 
exactly the same way as the acetylated lysine substrates (Figure 5.6). Therefore, they are both 





Figure 5. 6. Comparison of BRD4-BD1/I-BET762 complex with BRD4-BD1/JQ1 complex. Overlay of 
BRD4-BD1 (blue cartoon model) complexed with I-BET762 (red stick model) (PDB Code: 4C66) and BRD4-
BD1 (cyan) complexed with JQ1 (yellow stick model) (PDB Code: 3MXF). The overlay suggests that the 
binding mode is conserved regardless of the ligand type.  
 
 
Mutational analyses of the key residues involved in substrate binding were undertaken to 
understand the effects on ligand binding, including Tyr139 and Tyr432 in BRD4-BD1, or 
Tyr139 and Val439 residues in BRD4-BD2. Following the mutations, the mutant 
bromodomains experienced a change in binding affinity and impaired interaction with 
acetylated chromatin in comparison with wild-type bromodomains. Other studies investigated 
the consequences of mutating Asn140 in BRD4-BD1 and Asn433 in BRD4-BD2. Both of the 
mutations led to the inhibition of binding of di-acetylated H4 peptides, revealing the 
importance of the hydrogen bond formed with the well-conserved asparagine residue. It has 
been also revealed that the neighbouring residues to Asn140 are also important for the 
interaction of BRD4-BD1 with acetylated RelA, such as Tyr139. Interestingly, these studies 
confirm that certain residues from the active site of BRD4-BD1 are important for the binding 
of the bromodomain proteins to acetylated substrates, and therefore interference with those 
residues could easily result in a failure in substrate binding [176] – [180].  
Resistance mutations in many cancer drug targets is well described and therefore the 
development of next-generation inhibitors for bromodomains is essential. Further structural 
characterisation by X-ray crystallography would serve to improve the current understanding 
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of the mechanisms underlying specific interactions of bromodomains with chromatin. This 
would help in the design of future compounds with high potency targeting specifically the 
BET BRD4 family [176] – [180].  
 
5.2  Recombinant expression and purification of BRD4-BD1 from 
E.coli and crystallisation 
 
 
5.2.1 Recombinant expression and purification 
 
Recombinant human pET24a BRD4-BD1 (147 residues) with kanamycin resistance was 
expressed and purified to homogeneity in E.coli T7 express cells grown in 2 xYT media. A 
yield of 9 g pellet was obtained.  
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The first step of purification involved nickel-affinity chromatography using Buffer A on        
5 mL His-Trap Column (50 mM HEPES pH 7.5, 500 mM NaCl, 5 % (v/v) glycerol, 10 mM 
imidazole) for equilibration, and Buffer B (50 mM HEPES pH 7.5, 500 mM NaCl, 5 % (v/v) 
glycerol, 250 mM imidazole) for elution (Figure 5.7).  
Figure 5. 7. Elution Profile of BRD4-BD1 on His-Trap 5 mL Immobilised Nickel Affinity 
Chromatography The peak of elution (red rectangle) represent the His-tagged BRD4-BD1 protein. 
 
The first eluted fraction was subjected to TEV (stock: 2 units/μL) cleavage and was added on 
the basis of 2 units/mL, and the fraction was stored at 4 °C overnight. The final step of the 
purification of BRD4-BD1 was gel filtration chromatography using GF Buffer on Superdex 
S-75 Column (10 mM HEPES pH 7.5, 50 mM NaCl, 5 % (v/v) glycerol) for both 




Figure 5. 8. Elution Profile of BRD4-BD1 on Superdex S-75 Column Gel Filtration Chromatography 
Fractions A9 - A12 (blue rectangle) show the elution of aggregates and fractions B10 - B5 (red rectangle) show 











Figure 5. 9. Purification of BRD4-BD1 by Nickel-Affinity Chromatography and Gel Filtration 
Chromatography The purification fractions on the 4-12 % (w/v) Bis-tris gel show ~ 70 % purity of BRD4-BD1 
at the expected molecular weight of 15 kDa after nickel affinity chromatography (Ni). The gel shows ~ 90 % 
purity of protein after gel-filtration chromatography (B8-B5). Lys: lysate, FT: flow-through, Ni: Nickel elution 
of BRD4-BD1, A10 - B9: Aggregate peaks, B8 - B5: BRD4-BD1 purified protein.  
 
The final purified yield of BRD4-BD1 was 25 mg per litre.  
Lys     FT      Ni      A10    A11    B9     B8     B7     B6     
B5 
BRD4-BD1 – 15 kDa 
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5.2.2 Protein Crystallisation 
The crystallisation of BRD4-BD1 was performed following the crystallisation conditions 
described by Vollmuth, F. and Geyer, M [187]. The protein was concentrated at 12 mg/mL, 
equivalent to ~ 0.8 mM for crystallisation. Best crystals for diffraction were obtained from 
3.5 - 5 M sodium formate conditions after 24 hours at 4 °C (Figure 5.10). 
Figure 5. 10. BRD4-BD1 crystals in 3.5 M sodium formate The BRD4-BD1 crystals always tend to grow 
with an amount of precipitation in the background. The crystals diffracted up to 1.2 Å on IO4.1 beamline at a 
wavelength of 0.97949 Å, temperature of 100 Kelvin with a 100 % exposure for 0.1 seconds / 0.1º oscillation.  
 
The space group was P212121. Previous studies have shown that this is a soakable protein 
system [187]. 
 
5.2.3 Addition of Ligands 
Compounds for soaking as part of the development of the 
19
F fragment library were identified 
by Maybridge Ltd (Cambridge, UK) and Charles River Early Discovery. Surface Plasmon 
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Resonance (SPR) undertaken with Dr. Steve Irving (Charles River Early Discovery) and 
Kimberley Young was used to detect molecular interactions of ligands with BRD4-BD1, and 
determine the corresponding binding affinities (KD) using DMSO stock compounds. Seven 
best hits were selected for crystallographic studies within the micro-molar to nano-molar 
ranges (Table 5.1).  
 
Table 5. 1. Summary of the soak and co-crystallisation experiments  Data obtained,  No data could be 
obtained due to DMSO intolerance in soaks or no crystals were grown in co-crystallisation. 
 
DMSO is known to bind to BRD4-BD1, therefore compound solids were dissolved to         
100 mM stock in ethanol. Compounds were used in equimolar ratio with protein 
concentration (0.8 mM). Crystals were soaked for 2 days at 4 °C before cryo-cooling in liquid 
nitrogen with 20 % ethylene glycol cryosolvent for data collection.  





BTB 01148 433  Soak / Co-Crystal   
BTB 06033 590  Soak / Co-Crystal   
BTB 07004 198  Soak / Co-Crystal   
RJF 00210 320  Soak / Co-Crystal   
TG 00013 0.9  Soak / Co-Crystal   
HTS 05027 580  Soak / Co-Crystal   
RJF 00002 750  Soak / Co-Crystal   
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In addition, the co-crystals were performed at a ratio of 2 : 1 ligand to protein excess under 
the same conditions as apo crystal crystallisation conditions.  
 
5.3  Crystallographic Solutions of BRD4-BD1 
 
All data was collected at DIAMOND on IO4.1 beamline at a wavelength of 0.97949 Å, at a 
temperature of 100 Kelvin with a 100 % exposure for 0.1 seconds / 0.1º oscillation. The space 
group was orthorhombic P212121.  
Data was auto-processed through Xia2 [138]. As the auto-processed data sets missed a         
21 screw axis, a simple molecular replacement with Phaser [188] into P212121 was performed 
using the apo structure of BRD4-BD1 as search model. Ten rounds of structural refinement 
using Refmac5 [136] were performed and the difference density maps were examined for 
presence of the ligand. Once satisfied with the presence of the ligand, the structure was 
finalised with Buster. 
 
5.3.1 BRD4-BD1 with ligand structures 
 





Table 5. 2. Summary of the X-ray crystallography data collection of BRD4-BD1 with ligand structures 








































Unit Cell Angle 
(°) 













































0.1 0.1 0.1 0.1 0.1 0.1 0.1 
Overall 
rotation (°) 





40.19 - 1.79 31.24 - 1.72 30.29 - 1.27 39.32 - 
1.46 
40.63 - 1.55 26 - 1.69 
Multiplicity 5.7 (3.0) 6.1 (5.9) 6.2 (6.7) 6.2 (5.4) 5.9 (6.0) 5.4 (4.8) 6.3 (6.4) 
Completeness 
(overall) (%) 
97.3  99.3 98.2 99.8 99.4 99.4 98.9 
Mean I/sigma 
(I) (overall and 
last shell) 



































































1.18 1.79 1.72 1.27 1.46 1.55 1.69 
R-factor (%) 
(last shell) 
20 25.9 28.6 14.7 19 25.1 38.0 
R-free (%) 25 25.78 34.6 18.9 22 27.5 40.0 
RMSD Bond 
lengths (Å) 
0.024 0.020 0.016 0.037 0.022 0.019 0.0142 
RMSD Bond 
Angles (°) 












17.6 56.959 42.670 15.002 17.168 19.238 60.233 
 Number of 
Protein 
Residues 
124 122 122 123 126 124 123 
Number of 
water atoms  
modelled 




99.10 96.30 95.61 97.5 98.29 96.72 94.92 
Ramachandran 
allowed (%) 





0.00 0.00 0.00 0.83 0.85 0.00 1.69 
 
Table 5. 3. Summary of the X-ray crystallography structure refinement and Ramachandran Plot statistics 






Figure 5. 11. Crystal structure of BRD4-BD1 co-crystallised with the ligand BTB 07004  
The ligand BTB 07004 binds to BRD4-BD1. A detailed view reveals that BTB 07004 is binding in the loop 



























Figure 5. 12. Overlay of crystal structures of BRD4-BD1 in complex with the ligands BTB 01148 (blue), 
BTB 06033 (pink), RJF 00210 (yellow), TG 00013 (green), HTS 05027 (orange) and RJF 00002 (cyan) 
The ligands have bound to BRD4-BD1 in the same site but with different binding modes. The ligand binding in 
the loop region of the protein is conserved. 
 
All the solved crystal structures of BRD4-BD1 complexed with different ligands either by co-
crystallisation or soak show a common binding site with different modes of binding due to 
chemotype groups as observed in the known acetyl binding site with JQ1 [181]. As such, this 
suggests that the fragments are suitable for the development of new inhibitors.  
Binding site analysis was required in all complexes to identify key residues and interactions, 















Figure 5. 13. Ligplot representation of the binding site of BRD4-BD1 with BTB 07004 (A) |2Fo-Fc|αc 
electron density map of ligand BTB 07004 complexed with BRD4 contoured at 1.09 σ. (B) Ligplot 
representation  [172] of the interactions of BTB 07004 with key residues in BRD4-BD1 (dashed red semi-




















Figure 5. 14. Ligplot representations of the binding site of BRD4-BD1 with different ligands 
(A) BTB 01148 (B) HTS 05027 (C) RJF 00210 (D) BTB 06033 (E) TG 00013 and (F) RJF 00002. Dashed red 
semi-spheres represent hydrophobic interactions; green interactions represent hydrogen bond interactions.  
All these ligands are binding to BRD4-BD1. Their interactions with the key residues in the protein are being 
analysed through Ligplot studies. The examples show that the binding is conserved and the key residues 
responsible for binding are common in the ligand binding site of BRD4-BD1. 
 
 
Figures 5.13B and 5.14 show that the ligands are predominantly stabilised by hydrophobic 
interactions. There is also the presence of the conserved hydrogen bond interaction between 
the nitrogen groups of the ligands and the residue N140, as seen in previous studies [176] – 
[180], except for the ligand RJF 00002. Figure 5.13a shows the Wincoot representation of the 
BTB 07004 ligand bound to the protein, where the incorporation of the ligand is well 
established. Figures 5.13b and 5.14 confirm that the key residues involved in binding in 





The ligands BTB 01148 (Figure 5.14A) and HTS 05027 (Figure 5.14B) connect 
hydrophobically to other residues not listed above, which are V87 and M149, respectively. 
As opposed to the other structures, the RJF 0002 ligand (Figure 5.14F) is making an 
interaction with Y97, which was not observed in the other structures. Although Y97 has 
already been seen to be involved in the binding process of the other ligands, it seems to be 
more involved by the formation of hydrogen bonding, in comparison to previous hydrophobic 
interactions. Moreover, C136 and N135 are also taking part in the binding of the ligand to the 
protein.  
All these Ligplot interactions have characterised the ligand binding site of BRD4-BD1, which 
are highly conversed throughout all the studied structures. The residue N140 plays a major 
role by forming hydrogen bond interaction with each of the ligands studied, apart from the 
ligand RJF 00002, where only Y97 forms a hydrogen bonding. It is important to notice that 
the crucial interaction of hydrogen bonding with the residue N140 is conserved and observed 
in all the structures described above.  
Normal fragment-based approaches for drug screening require high concentration bio-assay 
or biophysical screening by SPR, NMR, ITC or Thermal Shift Assay to identify bindings 
followed by X-ray crystallography to determine three-dimensional positions for optimal 
chemistry follow-up.   X-ray fragment screening alone does not provide binding affinities but 
instead can be used as primary screen method. NMR can be used rather to infer binding 
affinity information through STD-NMR and titration experiments. NMR can only be used as 
a three-dimensional technique if the isotopically labelled protein is fully assigned, but the 
assignment can help in understanding protein-ligand interactions therefore obviating the need 
for X-ray crystallography.  
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5.4 Summary and Discussion 
 
BRD4-BD1 was studied as part of the development of the fluorinated fragment-based library 
in collaboration with Maybridge (Cambridge, UK). The collaborators also provided with 
several batches of fluorinated compounds, which were then tested on the SPR with Dr Steve 
Irving and Kimberley Young. The fragments were thought to be well behaved in SPR, with 
most binders revealing “square wave” fast on/off sensorgrams. The non-specific binds were 
suppressed from the final list of hits, and a hit rate of 2.9 % was attained for BRD4. Among 
the fragment hits, seven compounds were chosen on the basis of their KD and X-ray 
crystallography was performed. Seven compounds were successfully crystallised in complex 
with the protein, either by co-crystallisation or soaking techniques.  
X-ray crystallographic studies revealed a conserved binding site in the loop region of BRD4-
BD1, validating previous studies. The loops of BRD4-BD1 (ZA and BC) are important 
elements for the ligand binding in the acetyl lysine pocket. The types of amino acid residues 
forming the loops determine the specificity of binding of the protein to the particular 
acetylated lysines. The residues forming the bromodomain loops differ in every 
bromodomain type, which renders them unique, and act as interesting drug targets. 
Effectively, the inhibitors targeting the loop regions can prevent the interaction with 
acetylated proteins and reverse the post-translational modifications causing the human 
diseases [176] – [180] [182]. The fragment ligands used in this study can act as interesting 
scaffolds that can be developed further as anti-BRD4 drugs for targeting the loop region, and 
therefore act as a potent inhibitor for the actions of BRD4-BD1. The residue N140 is making 
an important hydrogen bonding, which was conserved in all the BRD4 structures. Therefore, 
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N140 plays an important role in the binding pocket, as suggested in previous studies [176] – 
[180] [182].   













H BRD4 complexed with BTB 07004. In addition, the 
19
F-CPMG was 
found out to be a very powerful and rapid screening technique.  
 
 




Ligand binding studies of BRD4-
BD1 using NMR 
197 
 
This chapter’s main emphasis is to understand the interactions of BRD4 with the ligand BTB 
07004 using various NMR methodologies, and to characterise the protein residues involved in 
ligand binding. The ligand BTB 07004 was chosen because of its affinity of 198 μM by SPR, 
which is a suitable range for testing binding. STD-NMR is known to be a good technique to 
understand protein-ligand interactions in the μM range [56] [59].  
The different NMR methods used were ligand-observed 
1
H STD and 
1





N chemical shift perturbation (which requires protein backbone assignment). The 
study also includes 
19
F-based NMR methods (CPMG) for detecting ligand binding. The crystal 
structure of the complex was already described (Chapter 5) and was used to highlight the 
advantages and disadvantages of each biophysical approach.  
  
6.1 Ligand-observed NMR screening methods of BRD4-BD1 with 
BTB 07004 
 
The ligand-observed NMR screening methods used in these studies are 
1
H STD and 
1
H CPMG. 
The purpose of these experiments is to identify the suitable binders to a protein. They do not 
require a full protein assignment or any NMR-based information about the receptor [56] [59] 
[66]. The structure of BTB 07004 bound to BRD4-BD1 is known from crystallography.  
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6.1.1 NMR Sample Preparation of BRD4-BD1/BTB 07004 complex 
 
The binding of BTB 07004 with BRD4-BD1 was evaluated with STD and CPMG experiments 
using an unlabelled sample of BRD4-BD1 expressed in E.coli T7 express cells grown in rich LB 
media and purified in GF Buffer (25 mM NaH2PO4, 100 mM NaCl and 1 mM DTT pH 6.5) as 




6.1.2 NMR Sample STD Data Acquisition 
 
1
H STD experiments were acquired on a Bruker Avance III 600 MHz spectrometer at 25°C, with 
16,384 points (spectral width 9615 Hz) in the direct F1 dimension (
1
H). A total number of       
256 scans were acquired with an acquisition time of 0.85 seconds. Saturation was achieved using 
an EBURP2 pulse of over a 20 ms saturation period, saturation was applied at -0.3 / -30 ppm for 
the on and off resonance experiments respectively. The type of water suppression used was 
excitation sculpting and the spectra were referenced against water. The relaxation delay time 
(D1) in the experiments was 4 seconds. Data were zero filled, Fourier transformed using 










H STD-NMR experiments performed at 25 °C on 0.1 mM BRD4-BD1 protein complexed with      
1 mM BTB 07004. Red spectrum off-resonance spectrum; Blue spectrum final difference STD difference spectrum. 




H     (ppm) 
1
H     (ppm) 
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As explained in Chapter 3.6.2, protons from the ligand that are closer to the protein receptor 
surface receive more saturation than protons that are further from the receptor. The off-resonance 
spectrum should show the ligand alone and the on-resonance should show the ligand signals with 
reduced intensities depending on how much saturation is transferred. Thus, the difference 
between on- and off-resonance gives the STD difference spectrum, revealing signals from ligand 
protons, which have bound to the protein receptor.  
Therefore, the BTB 07004 difference peaks (highlighted with *) show binding at 6.5 and 7 ppm. 





H Carr-Purcell- Meiboom Gill (CPMG) Data Acquisition and Analysis 
 
1
H CPMG experiments were acquired on a Bruker Avance III 600 Hz spectrometer at 25°C. Data 
were collected with 16,384 points and a spectral width of 9615 Hz in the direct F1 dimension 
(
1
H), with a total number of 128 scans and an acquisition time of 0.85s. The CPMG element used 
600 cycles with a delay of 1ms between 180-degree pulses. The relaxation delay time (D1) in the 
experiments was 0.1 seconds. Water suppression was achieved using a 3:9:19 watergate 
sequence and 100ms of pre-saturation.  Acquired data was processed in TopSpin 3.2 with an 





H CPMG experiments performed at 25 °C on 0.1 mM BRD4-BD1 protein complexed with 1 mM 
BTB 07004. Red spectrum BTB 07004 only; Blue spectrum BTB 07004 complexed with BRD4-BD1. All the 
1
H 
ligand peaks in the blue spectrum are attenuated in comparison to the red spectrum, indicating that BTB 07004 binds 
to BRD4-BD1.  
 
As explained in Chapter 3.5.4, attenuation of 
1
H peaks shows binding of the ligand to the protein 
in CPMG experiments. Therefore, Figure 6.2 indicates binding of BTB 07004 to BRD4-BD1. 
The CPMG experiment results confirm the crystallographic data and 
1
H STD experiments of the 
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As BTB 07004 was part of a fluorinated fragment library, binding of BTB 07004 to BRD4-BD1 
was examined by the use of 
19
F CPMG, where the measured signal is from a 
19





F CPMG is a similar experiment to 
1
H CPMG, where an attenuation of the 
19
F signal 
shows binding of the ligand to the protein. As for 
1
H CPMG, differentiation of binding is 
achieved through the spin-spin T2 relaxation of the nucleus. The T2 relaxation time shows a 
history of binding and unbinding events and the correlation time.  
 
6.1.4.1 NMR Sample 
19
F CPMG Data Acquisition 
 
19
F CPMG experiments were acquired on a Bruker Avance III 600 Hz spectrometer at 25°C. 
Data were collected with 32,768 points and a spectral width of 9615 Hz in the direct F1 
dimension (
1
H), with a total number of 128 scans. The CPMG sequence used 600 cycles with a 
delay of 1ms between 180 degree pulses. The relaxation delay time (D1) in the experiment was  
1 second. Data was processed with a line broadening of 5 Hz using exponential multiplication in 





F CPMG experiments performed at 25 °C on 0.1 mM BRD4-BD1 protein complexed with 1 mM 
BTB 07004. Blue spectrum BTB 07004 only; Red spectrum BRD4-BD1 and BTB 07004 complex A) with a 
1
H shift 
offset of the two spectra for clarity B) with no offset. The addition of the ligand causes the reduction of signal in the 
red spectrum, indicating binding of BTB 07004 to BRD4-BD1.  
 
19
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F peaks shows binding of the ligand to the protein in CPMG experiments. No 
changes in the 
19
F signals show non-binding. Therefore, the data in Figure 6.3 indicate binding of 
BTB 07004 to BRD4-BD1. The 
19
F CPMG experiment results confirm the crystallographic data, 
1
H STD and 
1
H CPMG experiments of the binding of BTB 07004 to BRD4-BD1.                       
 
All of these NMR screening methodologies are good tools to identify ligands/fragments that bind 
to the protein. 
19
F CPMG is a powerful and rapid screening technique due to a fast accumulation 
of spectra with little spectra overlap being present and no interference from buffer components 
etc. In comparison to 
1
H CPMG, the sensitivity does not differ much but a less crowded 
spectrum could be observed. 
19
F CPMG offers selective spectra based on the types of fluorines 
present in the ligand. Therefore, large number of compounds can be looked at in each spectrum 
of 
19
F CPMG without peaks overlapping. This is a great advantage in reducing the amount of 
NMR time and increasing throughput [66]. However, none of these ligand-based techniques are 
able to inform about the key residues in the protein binding site, and therefore are limited to 
simply identifying ligand “hits”. Consequently, this highlights the need for protein-observed 
methods for the prediction of protein ligand interactions in the application in structural-based 







6.2 Protein-observed NMR screening methods of BRD4-BD1 with 
BTB 07004 
 





H resonances of an isotopically labelled protein, for which the protein needs 
to be folded, soluble and stable at a concentration of > 300 µM for a period of at least 1-2 days 
while in use in  the spectrometer (typically in the temperature range of 10-25 °C, though lower or 
higher temperatures maybe used).   
 
6.2.1 NMR Sample Preparation of 
15
N BRD4-BD1  
The stability of BRD4-BD1 was investigated by proton-based experiments at 25 °C using a 
15
N 
isotopically enriched sample expressed in E.coli T7 express cells grown in minimal media and 
purified in GF Buffer (25 mM NaH2PO4, 100 mM NaCl and 1 mM DTT pH 6.5) as described in 




H Spectrum of BRD4-BD1 at 25 °C with water suppression. The peaks between 6 and 10 ppm 
originate from the amide/aromatics and side chain NH2s; peaks between 0 and 6 ppm contains the Cαs, water 
suppression artefacts and side chain CH, CH2 and CH3 resonances; peaks between 0 and -2 ppm originate from 




H BRD4-BD1 experiment (Figure 6.4) shows that the protein peaks are sharp and well 
















H Heteronuclear Single Quantum Correlation (HSQC) experiment was acquired on 
a Bruker Avance III spectrometer at 600 MHz (F2) and 60 MHz (F1) at 25°C, with 2048 points 
(9615 Hz) in the direct F2 dimension (
1






dimensions. There was a total of 8 scans per increment. Acquisition times were 0.11 seconds in 
F2 dimension and 0.07 seconds in the F1 dimension. Watergate was used for water suppression 
[190]. The relaxation delay time (D1) in the experiments was 1.2 seconds. The size of the 
processed spectrum was 4096 in the F2 dimension and 512 in the F1 dimension. Data was 






N HSQC Spectrum of BRD4-BD1 at 25 °C. There are 120 peaks in the spectrum, which are 
compatible with 147 amino acids of BRD4-BD1, 6 histidine amino acids from the His-tag and 9 amino acids from 
the thrombin cleavage site. The peaks are all sharp and clear, and well dispersed which suggest that the protein is 
folded and can be assigned with further triple resonance through-bond experiments.  






N HSQC experiments confirm that BRD4-BD1 is folded and informs the presence of 
certain types of amino acid groups. However, the spectrum needs to be assigned using through-
bond triple resonance experiments to be able to match each peak with a specific amino acid and 





Spectrum of CypA at 25 °C, it can be noticed that the BRD4 peaks are broader than CypA. 
Despite the fact that BRD4 is a smaller protein than CypA, the protein sample of BRD4 was 
slightly precipitated and cloudy suggesting mild oligomerisation of the protein, which could 








Assignments were performed using triple resonance spectra (HNCA, HN(CO)CA, HNCACB 
and HN(CO)CACB), which enable the identification of specific resonances of observed NMR 
active nuclei within a shift. Sequential assignment has always been the main method for amino 
acid backbone resonance assignment of proteins and has permitted the assignment of many large 




N HSQC and 
related spectra can be used for a variety of purposes, including measuring chemical shift 
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perturbations upon ligand binding, titrations to show the effect of changing pH, temperature, 
pressure and sophisticated experiments for measuring dynamics.   
In order to characterise BRD4-BD1 by NMR spectroscopy, it was essential to carry out a 
sequential backbone assignment by triple resonance. Triple resonance experiments require the 













Cβ atoms as well as all connected 
1
H atoms. The NMR spectrum 
consists of resonances, which are each linked with particular nuclei in the protein being analysed 
and are assigned to a spin-system and mapped to specific amino acid residues in the protein 
sequence. Consequently, the resonance should be accurate and assigned to the type of amino 
acid, and the assignment must also be specific for individual nuclei in each amino acid in the 
protein sequence [157]. 
Although BRD4-BD1 has been extensively studied crystallographically, few studies have looked 
into its characterisation by NMR, hence a complete assignment is not available in the literature 
or at the BioMagRes Bank (BMRB). The through-bond triple resonance experiments were 
performed to identify each amino acid by its distinctive spin-system. This was followed by 
matching the adjacent spin systems to uniquely identify the position within the protein sequence, 
enabling the complete assignment of BRD4-BD1 [157] – [159]. 




N with the 
13
C nuclei in 
a specific amino acid residue, known as “i”, and the 13C nuclei of the preceding residue, known 





N with the 
13
C nuclei of the preceding amino acid residue only                   
(i-1; HN(CO)CA, HN(CO)CACB, HNCO] (Figure 6.6). In this chapter, data from two pairs of 
210 
experiment [HNCA, HN(CO)CA, HNCACB, HN(CO)CACB] BRD4-BD1 is assigned. The 




N with the 
13
Cα of a residue i, and 
13
Cα of the previous 





N with the 
13
Cα of a residue and the preceding residue. HNCACB and 
HN(CO)CACB correlate atoms in a similar way with the addition of information from the CB 
atoms [157] – [159]. 
 Most of these experiments are carried in an out and back mode where the transfer of information 
is: H(i)  N(i)  Cα (i, i-1)*  N (i)* – H(i)*, where chemical shifts are only detected at the * 
residues. Transfer of magnetisation/information is achieved because of the large 1 bond 






C labelled atoms [157] – [159].  
Figure 6.6. Correlations in HNCACB and HN(CO)CACB experiments in a dipeptide fragment of a protein 
backbone. The diagram shows that the HNCACB and HN(CO)CACB experiments enable the correlation of each 








Once the triple resonance data has been used to combine spin systems into sequential fragment, 




N shifts, e.g.: a 
glycine has a 
13
Cα shift of ~45 ppm and an alanine has a 
13
Cβ shift of ~20 ppm. Fitting of 
chemical shifts to the proteins primary sequence was achieved using a mixture of Mapper 2 and 
manual methods [192]. In house python programs for the export of spin systems from CCPN 
Analysis to Mapper 2 were provided by G.S.Thompson at the University of Kent NMR Facility 
[157] – [159].  
 
6.3.2 The Assignment of BRD4-BD1 
 






H BRD4-BD1  
 
The backbone resonance assignment of BRD4-BD1 was obtained by through-bond triple 




C isotopically enriched sample expressed in E.coli T7 
express cells grown in minimal media and purified in GF Buffer (25 mM NaH2PO4, 100 mM 
NaCl and 1 mM DTT pH 6.5) as described in Chapter 2.5. The final concentration of the protein 
was 0.7 mM.  
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6.3.2.2 NMR Data Acquisition of HNCACB and HN(CO)CACB experiments 
 
HNCA, HN(CO)CA, HNCACB and HN(CO)CACB spectra were acquired at 25°C on a Bruker 
Avance III Spectrometer. Details of the experiments are summarised below: 










4.730 119.000 54.000 
Frequency (Hz) 9615.385 1824.293 4828.507 
Time Delay (points) 2048 (1024) 64 (32) 128 (64) 














4.699 120.000 38.997 
Frequency (Hz) 9615.385 1702.670 1136.644 
Time Delay (points) 1024 (512) 60 (30) 120 (60) 
Number of Scans HNCACB: 32 scans and HN(CO)CACB: 16 scans 
 
Table 6.1 NMR Experimental Details for  HNCA, HN(CO)CA, HNCACB and HN(CO)CACB experiments  
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Data were processed with NMRPipe with a cosine window applied in all dimension, water 
suppression using a convolution difference filter and linear prediction in the 
15
N dimension to 
increase the length of data by a factor of 2. All dimensions were zero-filled by a minimum of a 
factor of 2.   
 
6.3.2.3 Amino Acid Sequential Backbone Resonance Assignment 
 




Cβ for each amino acid. Certain amino acids can easily be identified, due to their 
characteristic chemical shifts, such as serine/threonine, which have a 
13
Cβ at a higher chemical 
shift field (60 – 70 ppm range) than the 13Cα. Similarly, alanine has a 
13
Cβ at a lower field than 
the 
13
Cβ of any other amino acid residues, rendering them easily distinguishable. Glycine is 
another amino acid that can be easily identified as it does not have a 
13
Cβ and only its 
13
Cα can be 
visualised in the spectrum at approximately 45 ppm. Other residues that can be identified from 
distinctive chemical shifts include valine, proline and isoleucine, which have higher than normal 
13






















Cβ resonances for each amino acid in random coil 
conformation.  The diagram clearly shows the distinctive patterns of serine/threonine, alanine and glycine in 
comparison to the other residues. Cysteine is shown in both its oxidised (Coxi) and reduced (Cred) forms. The most 






N random coil NMR 
chemical shifts of the common amino acids. I. Investigations of nearest-neighbour effects. J Biomol NMR, 5, 67-81 
[193].  
 
The spectra obtained from the HNCACB and HN(CO)CACB experiments with the BRD4-BD1 
protein were assigned using Analysis Version 2.3. The software helps analysing the data sets into 
spin systems and matching between the suitable spin systems. Linked spin systems (fragments) 
were then connected to the primary sequence using Mapper 2. The assignment of each of the 








Cβ resonances using the 
distinctive chemical shift patterns of serine/threonine, proline, glycine and alanine [190]. Spin 
Oxi Red 
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systems and fragments were manually and semi-automatically used with the software Mapper 2, 
which was used to place the fragments within the primary sequence. 
 
6.3.2.4 Sequential Backbone Assignment of BRD4-BD1 
 
The complete analysis of the triple resonance experiments for BRD4-BD1 led to the sequential 








Cβ nuclei. These are listed in Appendix 6.1. 









shifts was assigned, though the absolute placement of one spin system within the primary was 
not definitive (2 possibilities). An example of the assignment from H77 to W81 shows the 





(Figure 6.8). Of the remaining 20 % un-assigned residues, most were found to be residues 
adjacent to prolines (prolines are not visible on standard triple resonance assignment spectra 
because they lack an NH). As a result, the sequential link could not be established with those 
residues. One threonine residue could not be located either, possibly as it was situated next to 





























Figure 6.8. Sequential assignment example from backbone triple resonance assignment of BRD4-BD1 from 
H77 to W81. The red peaks HN(CO)CA, blue peaks HNCA, brown peaks HN(CO)CACB, orange peaks HNCACB. 
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15
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HN(CO)CA/ HNCA and HN(CO)CACB/ HNCACB show the assignment stretch for residues H77 to W81. 
Sequential matches are shown using the dotted arrows. The HN(CO)CACB/ HNCACB experiment shows the Cα and 
Cβ atoms of the preceding amino acid. The HN(CO)CA/ HNCA strips show the Cα as positive peaks in blue and the 
Cβ as negative peaks in orange. The horizontal lines show inter-residue connections and the vertical lines show the 
intra-residue connections. The relevant 
15
N chemical shift position of each plane is shown above the respective 
strips. The connectivities for both the Cα and Cβ peaks in the HN(CO)CACB and HNCACB experiments are shown 














H HSQC spectrum for BRD4-BD1. All the identified amide resonances are annotated on the spectrum. Experiments were run at 25°C with the 
protein sample at pH 6.5.
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6.3.2.5 Secondary Structure Prediction from Chemical Shifts using TALOS 
 
The secondary structure of BRD4-BD1 was predicted using TALOS (Torsion Angle Likelihood 
Obtained from Shift and sequence similarity) [194] [195]. TALOS is a database software used 
for the prediction of phi and psi backbone torsion angles from HA, CA, CB, CO and N chemical 
shifts of a protein sequence (Fig 6.10). TALOS arises from an algorithm that employs a Bayesian 
interference statistical way to predict the secondary structure of protein using the types and 
chemical shifts of an amino acid. TALOS also calculates the neighbouring amino acid residues 
leading to the formation of a structural chemical shift database for related sequences [196] [197].  
 
A protein backbone adopts various secondary structures (α-helices and β-sheets) through the 













Figure 6.10. Schematic representation of the Ramachandran Plot outlining the angles the Ψ (Psi) between the 
C and Cα bond against Φ (Phi) between Cα and N bond to characterise different types of secondary structural 
elements. Angles and secondary structural motifs of the protein backbone are shown by the blue regions.       
Adapted from: http://knowledgesun.com/ramachandran-plot/ [198] [199] 
 








Cβ in BRD4-BD1 were used with TALOS software to assign the secondary structure 
of the protein. Once the predictions using TALOS were successfully completed, the results were 
summarised in the form a sequential diagram (Fig 6.11 and Fig 6.12). The TALOS predictions 
are lists in Appendix 6.2. 
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Figure 6.12. A) Predictions of secondary structure of BRD4-BD1 using TALOS for BRD4-BD1. Structure 
coloured by dangle predictions from dangle, red is helix, blue is from unassigned residues and white is assigned 




        
 
 
27                                   42                           52                            62                        72 
HSSGVDLGTNLYFQ     SMPPPPNETS       NPNKPKRQTN      QLQYLLRVVL     KTLWKHQFAW 
 
                                       82                           92                           102                         112                              
                                       PFQQPVDAVK     LNLPDYYKII           KTPMDMGTIK     KRLENNYYWN    
 
                                      122                       132                         142                          152 
      AQECIQDFNT     MFTNCYIYNK       PGDDIVLMAE        ALEKLFLQKIN 
 
Figure 6.12. B) Comparison of secondary structure predictions of BRD4-BD1 from X-Ray Crystallography 
and NMR methods. The predicted structures are shown as a) BRD4-BD1 Experimental Crystal Structure b) NMR 
Structure, where α-helices are shown as blue cylinders and meanders shown as black arrows. Unassigned regions are 
represented as grey boxes. 
Experimental Crystal Structure 
NMR Secondary Structure 
42 52 62 72 
82 92 102 112 
122 132 142 152 162 
223 
TALOS was successful in predicting the secondary structures for BRD4-BD1. The X-ray 
structure was in agreement with the NMR structure for this construct. The structure is 
predominantly helical and containing loops and meanders. However, small differences were 
observed in the TALOS prediction between the two structures. Please note that there is a 
variation between the two constructs (T42/N43 are substituted as S42/M43 in the NMR 
structure). Both the constructs are the same from P44 to N162.  
M107 was shown as helix in the X-ray crystallography structure, but as a meander in the NMR 
structure. The sections from T109 to R113, A122 to I126, and E154 to F157 were represented as 
helices in the X-ray crystallography structure, whereas as meanders in the NMR structure. 
Therefore, only 15 residues were different between the X-ray structure and NMR structure, 
which suggests that TALOS is an efficient secondary structure prediction tool. 
 
6.4 The Chemical Shift Map of BRD4-BD1 complexed with             
BTB 07004 
 
6.4.1 The Theory of Chemical Shift Mapping 
 
As opposed to common units of frequency and wavelength in spectroscopy, NMR spectroscopy 
uses chemical shifts (ppm) as units, as absolute frequencies of NMR lines are directly 
proportional to the magnetic field strength. When doubling the magnetic field strength, the 
frequency is also doubled and therefore the comparison of absolute absorption frequencies 
224 
between spectrometers of different field strengths becomes impossible. However, when peak 
positions are described using chemical shift, they are independent of the field strength, making 
comparison between different spectrometers possible [200].  




H HSQC data of the protein, which have been perturbed by a ligand, 




H HSQC native protein for comparison purposes. 
The distances from the signals in the fully assigned spectrum to the closest peak of the 
unassigned spectrum is measured. The chemical shift mapping results in the generation of a 
graph representing the minimal chemical shift difference for each residue. This is called 
“Conservative Chemical Shift Mapping” [201] [202].  
 
The minimal chemical shift difference is measured using the following equation 1:  









N is the chemical shift 
change in the 
15
N dimension, in ppm. Since all the values are always squared, the shift difference 




N difference is multiplied by 1/5 to 
compensate for the chemical shift range of 
15
N being 25 ppm while that of 
1
HN is 5 ppm. The 




6.4.2 Chemical Shift Mapping of BRD4-BD1 with BTB 07004 
 
6.4.2.1 NMR Sample Preparation of 
15
N BRD4-BD1 with BTB 07004 
 




H HSQC in the presence and 
absence of the ligand BTB 07004. The protein sample was obtained from a 
15
N isotopically 
enriched sample expression in E.coli T7 express cells grown in minimal media and purified in 
GF Buffer (25 mM NaH2PO4, 100 mM NaCl and 1 mM DTT pH 6.5) as described in Chapter 
2.5. The final concentration of the protein was 0.7 mM in complex with 3 mM ligand             
BTB 07004 (KD = 198 μM) added in ethanol to give a final concentration of 5 % ethanol.       
5% D2O as used for the lock.  
 
6.4.2.2 NMR Data Acquisition of 
15
N BRD4-BD1 in the presence and absence of 
BTB 07004 
 
HSQC experiments were acquired at 25°C on a Bruker Avance III Spectrometer, with 2048 
points (9615 Hz) in the direct F2 dimension (
1
H), 256 points (2007 Hz) in F1 (
15
N) indirect 
dimensions. Carrier frequencies for the experiments were set to 4.730 ppm, and 119.000 ppm for 
1
H,  and 
15
N respectively.  Data were processed with NMRPipe with a cosine window applied in 
all dimension [191], water suppression using a convolution difference filter and linear prediction 
in the 
15
N dimension to increase the length of data by a factor of 2. All dimensions were zero-
filled by a minimum of a factor of 2.   
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The ligand binding site of BRD4-BD1 has been mapped through NMR chemical shift 
perturbation in the presence of the chemical ligand, BTB 07004 (Figure 6.13). Some peaks were 
not used due to the lower quality of the data in comparison to Figure 6.9. 
 
6.4.2.3 Chemical Shift Mapping Results of BRD4-BD1 and BTB 07004 complex 
The minimal chemical shift mapping is shown in Figure 6.14 and the data is tabulated in 
appendix 6.2. The NMR chemical shifts change (annotated peaks in Figure 6.13) highlight 










H HSQC Spectrum of 0.7 mM BRD4-BD1 in the presence and absence of 3 mM 
BTB 07004 at 25 °C. The blue spectrum represents the BRD4-BD1 and the red spectrum shows BRD4-BD1 in 
complex with BTB 07004. Addition of the unlabelled ligand to BRD4-BD1 caused chemical shift change in the 
protein. The residues with an observed chemical shift above the cut-off in Figure 6.15 are annotated in black. 
Residues that were expected to produce a chemical shift, but did not show any effects after the addition of the ligand 
are annotated in blue (this is in comparison with the crystal structure c.f.: section 5.3.2). 
In order to observe the effect of BTB07004 binding on the BRD4-BD1 protein, the assignments 
were used to follow the chemical shift in the protein. Minimal maps can be constructed by 
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measuring distances from signals in an assigned spectrum, in this case BTB07004, to the nearest 
peak in the unassigned spectra of BRD4-BD1. Figure 6.14 shows the shifts that occurred due to 
the binding of BTB07004 to BRD4-BD1. 
 
 
Figure 6.14. The minimal chemical shift perturbations between BRD4-BD1 and BTB 07004 as calculated by 
Equation 1. This plot shows the BRD4-BD1 chemical shift perturbations between BRD4-BD1 with and without an 
excess of BTB 07004. Chemical shift differences ranging above or equal to 0.3 ppm were considered significant and 




Chemical Shift Difference (ppm)
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The threshold for significant chemical shift changes was defined by looking for consistent 
sequence of residues that have a perturbation, which is localised on the protein surface. 
The key residues that showed a major chemical shift change are summarised in the table below 
with a comparison of the residues identified crystallographically (Chapter 5.3.3): 



















Table 6.1. Comparison of key residues in the active site BRD4-BD1 involved in binding of BTB 07004, 
characterised by both X-ray crystallography and NMR. The comparison confirms that the data obtained from 
NMR chemical shift mapping is in agreement with the X-ray crystallography data. Major chemical shift differences 
ranging above 0.3 ppm were observed at W81, V87, D88, A89, N93, L94, I146, A150, L158 and K160, from which 
4 residues match with the X-ray crystallography structure where there are residues directly in contact with the 
229 
ligand. Some of the residues which show shifts in the NMR data but are not part of the ligand binding site such as 
L158 and K160 are not easily explained by ligand binding but could be due to long range dynamics, changes in 




Figure 6.15. (A) The interactions of BTB 07004 with its environment residues in the binding site of BRD4-
BD1 based on the crystal structure from WinCoot Flev. Comparison of the BRD4-BD1 binding-site (B) 





resonances of BRD4-BD1 with BTB 07004, mapped on the crystal structure pictures prepared using 
Pymol. (A) The amino acids W81, V87, L94, Y97, C136, Y139, N140 and I146 are shown to be the key 
environment residues of BTB 07004 when bound to BRD4-BD1. (B) (C) Comparison of BRD4-BD1 ligand 
binding site between crystal and NMR structures. Residues involved in binding are shown in red. As shown in 
Table 6.1, W81, V87, L94 and I146 are the common residues between the crystal and NMR data for the binding 






The results in Figure 6.16 suggested that W81, V87, L94 and I146 were strongly involved in 
the binding process of the ligand, as their chemical shift difference ranged above 0.3 ppm, 
which characterises a major shift. Other residues identified in the crystal structure, such as 
P82, F83, L92, C136, Y139 and N140 were not identified in the NMR chemical shift 
mapping. P82 is present in the NMR spectrum as it doesn’t have an NH group and its 
adjacent residue F83 was not assigned. The residues D88, A89, N93 and A150 were also 
found to have shifted in the NMR spectrum. These residues still reside within the binding 
pocket region and could also be involved in ligand binding. However, the residues L158 and 
K160 are very distant from the binding site, and their shifts are not so easily explained. This 
could be due to changes in dynamics or changes in aggregation state. In addition, this is based 
on a minimal shift mapping, so measured shifts can be far less than those that actually occur. 
 
6.4.2.3 Chemical Shift Mapping Results of BRD4-BD1 in the presence of 
Ethanol 
 
Because DMSO can bind to the active site of BRD4-BD1, 5% Ethanol (final concentration) 
was used as a solvent. In order to ensure the fidelity of the data and rule out that the chemical 




H HSQC experiment was 
performed with 3mM BRD4-BD1 with the presence of 4.5 % EtOH, as the protein is quite 









H HSQC Spectrum of 0.7 mM BRD4-BD1 in the presence and absence of 4.5 
% EtOH at 25 °C. The blue spectrum represents the BRD4-BD1 and the red spectrum shows BRD4-BD1 in 
complex with EtOH. Addition of the 4.5 % EtOH to BRD4-BD1 has caused chemical shift change in the 
protein. The important residues with an observed chemical shift above the cut-off in Figure 6.18 are annotated in 
black. 
 
The addition of 4.5 % EtOH to BRD4-BD1 has caused a chemical shift perturbation in the 
protein. Therefore, the shifted residues were compared to Fig. 6.16. 
The comparison shows that the residues V70, L71, D88. T103 and L158 have shifted in 











comparing to the chemical shifts of BRD4-BD1 with BTB 07004. Moreover, the shifts with 
EtOH are not as strong as the ones observed with BTB 07004, which clearly confirms that the 
chemical shifts seen in Fig 6.13 are in response to BTB 07004 and not an effect of the EtOH. 
The average chemical shift was 0.08 ppm and the standard deviation was 0.10 ppm. 
BRD4-BD4 in 4.5% EtOH was not used as the control experiment to measure the chemical 
shift changes seen on the addition of BTB07004, as the quality of the spectrum was poorer 
and not all the peaks were assigned. Moreover, no significant changes were observed within 











Figure 6.17. The comparison of minimal chemical shift perturbations between BRD4-BD1, BTB 07004 
(top) and EtOH (bottom) as calculated by Equation 1. The greyed section represents the binding site of 






Figure 6.17. The comparison of minimal chemical shift perturbations between BRD4-BD1, BTB 07004 
(top) and EtOH (bottom) as calculated by Equation 1. The greyed section represents the binding site of 
















































































































































































































Table 6.2 compares the difference between the residues shifted in response to BTB 07004 
and EtOH. 
 
Table 6.2. Comparison of key residues in the active site BRD4-BD1 involved in binding of BTB 07004 and 
BRD4-BD1 with EtOH 
 
Figure 6.17 indicates and compares the chemical shift changes observed between the BRD4-
BD1 complexed with BTB07004 and BRD4-BD1 with 4.5 % EtOH. Although D88 and L158 
are both largely shifted in response to EtOH, the shift is not as big as with the ligand 
BTB07004, which confirms that these chemical shift changes are due to the ligand. 
 
 

















F-Fluoroindole-labelled BRD4-BD1 Spectrum 
 
BRD4-BD1 was also studied with 
19
F isotopic enrichment. The chemical shift mapping and 
crystallographic data indicated in the previous sections that W81 was present in the ligand 
binding site of BRD4-BD1. W81 and the other two tryptophan residues from BRD4-BD1 can 
then be utilised as an NMR screening tool to monitor ligand binding using 
19
F chemical shift 
correlations and shift changes. In comparison to section 6.1.4, where ligand-observed         
19
F CPMG was performed, and ligand binding was examined using the fluorinated fragments 
of BTB 07004, this section focuses rather on fluorinating the tryptophan residues, particularly 









C labelled methods are more commonly used in NMR studies, despite the fact 
that 
19
F is highly sensitive and 100 % abundant because 
19
F does not naturally occur in 
proteins. 
19
F NMR methods are less often applied due to the need of making an extra           
19
F labelled protein sample [203] [204].  
 
6.5.2 The expression and purification of 
19
F-Fluoroindole BRD4-BD1 
Previous studies have shown that not all isomers of fluoroindole can be accommodated 
within a protein, and therefore the most integrable fluoroindole needed to be identified.         
4′ fluoroindole, 5′ fluoroindole and 6′ fluoroindole were tried (Figure 6.18).  
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Figure 6. 18. The different types of fluoroindoles used to be accommodated within BRD4-BD1.                 
4′ fluoroindole, 5′ fluoroindole and 6′ fluoroindole were used to determine the most integrable fluoroindole with 
BRD4-BD1.  
 
Protein samples was obtained from a 
19
F isotopically enriched expression in E.coli T7 express 
cells grown in minimal media and purified in GF Buffer (25 mM NaH2PO4, 100 mM NaCl 
and 1 mM DTT pH 6.5) as described in Chapter 2.5. 60 ug/mL The final concentration of 
fluoroindole was added 15 minutes before the IPTG induction. The expression levels of 
BRD4-BD1 with the different types of fluoroindoles were assessed on SDS-PAGE gel with 







Figure 6. 19. BRD4-BD1 with the presence of different fluoroindoles. MP : molecular weight marker.    
A) Pre-induction sample of BRD4-BD1 with 4′ fluoroindole. B) Post-induction sample of BRD4-BD1 with     
4′ fluoroindole. C) Pre-induction sample of BRD4-BD1 with 5′ fluoroindole. D) Post-induction sample of 
BRD4-BD1 with 5′ fluoroindole. E) Pre-induction sample of BRD4-BD1 with 6′ fluoroindole. F) Post-
induction sample of BRD4-BD1 with 6′ fluoroindole. 
 
The SDS-PAGE gel in Figure 6.19 shows that, as anticipated, BRD4-BD1 is well expressed 
with the presence of all three fluoroindoles. The band intensity was observed to be greater 




6.5.3 MS experiments of 
19
F BRD4-BD1 
Figure 6. 20. Mass spectrometry spectrum plot of 
19
F BRD4-BD1. The results show the presence of four 
different peaks. The expected native of full labelled 13C-15N-19F-BRD4-BD1 is 15993Da allowing for 100% 
labelling. The most intense ion, at Mr = 15,947.6Da, is consistent with a fully labelled BRD4-BD1 with a 
labelling efficiency of ~95%. Two lower mass peaks have a molecular mass of Mr = 15,857.2 and 15,719.9, and 
are lighter than the base peak suggesting they are degradation products of the protein. The fourth peak is very 
far away from the actual base peak with Mr = 18,551.9 and is assumed to be a contaminant. 
 
The mass spectrometry in Figure 6.20 results confirms the expected mass of the BRD4-BD1. 
The expected mass of 
19
F BRD4-BD1 is 15947.6 Da, which is slightly lighter than the fully 
labelled expected mass at 15993 Da. However, the presence of multiple peaks in the spectrum 
suggests that the protein must have degraded. The protein therefore appears to possibly be 
slightly less stable on inclusion of fluoroindole. 
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F CPMG experiments were acquired on a Bruker Avance III 600 Hz spectrometer at 25°C. 
Data were collected with 32,768 points and a spectral width of 9615 Hz in the direct F1 
dimension (
19
F), with a total number of 128 scans. The CPMG sequence used 60 cycles with 
a delay of 1ms between 180 degree pulses. Data was processed with a line broadening of          
5 Hz using exponential multiplication. 0.1 mM BRD4-BD1 was used with 1 mM BTB 07004. 
Figure 6. 21. CPMG spectrum of 
19
F BRD4-BD1 in complex with BTB 07004 
The three peaks at approximately - 125 ppm (red region) derive from the three 5′ fluoroindole-labelled 
tryptophan residues within the protein molecule, and the two large peaks at - 135 ppm arise from the fluorine 
atoms from BTB 07004. This spectrum confirms that the tryptophan residues from the BRD4-BD1 protein 




The three 5′ Fluoroindole labelled 
TRYPTOPHANS in BRD4-BD1 
BTB 
19
F  (ppm) 
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Figure 6.21 shows that the tryptophan residues from the BRD4-BD1 protein sequence are 
labelled with 
19
F (three peaks in the range of 125 ppm). However, it does not inform us which 
one of the peaks corresponds to W75, W81 or W120. The two peaks in the 135 ppm range, 
correlate with the two fluorine atoms from BTB 07004. This experiment enables to observe 
both 
19
F BRD4-BD1 and BTB 07004 in the same spectrum, and therefore ligand binding can 











Figure 6. 22. 
19
F  CPMG spectrum of 
19
F BRD4-BD1 with the presence and absence of BTB 07004. The 
blue spectrum represents 
19
F BRD4-BD1 and the red spectrum represents 
19
F BRD4-BD1 complexed with BTB 
07004. The signals from the three fluoroindole-labelled tryptophan residues (1, 2 and 3) have reduced intensity 
with the addition of BTB 07004, confirming binding and highlighting the role of the tryptophan residues in the 
binding of BTB 07004 to BRD4-BD1. Peak 1 = ?, Peak 2 = ? and Peak 3 = W81, based on crystallographic and 
chemical shift mapping data.  
 
- BTB 07004 
BTB 07004 
+ BTB 07004 
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The binding of BTB 07004 with BRD4-BD1 was confirmed with 
19
F CPMG experiment 
(Figure 6.22). The intensity of the signals from the three tryptophan residues (1, 2 and 3) was 
reduced intensity with the addition of BTB 07004, confirming binding and highlighting the 
role of the tryptophan residues in the binding of BTB 07004 to BRD4-BD1. It should be 
noted that peak 3 has even shifted, indicating strong interaction of the residue with the ligand. 
The ligand binding site of BRD4-BD1 includes W81, and this residue associates with the 
chemical shift following the addition of BTB 07004. The crystallographic data show a 
hydrophobic interaction of BTB 07004 with W81, which is consistent with this result.  
Neither of the residues W75 and W120 have shown any significant 
1
H chemical shifts in the 
mapping of BRD4-BD1 with BTB 07004. However, W75 is the next closest from the ligand 
binding site after W81. Based on these, the highly attenuated and shifted peak 3 from Figure 
6.22 could be corresponding to W81. The least attenuated peak 1 could be W120, which is 
the furthest from the ligand binding site. As a result, peak 2 is assumed to be W75. This result 
is not conclusive. 
The control spectrum for this experiment did not contain 4.5% ethanol.  
 
6.6 Summary and Discussion 
 
Chapter 6 has characterised the binding of BTB 07004 to BRD4-BD1 using both ligand and 




F nuclei.  
NMR studies revealed that the protein was folded, in monomeric state and stable in the GF 





H CPMG and 
19
F CMPG were performed to show that BTB 07004 
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binds to BRD4-BD1. In comparison to the other protein systems studied in this project, 
BRD4 was the most suitable protein system for the comparison of both the X-ray 
crystallography and NMR methods due to its affinity. Its small size of 15 kDa and stability 
were advantageous and no gross oligomerisation was present.  
 







The triple resonance experiments HNCACB, HNCA, HN(CO)CA, HN(CO)CACB and 












N HSQC spectra 
with the addition of the ligand BTB 07004 showed chemical shift differences, indicating 
ligand binding and highlighting the key residues in the binding site of BRD4-BD1.  
 
Major chemical shift differences ranging above 0.3 ppm were observed for the residues W81, 
V87, D88, A89, N93, L94, I146, A150, L158 and K160. The chemical shift mapping was in 
agreement with the binding site in the BRD4-BD1 crystal structure, particularly for the 
residues W81, V87, L94 and I146.  
 
Further 1D heteronuclear 
19
F-based experiments were performed. BRD4-BD1 was 
isotopically enriched with 5′ fluoroindole to label the tryptophan residues of BRD4-BD1. 19F 
CMPG experiments rapidly confirmed that W81 is part of the binding site, and W75 and 
W120 are not part of the ligand binding site of BRD4-BD1.  
 
This work has established BRD4-BD1 as a good model system for comparing NMR results 
with X-ray crystallographic data so as to gain a better understanding of the protein’s binding 
site and the protein ligand interactions.  











7.1 General Summary 
 
Generally structural information for biomolecules and especially proteins has so far been 
determined by single methods, e.g. X-ray crystallography, Electron Microscopy (EM) or 
NMR only, although combined NMR X-ray and NMR EM refinements have also been made 
[79] and these approaches are becoming more popular as methods to look at the internal 
dynamics of proteins. Analysis of the PDB shows that 90 % of structures have been solved by 
X-ray crystallography, and these have been used to understand proteins three-dimensional 
structure, protein function and ligand interactions. Hydrophobic proteins from the lipid 
bilayer of cellular membranes have also been solved by X-ray crystallography, such as G-
protein coupled receptors, ion channels and transporters. However, X-ray crystallography 
requires the purification of large amount of very pure protein which then critically needs 
crystallising, these processes can take several months to years. Failure in the crystallographic 
pipeline can occur at any stages of the process: protein production, crystallisation, X-ray 
diffraction, X-ray data acquisition, X-ray data phasing and X-ray data refinement.  
The main aim of this thesis was developing novel approaches combining X-ray 
crystallography and isotope-edited ligand and protein-observed NMR methods to understand 
protein binding sites and interactions in proteins.  Significant effort was focused on a number 
of “model” systems to this end, including CypA, TbrPDEB1 and BRD4-BD1 to compare X-
ray crystallography and both ligand and protein-observed NMR methods.  




 X-ray Crystallography NMR 
 






CypA and Ligands 
X 






H WaterLOGSY and 
1
H 
CPMG. No further experiments done. 
 
APO TbrPDEB1 Protein  
X 
No spectra obtained. 
 
TbrPDEB1 and Ligands 
 











N HSQC  
 Majority of backbone HN, C ,C & N 
atoms assigned.  
BRD4-BD1 and Ligands 
 





H WaterLOGSY and 
1
H 
CPMG with ligand BTB 07004. 
19
F 
CPMG with ligand BTB 07004.  




Table 7.1. Summary of the main results with CypA, TbrPDEB1 and BRD4-BD1 using X-ray 
crystallography and NMR Experiment done and successful;  X Experiment done but unsuccessful.  
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7.1.1 CypA Conclusions  
 
CypA (18 kDa) was studied in complex with the ligands 3′Aminoacetophenone, 4′ 
Sulfamoylbenzoic Acid and 6′Aminoindazole using X-ray crystals. Results revealed that the 
crystal packing of CypA did not allow the binding of the ligands to CypA. This appears to be 
due to C-terminal residue Glu165, obstructing the ligand binding site of CypA. In an attempt 
to overcome the packing effect hindering the binding site and create a new crystal form, In-
situ mutagenesis was performed to remove the C-terminal Glu165 (CypA-165-6HIS), but 
the crystallisation of mutant CypA did not yield suitable crystal samples of 
3’aiminoacetophenone, 4′ Sulfamoylbenzoic Acid and 6′ Aminoindazole complexed with 
His-tagged CypA.  




H Waterlogsy and 
1
H CPMG were 
performed on both CypA-165-6HIS and wild type CypA, which clearly indicate that 
3′Aminoacetophenone and 4′Sulfamoylbenzoic Acid bind to CypA. This showed that both 
the wild type and mutant were binding competent and that that main problem was to achieve 









N HSQC) all of which gave good quality 
spectra.  
CypA is an example that illustrates the need for an advanced NMR method to determine 
ligand binding sites. This study highlighted the requirement for full protein assignment [133] 
and interaction studies of ligand-based observations in the absence of an X-ray structure. As 
the protein- and ligand-observed NMR could not be compared with X-ray structure for 
validation purposes, this target protein was abandoned.  
248 
 
7.1.2 TbrPDEB1 Conclusions  
 
TbrPDEB1 (37 kDa) was studied in complex with the ligands VUF 14234, PPS 59083,     
PPS 60036 and VUF 14450. X-ray crystallography studies revealed a conserved binding 
mode, where the active site contained the ligand and magnesium and zinc ions. The residue 
Gln874 conserved interaction all the crystal structures, and is the main residue which forms 
the parasite-specific P-pocket. In fact, all the ligands investigated in this study were directing 
themselves towards the P-pocket residue, which suggested that this P-pocket can be used as 
an important target in the design of therapeutic drugs for the treatment of HAT.  
 




H experiments resulted in broad and 
poorly dispersed peaks. Although thermal shift assays suggested that the melting temperature 
of TbrPDEB1 is between 51.5 °C and 55 °C, optimisation by increasing temperatures from 
25 °C to 50 °C did not improve the spectra of TbrPDEB1. Therefore, the NMR screening 
methods could not be performed due to the instability of TbrPDEB1.   
 
TbrPDEB1 becomes stabilised with the presence of a ligand, highlighting the need of a ligand 
to remain stable and in the conditions of native state. CD experiments also revealed that 
TbrPDEB1 remains predominantly α-helical at room temperature, as observed 
crystallographically.  
TbrPDEB1 was a good crystal example, as the interactions of the ligand with the protein 
could be characterised with the four different ligands studied. The protein’s size, stability in 
NMR buffer and NMR tumbling rate were considered as limiting factors for such NMR 
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studies. Therefore, this study highlighted that not all proteins can be suitable for the purpose 
of drug design using the NMR technique.  
 
7.1.3 BRD4-BD1 Conclusions  
 
BRD4-BD1 (15 kDa) was studied in complex with the ligands BTB 01148, BTB 06033,   
BTB 07004, RJF 00210, TG 00013, HTS 05027 and RJF 00002. X-ray crystallographic 
studies revealed a conserved binding site in the loop region of BRD4-BD1 with a conserved 
interaction with N140 in all studied structures.  
 





F nuclei. NMR studies revealed that the protein was folded, in 
monomeric state and highly stable in the GF buffer conditions, rendering it suitable for NMR 




H CPMG and 
19
F CMPG 
were performed to show that BTB 07004 binds to BRD4-BD1. 
Ligand binding of BTB 07004 to BRD4-BD1 was observed through the change of intensity 







H experiments and the pair of triple resonance experiments 
HNCA, HN(CO)CA, HNCACB, HN(CO)CACB for BRD4-BD1 led to the sequential 








Cβ nuclei. Major chemical shift differences 
ranging above 0.3 ppm were observed for the residues W81, V87, D88, A89, N93, L94, I146, 
A150, L158 and K160. The chemical shift mapping was in agreement with the binding site in 





F experiment were performed to look for site specific chemical shift 
perturbations. BRD4-BD1 was isotopically enriched with 5’fluoroindole to label the 
tryptophan residues of BRD4-BD1. Chemical shifts observed in 
19
F CMPG experiments 
rapidly confirmed that W81 is part of the binding site, and W75 and W120 are not part of the 
ligand binding site of BRD4-BD1. This showed that fluorine labelling of proteins can be used 
as a tool to selectively study protein-ligand interaction when a Tryptophan is present in or has 
close proximity to the ligand binding site.  
 
BRD4-BD1 was a good model system for comparing NMR results with X-ray 
crystallographic data and gain a better understanding of the protein’s binding site and the 
protein ligand interactions and showed good agreement between the observed NMR X-ray 
crystallography results.  
 
Overall its be concluded from a small sample of 3 systems, 1 was amenable to NMR studies 
but not X-ray crystallography due to problems with crystallisation and was expected to given 
good information on the ligand binding site. One was only amenable to X-ray crystallography 
but noy NMR to problems with the size of the system and the quality of spectra. In the third 
case (BRD4) the system was studied but both NMR and X-ray crystallography which gave 
information on ligand binding hits and the ligand binding site which were in good agreement. 
Clearly from this analysis a joint NMR and X-ray crystallography approach to analysing 
ligand binding is an effective approach with each technique having pros and cons and 




7.2 Future Studies: The development of Group Epitope Mapping 
 
The work in this thesis can be continued with the development of an advanced NMR 
technique for the creation of a Group Epitope Mapping (GEM) methodology. GEM 
determines the distances between the ligand and the receptor, creating the precise map of 
binding-sites for the target protein. GEM should inform about the ligand binding sites and 
interaction sites of any proteins without necessarily the crystal structure of a protein. It will 
be a good method for proteins with unknown crystal structures to find their ligand-binding 




The characterisation of CypA, TbrPDEB1 and BRD4-BD1 structures and their ligand binding 
sites has permitted to compare the advantages and disadvantages of X-ray crystallography 


















Requires large amounts (milligrams) 
of high quality protein that 
crystallises. Well-ordered crystals 
must diffract to obtain a three-
dimensional structure.  
 
Requires large amounts (milligrams) of 




Solid-frozen structure. Can be 
purified in any buffers. Samples 
exposed to radiation damage. 
In buffered solution. Highly suitable in 
phosphate buffer. Limited due to 
temperature restrictions. 
Protein Size Any size proteins and 
macromolecule complexes can be 
studied. 
Currently only proteins with less than a 




N methods. Large proteins are 
difficult to study by NMR due to signal 
overlap and signal broadening in the 
spectra due to slower tumbling rates. 
Experiment time Long time required for screening, 
crystallisation and optimisation for 
high quality crystals (weeks/months). 
Short time required for data 
acquisition and processing 
(minutes/hours).  
Short time required for sample 
preparation and data acquisition 
(minutes/hours). Long time required for 
data analysis and NMR protein 
assignment (weeks/months).  
Experiment quality Highly precise atomic resolution data 
can be obtained from well-ordered 
crystals. Good local resolutions and 
global resolution for 
Highly precise data can be obtained 
from pure protein sample. Solution-state 
dynamic studies can be obtained. Good 
local and lower global resolutions.  
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disordered/flexible regions.    
Conformational issues Crystal packing problems can result 
in change of protein conformation.  
Oligomerisation can be an issue and 
buffers can influence the folded state of 
a protein.  
Liganded structures Very quick (minutes/hours). Once 
the crystal structure of a protein is 
fully refined (hours), the binding of a 
ligand can be quickly determined 
(minutes).  
Quick (days/months). 100 – 1,000 






WaterLOGSY and CPMG NMR 





HSQC spectrum is fully assigned 
(months), chemical shift mapping can 
be done quickly for one ligand (1 day).  
 
Table 7.2. Comparison of X-ray crystallography and NMR 
 
X-ray crystallography and NMR are the most widely used techniques in protein structure 
determination and understanding of ligand binding interactions. Although they both have 
limitations, they mutually complement each other. For example, NMR might not be suitable 
for the study of large macromolecules, but can supplement a crystal structure with dynamics’ 
information, binding information and conformational changes in solution. Therefore, 
combining both the techniques can lead to advanced structural information about a protein 
and ligand-binding interaction topology. The evolution of advanced NMR techniques such 
1D and 2D qSTD allow for the quick determination of distances between the ligand and may 
have a important role to play the future. It should also be noted that recent developments of 
high resolution electron cryo-microscopy have highlighted this approach as a key tool in the 
structural biologists’ arsenal in understanding protein-protein and protein-ligand interactions.  
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APPENDIX 6.1 Resonance Assignment for BRD4-BD1 
The chemical shifts have been referenced in the C dimension by +1.25 ppm.   
The final errors in expected shifts vs observed shifts were Cα -0.34 Cβ 0.47 NH 0.40 (N not 
corrected) according to PANAV (Bowei Wang, Yunjun Wang and David S. Wishart. "A 
probabilistic approach for validating protein NMR chemical shift assignments". Journal of 
Biomolecular NMR. Volume 47, Number 2 / June 2010: 85-99). 
Residue Residue Name HN (ppm) NH (ppm) Cα (ppm) Cβ (ppm) 
27 His 8.61 121.06 55.14 28.59 
28 Ser 8.33 113.89 59.99 68.21 
29 Ser 8.15 117.30 56.36 62.59 
34 Gly 8.54 109.46 43.94 - 
35 Thr 7.98 113.19 60.49 67.93 
36 Glu 8.54 123.05 55.56 28.24 
37 Asn 8.37 119.22 51.76 37.04 
38 Leu 8.05 122.27 54.07 40.48 
39 Tyr 8.02 119.82 56.59 36.79 
40 Phe 7.94 120.83 56.41 37.65 
41 Gln 8.16 121.33 54.47 27.55 
42 Ser 8.17 116.37 56.89 62.04 
43 Met 8.17 121.34 53.75 31.37 
48 Asn 8.33 117.50 51.49 37.25 
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49 Glu 7.80 122.53 52.39 31.17 
64 Gln 8.54 119.41 57.77 26.83 
65 Tyr 7.92 121.75 60.19 36.88 
66 Leu 8.55 121.78 56.97 39.90 
67 Leu 7.89 118.79 56.33 41.23 
68 Arg 8.89 115.36 56.95 29.31 
69 Val 8.10 115.49 62.61 30.47 
70 Val 7.50 120.42 66.89 28.90 
71 Leu 9.47 119.91 57.14 39.79 
72 Lys 6.56 115.49 58.13 30.86 
73 Thr 7.37 112.19 65.25 67.18 
74 Leu 8.08 121.61 57.24 40.59 
75 Trp 9.20 117.14 59.37 27.73 
76 Lys 7.07 109.60 53.81 31.13 
77 His 7.63 123.82 57.36 30.52 
78 Gln 8.44 128.34 57.33 25.97 
79 Phe 11.53 122.03 51.47 35.87 
80 Ala 8.03 116.99 53.25 19.13 
81 Trp 7.58 116.11 59.83 25.38 
87 Val 8.55 124.89 62.76 30.61 
88 Asp 8.18 130.13 50.60 37.94 
89 Ala 8.16 125.92 52.99 17.80 
90 Val 7.95 118.42 63.87 30.10 
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91 Lys 7.90 122.79 57.25 30.92 
92 Leu 7.83 114.67 53.09 40.41 
93 Asn 7.54 116.83 52.17 35.12 
94 Leu 8.28 118.67 49.68 40.51 
97 Tyr 7.66 123.26 62.25 37.76 
98 Tyr 8.37 112.39 58.05 34.92 
99 Lys 7.32 118.31 56.15 31.08 
100 Ile 7.27 118.96 60.66 37.93 
101 Ile 8.26 121.83 55.89 31.96 
102 Lys 7.80 124.91 55.94 31.21 
103 Thr 8.27 112.42 55.57 67.87 
106 Asp 7.29 119.99 51.23 42.96 
107 Met 9.18 119.05 58.27 33.71 
108 Gly 8.73 113.07 46.06 - 
114 Leu 8.86 121.33 56.52 42.14 
115 Glu 8.69 119.48 57.20 28.29 
116 Asn 7.98 115.02 51.11 36.84 
117 Asn 7.88 115.73 53.01 35.02 
118 Tyr 8.46 117.21 59.16 38.78 
119 Tyr 7.77 114.91 55.64 37.76 
120 Trp 9.80 122.30 57.01 28.95 
124 Glu 8.10 115.69 55.05 30.50 




126 Ile 7.50 121.12 53.67 36.80 
127 Gln 7.03 116.11 53.14 27.83 
128 Asp 6.94 121.33 51.82 41.33 
130 Asn 8.52 116.23 55.31 36.68 
131 Thr 8.96 121.51 65.26 67.20 
132 Met 7.61 120.67 58.46 31.86 
133 Phe 7.77 117.26 59.84 36.06 
134 Thr 8.66 113.53 65.65 67.04 
135 Asn 8.76 119.59 53.40 36.41 
143 Gly 8.39 110.13 43.26 - 
144 Asp 8.00 122.04 53.08 39.91 
145 Asp 8.93 124.24 56.58 38.33 
146 Ile 8.72 117.16 61.45 35.97 
147 Val 6.96 123.02 65.03 29.60 
148 Leu 7.58 120.27 56.45 39.39 
150 Ala 8.42 122.13 54.16 17.73 
151 Glu 8.96 116.81 57.73 28.25 
158 Leu 8.06 120.53 55.97 40.72 
159 Gln 9.05 122.50 57.60 27.07 
160 Lys 7.83 118.60 58.34 30.70 
161 Ile 7.20 120.87 55.89 40.32 
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There were few ambiguities in the assignment:  
- Fragment 27 can be assigned to 21-25 or 136-138 or 154-156 (listed in shift table) 




















Appendix 6.2 TALOS Secondary Structure Predictions 
 
DATA SEQUENCE     HSSGVDLGTE NLYFQSMPPP PNETSNPNKP KRQTNQLQYL LRVVLKTLWK  
DATA PREDICTED      LLLXXXXLLL   LLLLLLXXXX     XLLXXXXXXX   XXXXXXXHHH  HHHHHHHHL  
 
DATA SEQUENCE     HQFAWPFQQP VDAVKLNLPD YYKIIKTPMD MGTIKKRLEN NYYWNAQECI  
DATA PREDICTED     LLLLLXXXXX       LLHHHHLLXX  HHHHLLLXXL LHXXXXXHHL LLLLXXXLLL  
 
DATA SEQUENCE     QDFNTMFTNC YIYNKPGDDI VLMAEALEKL FLQKIN 
DATA PREDICTED     LLHHHHHHHX XXXXXXLLHH HHHHHXXXXX XHHHLX 
 















Appendix 6.3 Chemical Shift Mapping of BRD4-BD1 with BTB 07004 














































































































































Appendix 6.4 Chemical Shift Mapping of BRD4-BD1 with EtOH 
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